



DIRECTORATE GENERAL HEALTH SERVICES
KHYBER PAKHTUNKHWA

CORRIGENDUM

SUBJECT: ADVERTISEMENT NO. INF(P) 277/26 DATED 18th JANUARY 2026 IN DAILY DAWN & AAJ NEWSPAPERS, AND EPADS TENDER NO. EPADS-K-26010530619 FOR THE SELECTION & RATE CONTRACTING OF DRUGS/ MEDICINES, MEDICAL DEVICES, SURGICAL DISPOSABLES, AND NON-DRUG ITEMS ETC OF GOVT. MCC FY 2026-27


Reference is made to the advertisement No. INF(P) 277/26 dated 18th June 2025 in daily Dawn & Aaj newspapers and EPADS Tender No. EPADS-K-26010530619 regarding the Selection and Rate Contracting of Drugs/Medicines, Medical Devices, Surgical Disposable, and Non-Drug Items for Government MCC FY 2026-27.

It is hereby informed that the **Bid Solicitation Documents (Revised After Pre-Bid Conference)** of the Govt. MCC FY 2026-27 along with Technical Evaluation Proforma's are available for download from the following official websites:

- 1) Health Department Khyber Pakhtunkhwa: <https://www.healthkp.gov.pk/>
- 2) Khyber Pakhtunkhwa Public Procurement Regulatory Authority (KPPRA): <http://kppra.gov.pk/>
- 3) EPADS Portal: <https://portalkp.eprocure.gov.pk/#/tenders/Epadtenders>

This corrigendum is issued for the information and necessary action of all prospective bidders.

All other conditions regarding bid submission shall remain the same as stated in the previous advertisement.


ADDITIONAL DIRECTOR MCC /
SECRETARY S&RCC
HEALTH DEPARTMENT,
KHYBER PAKHTUNKHWA



Government of Khyber Pakhtunkhwa
Health Department
Directorate General Health Services,
Khyber Pakhtunkhwa Peshawar

Bid Solicitation Documents (BSD)

REVISED AFTER PRE-BID

For National Competitive Bidding
Pakistan

For

**SELECTION AND RATE CONTRACTING OF DRUGS / MEDICINES,
MEDICAL DEVICES, SURGICAL DISPOSABLES &
NON-DRUG ITEMS**

FOR THE FINANCIAL YEARS 2026-27

MEDICINE COORDINATION CELL (MCC)

FEBRUARY 2026

PART ONE (UNCHANGEABLE)

- Instructions to Bidders (ITB)
- General Conditions of Contract (GCC)

Preface

These Bidding Documents have been prepared for use by procuring agencies and their implementing agencies in the procurement of goods through National Competitive Bidding (NCBs) as well International Competitive Bidding (ICBs) vide 41(g) KPPRA Rules 2014.

In order to simplify the preparation of bidding documents for each procurement, the Bidding Documents are grouped in two parts based on provisions which would remain the same for every procurement and that which are specific for each procurement. Provisions which are intended to be used unchanged are in Part one, which includes Section I, Instructions to Bidders, and Section II, General Conditions of Contract. Data and provisions specific to each procurement and contract are included in Part Two which is further organized into six sections. Sections I, II, III, IV, and V, respectively contain Invitation for Bids; Bid Data Sheet; Special Conditions of Contract; Schedule of Requirements; Technical Specifications; and the forms to be used, while Section VI is about Sample Forms.

This is Part one which is fixed and contains provisions which are to be used unchanged. Each section is prepared with notes intended only as information for the Procuring agency or the person drafting the bidding documents. They shall not be included in the final documents.

Table of Contents - Part One

PART ONE - SECTION I. INSTRUCTIONS TO BIDDERS	4
Notes on the Instruction to Bidders	5
Table of Clauses	6
Instructions to Bidders	7-17
PART ONE – SECTION II. GENERAL CONDITIONS OF CONTRACT	18
Notes on the General Conditions of Contracts	19
Table of Clauses	20
General Conditions of Contracts	21-27

Part One - Section I.

Instructions to Bidders

Notes on the Instructions to Bidders

This section of the bidding documents provides the information necessary for bidders to prepare responsive bids, in accordance with the requirements of the Procuring agency. It also provides information on bid submission, opening, and evaluation, and on the award of contract.

Part One Section I contains provisions that are to be used unchanged. Part Two Section II (Bid Data Sheet) consists of provisions that supplement, amend, or specify in detail information or requirements included in Part One Section I and which are specific to each procurement.

Matters governing the performance of the Supplier, payments under the contract, or matters affecting the risks, rights, and obligations of the parties under the contract are not normally included in this section, but rather under Part one Section II, General Conditions of Contract, and/or Part Two Section III, Special Conditions of Contract. If duplication of a subject is inevitable in the other sections of the document prepared by the Procuring agency, care must be exercised to avoid contradictions between clauses dealing with the same matter.

These Instructions to Bidders will not be part of the contract.

Table of Contents

A.	Introduction	7
1.	Source of Funds	7
2.	Eligible Bidders	7
3.	Eligible Goods and Service	8
4.	Cost of Bidding	8
B.	The Bidding Document	8
5.	Content of Bidding Documents	8
6.	Clarification of Bidding Documents	8
7.	Amendment of Bidding Documents	8
C.	Preparation of Bids	8
8.	Language of Bid	8
9.	Documents Comprising the Bid	8
10.	Bid Form	9
11.	Bid Prices	9
12.	Bid Currencies	9
13.	Documents Establishing Bidder's Eligibility and Qualification	9
14.	Documents Establishing Goods' Eligibility and Conformity to Bidding Documents	9
15.	Bid Security	10
16.	Period of Validity of bids	10
17.	Format and Signing of Bid	11
D.	Submission of Bids	11
18.	Sealing and Marking of bids	11
19.	Deadline for Submission of bids	11
20.	Late bids	11
21.	Modification and Withdrawal of Bids	11
E.	Opening and Evaluation of Bids	12
22.	Opening of Bids by the Procuring Agency	12
23.	Clarification of Bids	12
24.	Preliminary Examination	12
25.	Evaluation and Comparison of Bids	12
26.	Contacting the Procuring Agency	15
F.	Award of Contract	15
27.	Post-Qualification	15
28.	Award Criteria	15
29.	Procuring Agency's Right to Vary Quantities at Time of Award	15
30.	Procuring Agency's Right to Accept Any Bid and To Reject Any or All Bids	16
31.	Notification of Award	16
32.	Signing of Contract	16
33.	Performance Security	16
34.	Corrupt or Fraudulent Practices	16
35.	Integrity Pact	17

Instructions to Bidders

A. Introduction

1. Source of Funds	1.1	The Procuring agency has received/applied for loan/grant/federal/provincial/local government funds from the source(s) indicated in the bidding data in various currencies towards the cost of the project /schemes specified in the bidding data and it is intended that part of the proceeds of this loan/grant/funds/ will be applied to eligible payments under the contract for which these bidding documents are issued.
	1.2	The funds referred to above in addition shall be “Public Fund” which according to 2 (l) of KPP Rules 2014 means (i) Provincial Consolidated Fund; (ii) Foreign assistance; (iii) all moneys standing in the Public Account; and (iv) Funds of enterprises wholly or partly owned or managed or controlled by Government.
	1.3	Payment by the Fund will be made only at the request of the Procuring agency and upon approval by the Government of Khyber Pakhtunkhwa., and in case of a project will be subject in all respect to the terms and conditions of the agreement. The Project Agreement prohibits a withdrawal from the allocated fund account for the purpose of any payment to persons or entities, or for any import of goods, if such payment or import, to the knowledge of the Federal Government/ Khyber Pakhtunkhwa Government, is prohibited by a decision of the United Nations Security Council taken under Chapter VII of the Charter of the United Nations. No party other than the Procuring agency shall derive any rights from the Project Agreement or have any claim to the allocated fund proceeds.
2. Eligible Bidders	2.1	This Invitation for Bids is open to all suppliers from eligible source as defined in the KPP Rules, 2014 and its Bidding Documents except as provided hereinafter.
	2.2	Bidders should not be associated, or have been associated in the past, directly or indirectly, with a firm or any of its affiliates which have been engaged by the Procuring agency to provide consulting services for the preparation of the design, specifications, and other documents to be used for the procurement of the goods to be purchased under this Invitation for Bids.
	2.3	Government-owned enterprises in the Province of Khyber Pakhtunkhwa may participate only if they are legally and financially autonomous, if they operate under commercial law, and if they are not a dependent agency of the Government of Khyber Pakhtunkhwa.
	2.4	Bidders shall not be eligible to bid if they are under a declaration of ineligibility for corrupt and fraudulent practices issued by any government organization in accordance with the Section 44(1) KPP Rules, 2014.
3. Eligible Goods and Services	3.1	All goods and related services to be supplied under the contract shall have their origin in eligible source countries of the world with whom the Islamic Republic of Pakistan has commercial relations and its Bidding Documents and all expenditures made under the contract will be limited to such goods and services.
	3.2	For purposes of this clause, “origin” means the place where the goods are mined, grown, or produced, or the place from which the related services are supplied. Goods are produced when, through manufacturing, processing, or substantial and major assembly of components, a commercially recognized product results that is substantially different in basic characteristics or in purpose or utility from its components.
	3.3	The origin of goods and services is distinct from the nationality of the Bidder.

4. Cost of Bidding	4.1	The Bidder shall bear all costs associated with the preparation and submission of its bid, and the Procuring agency named in the Bid Data Sheet, hereinafter referred to as “the Procuring agency,” will in no case be responsible or liable for those costs, regardless of the conduct or outcome of the bidding process.
B. The Bidding Documents		
5. Content of Bidding Documents	5.1	The bidding documents include: a) Instructions to Bidders (ITB) b) Bid Data Sheet c) General Conditions of Contract (GCC) d) Special Conditions of Contract (SCC) e) Schedule of Requirements f) Technical Specifications g) Bid Form and Price Schedules h) Bid Security Form i) Contract Form j) Performance Security Form k) Manufacturer’s Authorization Form
	5.2	The Bidder is expected to examine all instructions, forms, terms, and specifications in the bidding documents. Failure to furnish all information required by the bidding documents or to submit a bid not substantially responsive to the bidding documents in every respect will be at the Bidder’s risk and may result in the rejection of its bid.
6. Clarification of Bidding Documents	6.1	An interested Bidder requiring any clarification of the bidding documents may notify the Procuring agency in writing. The Bidding Procuring agency will respond in writing to any request for Document’s clarification of the bidding documents which it receives no later than three working days prior to the deadline for the submission of bids prescribed in the Bid Data Sheet. Written copies of the Procuring agency’s response (including an explanation of the query but without identifying the source of inquiry) will be sent to all interested bidders that have received the bidding documents.
7. Amendment of Bidding Documents	7.1	At any time prior to the deadline for submission of bids, the Procuring agency, for any reason, whether at its own initiative or in response to a clarification requested by a interested Bidder, may modify the bidding documents by amendment.
	7.2	All interested bidders that have received the bidding documents will be notified of the amendment in writing and will be binding on them.
	7.3	In order to allow interested bidders reasonable time in which to take the amendment into account in preparing their bids, the Procuring agency, at its discretion, may extend the deadline for the submission of bids.
C. Preparation of Bids		
8. Language of Bid	8.1	The bid prepared by the Bidder, as well as all correspondence and documents relating to the bid exchanged by the Bidder and the Procuring agency shall be written in the language specified in the Bid Data Sheet. Supporting documents and printed literature furnished by the Bidder may be in another language provided they are accompanied by an accurate translation of the relevant passages in the language specified in the Bid Data Sheet, in which case, for purposes of interpretation of the Bid, the translation shall govern.
9. Documents Comprising the Bid	9.1	The bid prepared by the Bidder shall comprise the following components: a) A Bid Form and a Price Schedule completed in accordance with ITB Clauses 10, 11, and 12. b) Documentary evidence established in accordance with ITB Clause 13 that the Bidder is eligible to bid and is qualified to perform the contract if its bid is accepted. c) Documentary evidence established in accordance with ITB Clause 14 that the

		goods and ancillary services to be supplied by the Bidder are eligible goods and services and conform to the bidding documents; and Bid security furnished in accordance with ITB Clause 15.
10. Bid Form	10.1	The Bidder shall complete the Bid Form and the appropriate Price Schedule furnished in the bidding documents, indicating the goods to be supplied, a brief description of the goods, and their country of origin, quantity, and prices.
11. Bid Prices	11.1	The Bidder shall indicate on the appropriate Price Schedule, the unit prices (where applicable) and total bid price of the goods it proposes to supply under the contract.
	11.2	Prices indicated on the Price Schedule shall be Delivered Duty Paid (DDP) prices. The price of other (incidental) services, if any, listed in the Bid Data Sheet will be entered separately.
	11.3	The Bidder's separation of price components in accordance with ITB Clause 11.2 above will be solely for the purpose of facilitating the comparison of bids by the Procuring agency and will not in any way limit the Procuring agency's right to contract on any of the terms offered.
	11.4	Prices quoted by the Bidder shall be fixed during the Bidder's performance of the contract and not subject to variation on any account, unless otherwise specified in the Bid Data Sheet. A bid submitted with an adjustable price quotation will be treated as nonresponsive and will be rejected, pursuant to ITB Clause 24. If, however, in accordance with the Bid Data Sheet, prices quoted by the Bidder shall be subject to adjustment during the performance of the contract, a bid submitted with a fixed price quotation will not be rejected, but the price adjustment would be treated as zero.
12. Bid Currencies	12.1	Prices shall be quoted in Pak Rupees unless otherwise specified in the Bid Data Sheet.
13. Documents Establishing Bidder's Eligibility and Qualification	13.1	Pursuant to ITB Clause 9, the Bidder shall furnish, as part of its bid, documents establishing the Bidder's eligibility to bid and its qualifications to perform the contract if its bid is accepted.
	13.2	The documentary evidence of the Bidder's eligibility to bid shall establish to the Procuring agency's satisfaction that the Bidder, at the time of submission of its bid, is from an eligible country as defined under ITB Clause 3.
	13.3	The documentary evidence of the Bidder's qualifications to perform the contract if its bid is accepted shall establish to the Procuring agency's satisfaction: <ul style="list-style-type: none"> a) that, in the case of a Bidder offering to supply goods under the contract which the Bidder did not manufacture or otherwise produce, the Bidder has been duly authorized by the goods' Manufacturer or producer to supply the goods in the Procuring agency's country. b) that the Bidder has the financial, technical, and production capability necessary to perform the contract. c) that, in the case of a Bidder not doing business within the Procuring agency's country, the Bidder is or will be (if awarded the contract) represented by an Agent in that country equipped, and able to carry out the Supplier's maintenance, repair, and spare parts-stocking obligations prescribed in the Conditions of Contract and/or Technical Specifications; and d) that the Bidder meets the qualification criteria listed in the Bid Data Sheet.
14. Documents Establishing Goods' Eligibility Conformity to Bidding Documents	14.1	Pursuant to ITB Clause 9, the Bidder shall furnish, as part of its bid, documents establishing the eligibility and conformity to the bidding documents of all goods and services which the Bidder proposes to supply under the contract.
	14.2	The documentary evidence of the eligibility of the goods and services shall consist of a statement in the Price Schedule of the country of origin of the goods and services offered which shall be confirmed by a certificate of origin issued at the time of shipment.
	14.3	The documentary evidence of conformity of the goods and services to the bidding documents may be in the form of literature, drawings, and data, and shall consist of:

		<ul style="list-style-type: none"> a) a detailed description of the essential technical and performance characteristics of the goods; b) a list giving full particulars, including available sources and current prices of spare parts, special tools, etc., necessary for the proper and continuing functioning of the goods for a period to be specified in the Bid Data Sheet, following commencement of the use of the goods by the Procuring agency; and c) an item-by-item commentary on the procuring agency's Technical Specifications demonstrating substantial responsiveness of the goods and services to those specifications, or a statement of deviation, and exceptions to the provisions of the Technical Specifications.
	14.4	For purposes of the commentary to be furnished pursuant to ITB Clause 14.3(c) above, the Bidder shall note that standards for workmanship, material, and equipment, as well as references to brand names or catalogue numbers designated by the Procuring agency in its Technical Specifications, are intended to be descriptive only and not restrictive. The Bidder may substitute alternative standards, brand names, and/or catalogue numbers in its bid, provided that it demonstrates to the Procuring agency's satisfaction that the substitutions ensure substantial equivalence to those designated in the Technical Specifications.
15. Bid Security	15.1	Pursuant to ITB Clause 9, the Bidder shall furnish, as part of its bid, a bid security in the amount specified in the Bid Data Sheet.
	15.2	The bid security is required to protect the Procuring agency against the risk of Bidder's conduct which would warrant the security's forfeiture, pursuant to ITB Clause 15.7.
	15.3	<p>The bid security shall be in Pak. Rupees and shall be in one of the following forms:</p> <ul style="list-style-type: none"> a) a bank guarantee or an irrevocable letter of credit issued by a reputable bank located in the Procuring agency's country, in the form provided in the bidding documents or another form acceptable to the Procuring agency and valid for thirty (30) days beyond the validity of the bid; or b) Irrevocable encashable on-demand Bank call-deposit.
	15.4	Any bid not secured in accordance with ITB Clauses 15.1 and 15.3 will be rejected by the Procuring agency as non-responsive, pursuant to ITB Clause 24.
	15.5	Unsuccessful bidders' bid security will be discharged or returned as promptly as possible but not later than thirty (30) days after the expiration of the period of bid validity prescribed by the Procuring agency pursuant to ITB Clause 16.
	15.6	The successful Bidder's bid security will be discharged upon the Bidder signing the contract, pursuant to ITB Clause 32, and furnishing the performance security, pursuant to ITB Clause 33.
	15.7	<p>The bid security may be forfeited:</p> <ul style="list-style-type: none"> a) if a Bidder withdraws its bid during the period of bid validity specified by the Bidder on the Bid Form; or b) in the case of a successful Bidder, if the Bidder fails: <ul style="list-style-type: none"> (i) to sign the contract in accordance with ITB Clause 32; or to furnish performance security in accordance with ITB Clause 33.
16. Period of Validity of Bids	16.1	Bids shall remain valid for the period specified in the Bid Data Sheet after the date of bid opening prescribed by the Procuring agency, pursuant to ITB Clause 19. A bid valid for a shorter period shall be rejected by the Procuring agency as non-responsive.
	16.2	In exceptional circumstances, the Procuring agency may solicit the Bidder's consent to an extension of the period of validity. The request and the responses thereto shall be made in writing. The bid security provided under ITB Clause 15 shall also be suitably extended. A Bidder may refuse the request without forfeiting its bid security. A Bidder granting the request will not be required nor permitted to modify its bid, except as provided in the bidding document.

17. Format and Signing of Bid	17.1	The Bidder shall prepare an original and the number of copies of the bid indicated in the Bid Data Sheet, clearly marking each “ORIGINAL BID” and “COPY OF BID,” as appropriate. In the event of any discrepancy between them, the original shall govern.
	17.2	The original and the copy or copies of the bid shall be typed or written in indelible ink and shall be signed by the Bidder or a person or persons duly authorized to bind the Bidder to the contract. All pages of the bid, except for un-amended printed literature, shall be initialed by the person or persons signing the bid.
	17.3	Any interlineations, erasures, or overwriting shall be valid only if they are initialed by the person or persons signing the bid.
	17.4	The Bidder shall furnish information as described in the Form of Bid on commissions or gratuities, if any, paid or to be paid to agents relating to this Bid, and to contract execution if the Bidder is awarded the contract.
D. Submission of Bids		
18. Sealing and Marking of Bids	18.1	The Bidder shall seal the original and each copy of the bid in separate envelopes, duly marking the envelopes as “ORIGINAL” and “COPY.” The envelopes shall then be sealed in an outer envelope.
	18.2	The inner and outer envelopes shall: a. be addressed to the Procuring agency at the address given in the Bid Data Sheet; and bear the Project name indicated in the Bid Data Sheet, the Invitation for Bids (IFB) title and number indicated in the Bid Data Sheet, and a statement: “DO NOT OPEN BEFORE,” to be completed with the time and the date specified in the Bid Data Sheet, pursuant to ITB Clause 2.2.
	18.3	The inner envelopes shall also indicate the name and address of the Bidder to enable the bid to be returned unopened in case it is declared “late”.
	18.4	If the outer envelope is not sealed and marked as required by ITB Clause 18.2, the Procuring agency will assume no responsibility for the bid’s misplacement or premature opening.
19. Deadline for Submission of Bids	19.1	Bids must be received by the Procuring agency at the address specified under ITB Clause 18.2 no later than the time and date specified in the Bid data sheet.
	19.2	The Procuring agency may, at its discretion, extend this deadline for the submission of bids by amending the bidding documents in accordance with ITB Clause 7, in which case all rights and obligations of the Procuring agency and bidders previously subject to the deadline will thereafter be subject to the deadline as extended.
20. Late Bids	20.1	Any bid received by the Procuring agency after the deadline for submission of bids prescribed by the Procuring agency pursuant to ITB Clause 19 will be rejected and returned unopened to the Bidder.
21. Modification And Withdrawal of Bids	21.1	The Bidder may modify or withdraw its bid after the bid’s submission, provided that written notice of the modification, including substitution or withdrawal of the bids, is received by the Procuring agency prior to the deadline prescribed for submission of bids.
	21.2	The Bidder’s modification or withdrawal notice shall be prepared, sealed, marked, and dispatched in accordance with the provisions of ITB Clause 18. by a signed confirmation copy, postmarked not later than the deadline for submission of bids.
	21.3	No bid may be modified after the deadline for submission of bids.
	21.4	No bid may be withdrawn in the interval between the deadline for submission of bids and the expiration of the period of bid validity specified by the Bidder on the Bid Form. Withdrawal of a bid during this interval may result in the Bidder’s forfeiture of its bid security, pursuant to the ITB Clause 15.7.

		E. Opening and Evaluation of Bids
22. Opening of Bids by the Procuring Agency	22.1	The Procuring agency will open all bids in the presence of bidders' representatives who choose to attend, at the time, on the date, and at the place specified in the Bid Data Sheet. The bidders' representatives who are present shall sign a register evidencing their attendance.
	22.2	The bidders' names, bid modifications or withdrawals, bid prices, discounts, and the presence or absence of requisite bid security and such other details as the Procuring agency, at its discretion, may consider appropriate, will be announced at the opening. No bid shall be rejected at bid opening, except for late bids, which shall be returned unopened to the Bidder pursuant to ITB Clause 20.
	22.3	Bids (and modifications sent pursuant to ITB Clause 21.2) that are not opened and read out at bid opening shall not be considered further for evaluation, irrespective of the circumstances. Withdrawn bids will be returned unopened to the bidders.
	22.4	The Procuring agency will prepare minutes of the bid opening.
23. Clarification of Bids	23.1	During evaluation of the bids, the Procuring agency may, at its discretion, ask the Bidder for a clarification of its bid. The Bids request for clarification and the response shall be in writing, and no change in the prices or substance of the bid shall be sought, offered, or permitted.
24. Preliminary Examination	24.1	The Procuring agency will examine the bids to determine whether they are complete, whether any computational errors have been made, whether required sureties have been furnished, whether the documents have been properly signed, and whether the bids are generally in order.
	24.2	Arithmetical errors will be rectified on the following basis. If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail, and the total price shall be corrected. If the Supplier does not accept the correction of the errors, its bid will be rejected, and its bid security may be forfeited. If there is a discrepancy between words and figures, the amount in words will prevail.
	24.3	The Procuring agency may waive any minor informality, nonconformity, or irregularity in a bid which does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any Bidder.
	24.4	Prior to the detailed evaluation, pursuant to ITB Clause 25 the Procuring agency will determine the substantial responsiveness of each bid to the bidding documents. For purposes of these Clauses, a substantially responsive bid is one which conforms to all the terms and conditions of the bidding documents without material deviations. Deviations from, or objections or reservations to critical provisions, such as those concerning Bid Security (ITB Clause 15), Applicable Law (GCC Clause 30), and Taxes and Duties (GCC Clause 32), will be deemed to be a material deviation. The Procuring agency's determination of a bid's responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence.
	24.5	If a bid is not substantially responsive, it will be rejected by the Procuring agency and may not subsequently be made responsive by the Bidder by correction of the nonconformity.
25. Evaluation and Comparison of Bids	25.1	The Procuring agency will evaluate and compare the bids which have been determined to be substantially responsive, pursuant to ITB Clause 24.
	25.2	The Procuring agency's evaluation of a bid will be on delivered duty paid (DDP) price inclusive of prevailing duties and will exclude any allowance for price adjustment during the period of execution of the contract, if provided in the bid.
	25.3	The Procuring agency's evaluation of a bid will take into account, in addition to the bid price quoted in accordance with ITB Clause 11.2, one or more of the following factors as specified in the Bid Data Sheet, and quantified in ITB

		<p>Clause 25.4:</p> <ul style="list-style-type: none"> a. incidental costs b. delivery schedule offered in the bid; c. deviations in payment schedule from that specified in the Special Conditions of Contract. d. the cost of components, mandatory spare parts, and service; e. the availability Procuring agency of spare parts and after-sales services for the equipment offered in the bid; the projected operating and maintenance costs during the life of the equipment; the performance and productivity of the equipment offered; and/or g. other specific criteria indicated in the Bid Data Sheet and/or In the Technical Specifications.
	25.4	<p>For factors retained in the Bid Data Sheet pursuant to ITB 25.3, one or more of the following quantification methods will be applied, as detailed in the Bid Data Sheet:</p> <ul style="list-style-type: none"> a. Incidental costs provided by the bidder will be added by Procuring agency to the delivered duty paid (DDP) price at the final destination. b. Delivery schedule. <ul style="list-style-type: none"> i The Procuring agency requires that the goods under the Invitation for Bids shall be delivered at the time specified in the Schedule of Requirements which will be treated as the base, a delivery “adjustment” will be calculated for bids by applying a percentage, specified in the Bid Data Sheet, of the DDP price for each week of delay beyond the base, and this will be added to the bid price for evaluation. No credit shall be given to early delivery. or ii. The goods covered under this invitation are required to be delivered (shipped) within an acceptable range of weeks specified in the Schedule of Requirement. No credit will be given to earlier deliveries, and bids offering delivery beyond this range will be treated as non-responsive. Within this acceptable range, an adjustment per week, as specified in the Bid Data Sheet, will be added for evaluation to the bid price of bids offering deliveries later than the earliest delivery period specified in the Schedule of Requirements. or iii. The goods covered under this invitation are required to be delivered in partial shipments, as specified in the Schedule of Requirements. Bids offering deliveries earlier or later than the specified deliveries will be adjusted in the evaluation by adding to the bid price a factor equal to a percentage, specified in the Bid Data Sheet, of DDP price per week of variation from the specified delivery schedule. c. Deviation in payment schedule: <ul style="list-style-type: none"> i Bidders shall state their bid price for the payment schedule outlined in the SCC. Bids will be evaluated on the basis of this base price. Bidders are, however, permitted to state an alternative payment schedule and indicate the reduction in bid price they wish to offer for such alternative payment schedule. The Procuring agency may consider the alternative payment schedule offered by the selected Bidder. or ii. The SCC stipulates the payment schedule offered by the Procuring agency. If a bid deviates from the schedule and if such deviation is considered acceptable to the Procuring agency, the

		<p>bid will be evaluated by calculating interest earned for any earlier payments involved in the terms outlined in the bid as compared with those stipulated in this invitation, at the rate per annum specified in the Bid Data Sheet.</p> <p>d. Cost of spare parts.</p> <p>i. The list of items and quantities of major assemblies, components, and selected spare parts, likely to be required during the initial period of operation specified in the Bid Data Sheet, is annexed to the Technical Specifications. The total cost of these items, at the unit prices quoted in each bid, will be added to the bid price.</p> <p>or</p> <p>ii. The Procuring agency will draw up a list of high- usage and high-value items of components and spare parts, along with estimated quantities of usage in the initial period of operation specified in the Bid Data Sheet. The total cost of these items and quantities will be computed from spare parts unit prices submitted by the Bidder and added to the bid price.</p> <p>or</p> <p>iii. The Procuring agency will estimate the cost of spare parts usage in the initial period of operation specified in the Bid Data Sheet, based on information furnished by each Bidder, as well as on past experience of the Procuring agency or other procuring agencies in similar situations. Such costs shall be added to the bid price for evaluation.</p> <p>e. Spare parts and after sales service facilities in the Procuring agency's country.</p> <p>The cost to the Procuring agency of establishing the minimum service facilities and parts inventories, as outlined in the Bid Data Sheet or elsewhere in the bidding documents, if quoted separately, shall be added to the bid price.</p> <p>f. Operating and maintenance costs.</p> <p>Since the operating and maintenance costs of the goods under procurement form a major part of the life cycle cost of the equipment, these costs will be evaluated in accordance with the criteria specified in the Bid Data Sheet or in the Technical Specifications.</p> <p>g. Performance and productivity of the equipment.</p> <p>i. Bidders shall state the guaranteed performance or efficiency in response to the Technical Specification. For each drop in the performance or efficiency below the norm of 100, an adjustment for an amount specified in the Bid Data Sheet will be added to the bid price, representing the capitalized cost of additional operating costs over the life of the plant, using the methodology specified in the Bid Data Sheet or in the Technical Specifications. or</p> <p>ii. Goods offered shall have a minimum productivity specified under the relevant provision in the Technical Specifications to be considered responsive. Evaluation shall be based on the cost per unit of the actual productivity of goods offered in the bid, and adjustment will be added to the bid price using the methodology specified in the Bid Data Sheet or in the Technical Specifications.</p> <p>h. Specific additional criteria indicated in the Bid Data Sheet and/or in the Technical Specifications.</p> <p>The relevant evaluation method shall be detailed in the Bid Data Sheet and/or in the Technical Specifications</p>
--	--	--

Alternative	25.4	25.4 Merit Point System:
		The following merit point system for weighing evaluation factors can be applied if none of the evaluation methods listed in 25.4 above has been retained in the Bid Data Sheet. The number of points allocated to each factor shall be specified in the Bid Data Sheet.
		[In the Bid Data Sheet, choose from the range of]
		Evaluated price of the goods 60 to 90
		Cost of common list spare parts 0 to 20
		Technical features, and maintenance and operating costs 0 to 20
		Availability of service and spare parts 0 to 20
		Standardization 0 to 20
		Total 100
		The bid scoring the highest number of points will be deemed to be the lowest evaluated bid.
26. Contacting the Procuring Agency	26.1	Subject to ITB Clause 23, no Bidder shall contact the Procuring agency on any matter relating to its bid, from the time of the bid opening to the time the contract is awarded. If the Bidder wishes to bring additional information to the notice of the Procuring agency, it should do so in writing.
	26.2	Any effort by a Bidder to influence the Procuring agency in its decisions on bid evaluation, bid comparison, or contract award may result in the rejection of the Bidder's bid.
F. Award of Contract		
27. Post- qualification	27.1	In the absence of prequalification, the Procuring agency will determine to its satisfaction whether the Bidder that is selected as having submitted the lowest evaluated responsive bid is qualified to perform the contract satisfactorily, in accordance with the criteria listed in ITB Clause 13.3.
	27.2	The determination will take into account the Bidder's financial, technical, and production capabilities. It will be based upon an examination of the documentary evidence of the Bidder's qualifications submitted by the Bidder, pursuant to ITB Clause 13.3, as well as such other information as the Procuring agency deems necessary and appropriate.
	27.3	An affirmative determination will be a prerequisite for award of the contract to the Bidder. A negative determination will result in rejection of the Bidder's bid, in which event the Procuring agency will proceed to the next lowest evaluated bid to make a similar determination of that Bidder's capabilities to perform satisfactorily.
28. Award Criteria	28.1	Subject to ITB Clause 30, the Procuring agency will award the contract to the successful Bidder whose bid has been determined to be substantially responsive and has been determined to be the lowest evaluated bid, provided further that the Bidder is determined to be qualified to perform the contract satisfactorily.
29. Procuring agency's Right to Vary Quantities at Time of Award	29.1	The Procuring agency reserves the right at the time of contract award to increase or decrease, by the percentage indicated in the Bid Data Sheet, the quantity of goods and services originally specified in the Schedule of Requirements without any change in unit price or other terms and conditions.

30. Procuring agency's Right to Accept any Bid and to Reject any or All Bids	30.1	The Procuring agency reserves the right to accept or reject any bid, and to annul the bidding process and reject all bids at any time prior to contract award, without thereby incurring any liability to the affected Bidder or bidders or any obligation to inform the affected Bidder or bidders of the grounds for the Procuring agency's action.
31. Notification of Award	31.1	Prior to the expiration of the period of bid validity, the Procuring agency will notify the successful Bidder in writing by registered letter or by cable, to be confirmed in writing by registered letter, that its bid has been accepted.
	31.2	The notification of award will constitute the formation of the Contract.
	31.3	Upon the successful Bidder's furnishing of the performance security pursuant to ITB Clause 33, the Procuring agency will promptly notify each unsuccessful Bidder and will discharge its bid security, pursuant to ITB Clause 15.
32. Signing of Contract	32.1	At the same time as the Procuring agency notifies the successful Bidder that its bid has been accepted, the Procuring agency will send the Bidder the Contract Form provided in the bidding documents, incorporating all agreements between the parties.
	32.2	Within thirty (30) days of receipt of the Contract Form, the successful Bidder shall sign and date the contract and return it to the Procuring agency.
33 Performance Security	33.1	Within twenty (20) days of the receipt of notification of award from the Procuring agency, the successful Bidder shall furnish the performance security in accordance with the Conditions of Contract, in the Performance Security Form provided in the bidding documents, or in another form acceptable to the Procuring agency.
	33.2	Failure of the successful Bidder to comply with the requirement of ITB Clause 32 or ITB Clause 33.1 shall constitute sufficient grounds for the annulment of the award and forfeiture of the bid security, in which event the Procuring agency may make the award to the next lowest evaluated Bidder or call for new bids.
34. Corrupt or Fraudulent Practices	34.1	<p>The Government of Khyber Pakhtunkhwa requires that Procuring agency's (including beneficiaries of donor agencies' loans), as well as Bidders/Suppliers/Contractors under Government-financed contracts, observe the highest standard of ethics during the procurement and execution of such contracts. In pursuance of this policy, the KPPRA, in accordance with the KPP Act, 2009 and Rules made thereunder:</p> <ol style="list-style-type: none"> defines, for the purposes of this provision, the terms set forth below as follows: <ol style="list-style-type: none"> "corrupt practice" means the offering, giving, receiving or soliciting of anything of value to influence the action of a public official in the procurement process or in contract execution; and "fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Procuring agency, and includes collusive practice among Bidders (prior to or after bid submission) designed to establish bid prices at artificial non-competitive levels and to deprive the Procuring agency of the benefits of free and open competition; will reject a proposal for award if it determines that the Bidder recommended for award has engaged in corrupt or fraudulent practices in competing for the contract in question; will declare a firm ineligible, either indefinitely or for a stated period of time, to be awarded a Government-financed contract if it at any time determines that the firm has engaged in corrupt or fraudulent practices in competing for, or in executing, a Government-financed contract.

	34.2	Furthermore, Bidders shall be aware of the provision stated in sub-clause 5.4 and sub-clause 24.1 of the General Conditions of Contract.
35. Integrity Pact	35.1	The Bidder shall sign and stamp the Integrity Pact provided at Form - 7 to Bid in the Bidding Document for all Provincial Government procurement contracts exceeding Rupees ten million. Failure to such Integrity Pact shall make the bidder non-responsive.

Part One - Section II.

General Conditions of Contract

Notes on the General Conditions of Contract (GCC)

The General Conditions of Contract in Part One Section II, read in conjunction with the Special Conditions of Contract in Part Two Section III and other documents listed therein, should be a complete document expressing all the rights and obligations of the parties.

The General Conditions of Contract herein shall not be altered. Any changes and complementary information, which may be needed, shall be introduced only through the Special Conditions of Contract in Part Two Section III.

Table of Clauses

1.	Definitions	21
2.	Application	21
3.	Country of Origin	21
4.	Standards	21
5.	Use of Contract Documents and Information, Inspection and Audit by the Bank	21
6.	Patent Rights	22
7.	Performance Security	22
8.	Inspections and Tests	22
9.	Packing	23
10.	Delivery and Documents	23
11.	Insurance	23
12.	Transportation	23
13.	Incidental Services	23
14.	Spare Parts	23
15.	Warranty	24
16.	Payment	24
17.	Prices	24
18.	Change Orders	24
19.	Contract Amendments	25
20.	Assignment	25
21.	Subcontracts	25
22.	Delays in the Supplier's Performance	25
23.	Liquidated Damages	25
24.	Termination for Default	26
25.	Force Majeure	26
26.	Termination for Insolvency	26
27.	Termination for Convenience	27
28.	Resolution of Disputes	27
29.	Governing Language	27
30.	Applicable Law	27
31.	Notices	27
32.	Taxes and Duties	27

General Conditions of Contract

1. Definitions	1.1	<p>In this Contract, the following terms shall be interpreted as indicated:</p> <ul style="list-style-type: none"> a. “The Contract” means the agreement entered into between the Procuring agency and the Supplier, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein. b. “The Contract Price” means the price payable to the Supplier under the Contract for the full and proper performance of its contractual obligations. c. “The Goods” means all of the equipment, machinery, and/or other materials which the Supplier is required to supply to the Procuring agency under the Contract. d. “The Services” means those services ancillary to the supply of the Goods, such as transportation and insurance, and any other incidental services, such as installation, commissioning, provision of technical assistance, training, and other such obligations of the Supplier covered under the Contract. e. “GCC” means the General Conditions of Contract contained in this section. f. “SCC” means the Special Conditions of Contract. g. “The Procuring agency” means the organization purchasing the Goods, as named in SCC. h. “The Procuring agency’s country” is the country named in SCC. i. “The Supplier” means the individual or firm supplying the Goods and Services under this Contract. j. “The Project Site,” where applicable, means the place or places named in SCC. k. “Day” means calendar day.
2. Application	2.1	These General Conditions shall apply to the extent that they are not superseded by provisions of other parts of the Contract.
3. Country of Origin	3.1	All Goods and Services supplied under the Contract shall have their origin in the countries and territories eligible under the rules and further elaborated in the SCC.
	3.2	For purposes of this Clause, “origin” means the place where the Goods were mined, grown, or produced, or from which the Services are supplied. Goods are produced when, through manufacturing, processing, or substantial and major assembly of components, a commercially recognized new product results that is substantially different in basic characteristics or in purpose or utility from its components.
	3.3	The origin of Goods and Services is distinct from the nationality of the Supplier.
4. Standards	4.1	The Goods supplied under this Contract shall conform to the standards mentioned in the Technical Specifications, and, when no applicable standard is mentioned, to the authoritative standards appropriate to the Goods’ country of origin. Such standards shall be the latest issued by the concerned institution.
5. Use of Contract	5.1	The Supplier shall not, without the Procuring agency’s prior written consent, disclose the Contract, or any provision thereof, or any specification, plan,

Documents and Information; Inspection and Audit by the Government		drawing, pattern, sample, or information furnished by or on behalf of the Procuring agency in connection therewith, to any person other than a person employed by the Supplier in the performance of the Contract. Disclosure to any such employed person shall be made in confidence and shall extend only so far as may be necessary for purposes of such performance.
	5.2	The Supplier shall not, without the Procuring agency's prior written consent, make use of any document or information enumerated in GCC Clause 5.1 except for purposes of performing the Contract.
	5.3	Any document, other than the Contract itself, enumerated in GCC Clause 5.1 shall remain the property of the Procuring agency and shall be returned (all copies) to the Procuring agency on completion of the Supplier's performance under the Contract if so required by the Procuring agency.
	5.4	The Supplier shall permit the Procuring agency to inspect the Supplier's accounts and records relating to the performance of the Supplier and to have them audited by auditors appointed by the procuring agency, if so required.
6. Patent Rights	6.1	The Supplier shall indemnify the Procuring agency against all third- party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof in the Procuring agency's country.
7. Performance Security	7.1	Within twenty (20) days of receipt of the notification of Contract award, the successful Bidder shall furnish to the Procuring agency the performance security in the amount specified in SCC.
	7.2	The proceeds of the performance security shall be payable to the Procuring agency as compensation for any loss resulting from the Supplier's failure to complete its obligations under the Contract.
	7.3	The performance security shall be denominated in the currency of the Contract acceptable to the Procuring agency and shall be in one of the following forms: <ul style="list-style-type: none"> a. a bank guarantee or an irrevocable letter of credit issued by a reputable bank located in the Procuring agency's country, in the form provided in the bidding documents or another form acceptable to the Procuring agency; or b. a cashier's or certified check
	7.4	The performance security will be discharged by the Procuring agency and returned to the Supplier not later than thirty (30) days following the date of completion of the Supplier's performance obligations under the Contract, including any warranty obligations, unless specified otherwise in SCC.
8. Inspections and Tests	8.1	The Procuring agency or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Contract specifications at no extra cost to the Procuring agency. SCC and the Technical Specifications shall specify what inspections and tests the Procuring agency requires and where they are to be conducted. The Procuring agency shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.
	8.2	The inspections and tests may be conducted on the premises of the Supplier or its subcontractor(s), at point of delivery, and/or at the Goods' final destination. If conducted on the premises of the Supplier or its subcontractor(s), all reasonable facilities and assistance, including access to drawings and production data, shall be furnished to the inspectors at no charge to the Procuring agency.
	8.3	Should any inspected or tested Goods fail to conform to the Specifications, the Procuring agency may reject the Goods, and the Supplier shall either replace the rejected Goods or make alterations necessary to meet specification requirements free of cost to the Procuring agency.

	8.4	The Procuring agency's right to inspect, test and, where necessary, reject the Goods after the Goods' arrival in the Procuring agency's country shall in no way be limited or waived by reason of the Goods having previously been inspected, tested, and passed by the Procuring agency or its representative prior to the Goods' shipment from the country of origin.
	8.5	Nothing in GCC Clause 8 shall in any way release the Supplier from any warranty or other obligations under this Contract.
9. Packing	9.1	The Supplier shall provide such packing of the Goods as is required to prevent their damage or deterioration during transit to their destination, as indicated in the Contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packing case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' destination and the absence of heavy handling facilities at all points in transit.
	9.2	The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified in SCC, and in any subsequent Instructions ordered by the Procuring agency.
10. Delivery and Documents	10.1	Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in the Schedule of Requirements. The details of shipping and/or other documents to be furnished by the Supplier are specified in SCC.
	10.2	Documents to be submitted by the Supplier are specified in SCC.
11. Insurance	11.1	The Goods supplied under the Contract shall be delivered duty paid (DDP) under which risk is transferred to the buyer after having been delivered; hence insurance coverage is seller's responsibility.
12. Transportation	12.1	The Supplier is required under the Contract to transport the Goods to a specified place of destination within the Procuring agency's country, transport to such place of destination in the Procuring agency's country, including insurance and storage, as shall be specified in the Contract, shall be arranged by the Supplier, and related costs shall be included in the Contract Price.
13. Incidental Services	13.1	The Supplier may be required to provide any or all of the following services, including additional services, if any, specified in SCC: <ul style="list-style-type: none"> a. performance or supervision of on-site assembly and/or start-up of the supplied Goods; b. furnishing of tools required for assembly and / or maintenance of the supplied Goods; c. furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied Goods; d. performance or supervision or maintenance and/or repair of the supplied Goods, for a period of time agreed by the parties, provided that this service shall not relieve the Supplier of any warranty obligations under this Contract; and e. training of the Procuring agency's personnel, at the Supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied Goods.
	13.2	Prices charged by the Supplier for incidental services, if not included in the Contract Price for the Goods, shall be agreed upon in advance by the parties and shall not exceed the prevailing rates charged for other parties by the Supplier for similar services.
14. Spare Parts	14.1	As specified in SCC, the Supplier may be required to provide any or all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the Supplier:

		<p>a. such spare parts as the Procuring agency may elect to purchase from the Supplier, provided that this election shall not relieve the Supplier of any warranty obligations under the Contract; and</p> <p>b. in the event of termination of production of the spare parts:</p> <p>i. advance notification to the Procuring agency of the pending termination, in sufficient time to permit the Procuring agency to procure needed requirements;</p> <p>ii. Following such termination, furnishing at no cost to the Procuring agency, the blueprints, drawings, and specifications of the spare parts, if requested.</p>
15. Warranty	15.1	The Supplier warrants that the Goods supplied under the Contract are new, unused, of the most recent or current models, and that they incorporate all recent improvements in design and materials unless provided otherwise in the Contract. The Supplier further warrants that all Goods supplied under this Contract shall have no defect, arising from design, materials, or workmanship (except when the design and/or material is required by the Procuring agency's specifications) or from any act or omission of the Supplier, that may develop under normal use of the supplied Goods in the conditions prevailing in the country of final destination.
	15.2	This warranty shall remain valid for twelve (12) months after the Goods, or any portion thereof as the case may be, have been delivered to and accepted at the final destination indicated in the Contract, or for eighteen (18) months after the date of shipment from the port or place of loading in the source country, whichever period concludes earlier, unless specified otherwise in SCC.
	15.3	The Procuring agency shall promptly notify the Supplier in writing of any claims arising under this warranty.
	15.4	Upon receipt of such notice, the Supplier shall, within the period specified in SCC and with all reasonable speed, repair or replace the defective Goods or parts thereof, without costs to the Procuring agency.
	15.5	If the Supplier, having been notified, fails to remedy the defect(s) within the period specified in SCC, within a reasonable period, the Procuring agency may proceed to take such remedial action as may be necessary, at the Supplier's risk and expense and without prejudice to any other rights which the Procuring agency may have against the Supplier under the Contract.
16. Payment	16.1	The method and conditions of payment to be made to the Supplier under this Contract shall be specified in SCC.
	16.2	The Supplier's request(s) for payment shall be made to the Procuring agency in writing, accompanied by an invoice describing, as appropriate, the Goods delivered and Services performed, and by documents submitted pursuant to GCC Clause 10, and upon fulfillment of other obligations stipulated in the Contract.
	16.3	Payments shall be made promptly by the Procuring agency, but in no case later than Ninety (90) days after submission of an invoice or claim by the Supplier.
	16.4	The currency of payment is Pak. Rupees.
17. Prices	17.1	Prices charged by the Supplier for Goods delivered and Services performed under the Contract shall not vary from the prices quoted by the Supplier in its bid, with the exception of any price adjustments authorized in SCC or in the Procuring agency's request for bid validity extension, as the case may be.
18. Change Orders	18.1	The Procuring agency may at any time, by a written order given to the Supplier pursuant to GCC Clause 31, make changes within the general scope of the Contract in any one or more of the following:

		<ul style="list-style-type: none"> a drawings, designs, or specifications, where Goods to be furnished under the Contract are to be specifically manufactured for the Procuring agency; b the method of shipment or packing; c the place of delivery; and/or d the Services to be provided by the Supplier.
	18.2	If any such change causes an increase or decrease in the cost of, or the time required for, the Supplier's performance of any provisions under the Contract, an equitable adjustment shall be made in the Contract Price or delivery schedule, or both, and the Contract shall accordingly be amended. Any claims by the Supplier for adjustment under this clause must be asserted within thirty (30) days from the date of the Supplier's receipt of the Procuring agency's change order.
19. Contract Amendments	19.1	Subject to GCC Clause 18, no variation in or modification of the terms of the Contract shall be made except by written amendment signed by the parties.
20. Assignment	20.1	The Supplier shall not assign, in whole or in part, its obligations to perform under this Contract, except with the Procuring agency's prior written consent.
21. Subcontracts	21.1	The Supplier shall notify the Procuring agency in writing of all subcontracts awarded under this Contract if not already specified in the bid. Such notification, in the original bid or later, shall not relieve the Supplier from any liability or obligation under the Contract.
	21.2	Subcontracts must comply with the provisions of GCC Clause 3.
22. Delays in the Supplier's Performance	22.1	Delivery of the Goods and performance of Services shall be made by the Supplier in accordance with the time schedule prescribed by the Procuring agency in the Schedule of Requirements.
	22.2	If at any time during performance of the Contract, the Supplier or its subcontractor(s) should encounter conditions impeding timely delivery of the Goods and performance of Services, the Supplier shall promptly notify the Procuring agency in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable after receipt of the Supplier's notice, the Procuring agency shall evaluate the situation and may at its discretion extend the Supplier's time for performance, with or without liquidated damages, in which case the extension shall be ratified by the parties by amendment of Contract.
	22.3	Except as provided under GCC Clause 25, a delay by the Supplier in the performance of its delivery obligations shall render the Supplier liable to the imposition of liquidated damages pursuant to GCC Clause 23, unless an extension of time is agreed upon pursuant to GCC Clause 22.2 without the application of liquidated damages.
23. Liquidated Damages	23.1	Subject to GCC Clause 25, if the Supplier fails to deliver any or all of the Goods or to perform the Services within the period(s) specified in the Contract, the Procuring agency shall, without prejudice to its other remedies under the Contract, deduct from the Contract Price, as liquidated damages, a sum equivalent to the percentage specified in SCC of the delivered price of the delayed Goods or unperformed Services for each week or part thereof of delay until actual delivery or performance, up to a maximum deduction of the percentage specified in SCC. Once the maximum is reached, the Procuring agency may consider termination of the Contract pursuant to GCC Clause 24.
24. Termination for Default	24.1	<p>The Procuring agency, without prejudice to any other remedy for breach of Contract, by written notice of default sent to the Supplier, may terminate this Contract in whole or in part:</p> <ul style="list-style-type: none"> a if the Supplier fails to deliver any or all of the Goods within the period(s) specified in the Contract, or within any extension thereof granted by the

		<p>Procuring agency pursuant to GCC Clause 22; or</p> <p>b. if the Supplier fails to perform any other obligation(s) under the Contract.</p> <p>c. if the Supplier, in the judgment of the Procuring agency has engaged in corrupt or fraudulent practices in competing for or in executing the Contract.</p> <p>For the purpose of this clause: “corrupt practice” means the offering, giving, receiving or soliciting of anything of value to influence the action of a public official in the procurement process or in contract execution.</p> <p>“fraudulent practice” means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Borrower, and includes collusive practice among Bidders (prior to or after bid submission) designed to establish bid prices at artificial non-competitive levels and to deprive the Borrower of the benefits of free and open competition.</p>
	24.2	In the event the Procuring agency terminates the Contract in whole or in part, pursuant to GCC Clause 24.1, the Procuring agency may procure, upon such terms and in such manner as it deems appropriate, Goods or Services similar to those undelivered, and the Supplier shall be liable to the Procuring agency for any excess costs for such similar Goods or Services. However, the Supplier shall continue performance of the Contract to the extent not terminated.
25. Force Majeure	25.1	Notwithstanding the provisions of GCC Clauses 22, 23, and 24, the Supplier shall not be liable for forfeiture of its performance security, liquidated damages, or termination for default if and to the extent that its delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure.
	25.2	For purposes of this clause, “Force Majeure” means an event beyond the control of the Supplier and not involving the Supplier’s fault or negligence and not foreseeable. Such events may include, but are not restricted to, acts of the Procuring agency in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight embargoes.
	25.3	If a Force Majeure situation arises, the Supplier shall promptly notify the Procuring agency in writing of such condition and the cause thereof. Unless otherwise directed by the Procuring agency in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.
26. Termination for Insolvency	26.1	The Procuring agency may at any time terminate the Contract by giving written notice to the Supplier if the Supplier becomes bankrupt or otherwise insolvent. In this event, termination will be without compensation to the Supplier, provided that such termination will not prejudice or affect any right of action or remedy which has accrued or will accrue thereafter to the Procuring agency.
27. Termination for Convenience	27.1	The Procuring agency, by written notice sent to the Supplier, may terminate the Contract, in whole or in part, at any time for its convenience. The notice of termination shall specify that termination is for the Procuring agency’s convenience, the extent to which performance of the Supplier under the Contract is terminated, and the date upon which such termination becomes effective.
	27.2	The Goods that are complete and ready for shipment within thirty (30) days

		<p>after the Supplier's receipt of notice of termination shall be accepted by the Procuring agency at the Contract terms and prices. For the remaining Goods, the Procuring agency may elect:</p> <ol style="list-style-type: none"> a. to have any portion completed and delivered at the Contract terms and prices; and/or b. to cancel the remainder and pay to the Supplier an agreed amount for partially completed Goods and Services and for materials and parts previously procured by the Supplier.
28. Resolution of Disputes	28.1	The Procuring agency and the Supplier shall make every effort to resolve amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the Contract.
	28.2	If, after thirty (30) days from the commencement of such informal negotiations, the Procuring agency and the Supplier have been unable to resolve amicably a Contract dispute, either party may require that the dispute be referred for resolution to the formal mechanisms specified in SCC. These mechanisms may include, but are not restricted to, conciliation mediated by a third party, adjudication in an agreed manner and/or arbitration.
29. Governing Language	29.1	The Contract shall be written in the language specified in SCC. Subject to GCC Clause 30, the version of the Contract written in the specified language shall govern its interpretation. All correspondence and other documents pertaining to the Contract which are exchanged by the parties shall be written in the same language.
30. Applicable Law	30.1	The Contract shall be interpreted in accordance with the laws of the Procuring agency's country, unless otherwise specified in SCC.
31. Notices	31.1	Any notice given by one party to the other pursuant to this Contract shall be sent to the other party in writing or by cable, telex, or facsimile and confirmed in writing to the other party's address specified in SCC.
	31.2	A notice shall be effective when delivered or on the notice's effective date, whichever is later.
32. Taxes and Duties	32.1	Supplier shall be entirely responsible for all taxes, duties, license fees, etc., incurred until delivery of the contracted Goods to the Procuring agency.



Government of Khyber Pakhtunkhwa

Health Department

Directorate General Health Services

Khyber Pakhtunkhwa Peshawar

Bid Solicitation Documents

REVISED AFTER PRE-BID

**For National Competitive Bidding
Pakistan**

For

**SELECTION AND RATE CONTRACTING OF DRUGS / MEDICINES,
MEDICAL DEVICES, SURGICAL DISPOSABLES &
NON-DRUG ITEMS**

FOR THE FINANCIAL YEARS 2026-27

MEDICINE COORDINATION CELL (MCC)

FEBRUARY 2026

PART TWO (PROCUREMENT SPECIFIC PROVISIONS)

- Invitation for Bids (IFB)
- Bid Data Sheet (BDS)
- Special Conditions of Contract (SCC)
- Schedule of Requirements
- Technical Specifications
- Sample Forms
- Eligibility

Preface

These Bidding Documents have been prepared for use by procuring agencies in the procurement of goods through National Competitive Bidding (NCB).

In order to simplify the preparation of bidding documents for each procurement, the Bidding Documents are grouped in two parts based on provisions which are fixed and that which are specific for each procurement. Provisions which are intended to be used unchanged are in Part one, which includes Section I, Instructions to Bidders, and Section II, General Conditions of Contract. Data and provisions specific to each procurement and contract are included in Part Two which includes Section II, Bid Data Sheet; Section III, Special Conditions of Contract; Section IV, Schedule of Requirements; Section V, Technical Specifications; and the forms to be used in Section I, Invitation for Bids, and Section VI, Sample Forms.

This is Part Two and contains data and provisions specific to each procurement. Care should be taken to check the relevance of the provisions of the Bidding Documents against the requirements of the specific goods to be procured. The following general directions should be observed when using the documents. In addition, each section is prepared with notes intended only as information for the Procuring agency or the person drafting the bidding documents. They shall not be included in the final documents, except for the notes introducing Section VI, Forms, where the information is useful for the Bidder.

- a. Specific details, such as the “name of the Procuring agency” and “address for bid submission,” should be furnished in the Invitation for Bids, in the Bid Data Sheet, and in the Special Conditions of Contract. The final documents should contain neither blank spaces nor options.
- b. Amendments, if any, to the Instructions to Bidders and to the General Conditions of Contract should be made through the Bid Data Sheet and the Special Conditions of Contract, respectively.
- c. Footnotes or notes in italics included in the Invitation for Bids, Bid Data Sheet, Special Conditions of Contract, and in the Schedule of Requirements are not part of the text of the document, although they contain instructions that the Procuring agency should strictly follow. The final document should contain no footnotes.
- d. The criteria for bid evaluation and the various methods of evaluation in the Instructions to Bidders (Clauses 25.3 and 25.4, respectively) should be carefully reviewed. Only those that are selected to be used for the procurement in question should be retained and expanded, as required, in the Bid Data Sheet or in the Technical Specifications, as appropriate. The criteria that are not applicable should be deleted from the Bid Data Sheet.
- e. Clauses included in the Special Conditions of Contract are illustrative of the provisions that should be drafted specifically by the Procuring agency for each procurement.
- f. The forms provided in Section VI should be completed by the Bidder or the Supplier; the footnotes in these forms should remain, since they contain instructions which the Bidder or the Supplier should follow.

PART TWO (CHANGEABLE PART)

- Table of Contents

Contents	Page No.
Section I. Invitation for Bids	33-35
Section II. Bid Data Sheet	36-38
Section III. Special Conditions of Contract	39
Table of clauses	40
Special Conditions of Contract	41-45
Section IV. Schedule of Requirements (SOR)	46-99
List of Abbreviations	100
Section V. Technical Specifications	101-119
Section VI. Sample Forms	120
1. Bid Cover Sheet Bid Form-1	138-141
2. Letter of Intention Bid Form- 2	142
3. Affidavit Bid Form-3	143
4. Integrity Pact Bid Form-4	144
5. Technical Proposal Format Bid Form -5	145
6. Financial Proposal Format Bid Form-6	146
7. Bank Guarantee Bid Form-7	147
8. MCC Rate Contract Agreement Bid Form-8	148-154
9. Declaration/Code of Ethics Form-9	155-156
10. Physical Inspection Report for MCC approved items in Health Facilities of Khyber Pakhtunkhwa Bid Form-10	157
11. Bid Form-11 (for use of End User Consultants)	158

Part Two

Section I. Invitation for Bids

Notes on the Invitation for Bids

The Invitation for Bids (IFB) has been issued as an advertisement in leading newspapers of general circulation in the Province of Khyber Pakhtunkhwa as well as on the web site of the Khyber Pakhtunkhwa Public Procurement Regulatory Authority (KPPRA) (www.kppra.gov.pk), Health Department (www.healthkp.gov.pk) and (www.dghskp.gov.pk) by allowing at least fifteen days for NCB for bid preparation and submission.

The Invitation for Bids provides information that enables interested bidders to decide whether to participate. Apart from the essential items listed in the Bid Solicitation Documents (BSD), the Invitation for Bids also indicates the important bid evaluation criteria or qualification requirement (for example, a requirement for a minimum level of experience in manufacturing a similar type of goods for which the Invitation for Bids is issued) so that the bidders should give their best and final prices. For negotiation on price, KPPRA amendments notification No. SO (A)/FD/1-40/2022, KPPRA Rules 2014, dated 17-08-2022 will be followed, when required.

The Invitation for Bids is incorporated into these Bid Solicitation Documents (BSDs). The information contained in the Invitation for Bids (IFB) conforms to the bidding documents and in particular to the relevant information in the Bid Data Sheet.

INVITATION FOR BIDS THROUGH EPADS

GOVERNMENT MEDICINE COORDINATION CELL, DIRECTORATE GENERAL HEALTH SERVICES, KHYBER PAKHTUNKHWA, PESHAWAR

SELECTION AND RATE CONTRACTING (CONTRACT FRAMEWORK AGREEMENT) OF DRUGS / MEDICINES, MEDICAL DEVICES, SURGICAL DISPOSABLES & NON-DRUG ITEMS FOR THE FY 2026-27

1. In compliance with the Khyber Pakhtunkhwa Public Procurement Regulatory Authority (KPPRA) Act, 2012 and KPPRA Rules, 2014, Government Medicine Coordination Cell (Govt. MCC), Directorate General Health Services (DGHS), Khyber Pakhtunkhwa, Warsak Road, Peshawar invites bids through **E-Pak Acquisition and Disposal (EPADS) System (<https://kp.eprocure.gov.pk/>)**, from:
 - (i) Manufacturer/s and/or Importer/s of drugs/medicines authorized by the goods' Principal Manufacturer or producer for import/supply of the said quoted goods in Pakistan, registered as such with the Drug Regulatory Authority of Pakistan (DRAP) for the quoted item/s falling under The Drug Act 1976 & Rules framed there under; and
 - (ii) Manufacturer/s of Medical Devices in Pakistan, registered as such with the DRAP for the quoted item/s and regulated under the DRAP Act 2012 and the Rules framed thereunder; and
 - (iii) Importer/s and/or Indenter/s of Medical Devices, duly authorized by the goods Principal Manufacturer or producer to import / supply the said goods in Pakistan, as registered and regulated as such for the quoted item/s under the DRAP Act 2012 and Rules framed thereunder; and
 - (iv) Manufacturer/s of Non-Drug Items (NDIs) in Pakistan; and
 - (v) Importer/s and/or Indenter/s of NDIs, duly authorized by the goods' Principal Manufacturer or producer for import / supply of the said quoted goods in Pakistan.
2. Manufacturer/s and/or Importer/s and/or Indenter/s of various items interested to enter in this bidding competition must obtain a separate application form @ non-refundable cash payment of PKR 5000/- per category, under Rule 36 (2) of the KPPRA Rules 2014, from the office of the Director Govt. MCC, Directorate General Drug Control & Pharmacy Services (DG, DC&PS), 2nd Floor Block-B, Old FATA Secretariat, Warsak Road Peshawar on any working day on or before **(05:00 PM) Monday, 16th February 2026**. No Application Form shall be issued after **05:00 PM, Monday, 16th February 2026**.
3. The bidder must attach the original tender receipt of PKR 5000/- on the top of its technical bid submitted through the EPADS.
4. Bidding competition under this advertisement shall be conducted through **Single Stage–Two Envelopes Bidding Procedure** as per KPPRA Act 2012 and Rules framed there under. Under this procedure, the bidders

shall submit the technical & financial bid through EPADS and must ensure that the scanned bids uploaded through the EPADS are **clear & easy to read**.

5. The Mandatory Bid Security / Earnest Money amounting to a flat rate of **Rupees Ten Hundred Thousand only (Rs.10,00,000/-)** from the account of the firm/ manufacturer/importer/indenter, in the shape of **Call Deposit Receipt (CDR)/ Bank Guarantee** in the name of the **Director General Health Services, Khyber Pakhtunkhwa** is required to be submitted in original in a sealed envelope on the day of bid opening (**Tuesday, 17th February 2026**), and must bear the Full & complete identification of the bidder along with its postal, email address & contact number. **Ordinary, crossed or open Cheques shall not be acceptable as Bid's security.**
6. A scanned copy of the Bid Security should be uploaded with the **Original Financial Bid** through EPADS.
7. All the bidders in this bidding competition shall submit their bids on the standard formats/ mandatory bid forms for technical & financial proposals in the bidding documents.
8. The Bid Solicitation Documents (BSDs) for this bidding competition may be downloaded from the **www.kppra.gov.pk, www.healthkp.gov.pk and <https://portalkp.eprocure.gov.pk/#/>**
9. A Pre bid meeting is scheduled to be held on **Tuesday 27th January 2026 (10:00 AM)**, at the Committee room of Directorate General Health Services, Khyber Pakhtunkhwa, Warsak Road Peshawar in the following groups: **Manufacturer & Importers**. The bidders shall thoroughly study the BSDs before the Pre-Bid meeting and bring their query(ies) / suggestion(s) to the forum for clarification and the same shall be submitted through the official email of the Govt. MCC { **mccdgdcps@gmail.com** } on or before **Friday 23rd January 2026**.
10. Quotation must be computer typed & printed; the Offered rate, Trade Price (TP) and Maximum Retail Price (MRP) must be written both in words & figures. All pages of the submitted bid shall be signed, numbered, and duly stamped by the authorized person of the bidding entity as mentioned in the BSDs.
11. The bidders shall not quote the offered prices more than the trade price of individual quoted item/s. Bidders are required and encouraged to offer the most competitive lowest price/s of their quoted item/s.
12. Quotations with cutting, erasing, and over-writing shall not be accepted to the extent of that particular quoted item.
13. To facilitate the bid evaluation, bidders must submit the quoted product list/ technical offer on the prescribed schedule in MS Excel through official email of the Govt. MCC before the closing date.
14. Bids will be opened by the Technical & Evaluation Committee of Government MCC at **11:00 AM (Sharp)** on **Tuesday, 17th February 2026** in the Committee Room of the Directorate General Health Services, Warsak Road, Khyber Pakhtunkhwa, Peshawar in the presence of bidders or their representatives (who choose to attend the bids opening process).
15. Bidders offering Medical devices, Surgical Disposables, Cotton and Related Goods, & Non-Drug Items are required to submit the sample (s) of their quoted products, along with the quoted product list, both in hard and soft form, to the office of Director Govt. MCC, in sufficient quantities (**in 2 Separate Packages; one for DTL analysis and the other for end user evaluation**) on or before the day of bid opening (**Tuesday, 17th February**

2026) up to 05:00 PM. Sample/s submitted after the due date shall not be accepted and the same item/s will be considered non-responsive.

- 16.** The Directorate General Health Services, Khyber Pakhtunkhwa reserves the right to reject any or all the bids under Rule 47 (1) of KPPRA Rules, 2014.

Director General Health Services
Directorate General Health Services, Khyber Pakhtunkhwa,
Warsak Road, Peshawar
Tel No: 091-9210269, 091-9211702
Email: mccdgdcp@gmail.com

Section II. Bid Data Sheet

BID DATA SHEET

ITB Ref.	Introduction/Description	Detail
ITB 1.1	Name of Procuring Entity/Agency of Government of Khyber Pakhtunkhwa.	Directorate General Health Services, Khyber Pakhtunkhwa, Peshawar through its notified committee's i.e., Selection & Rate Contracting Committee and Technical & Evaluation Committee.
ITB 1.1	Loan or credit or Project allocation number. Loan or credit or Project allocation amount.	Not Applicable
ITB 1.1	Name of Project	Not Applicable
ITB 1.1	Name of Contract	Selection & Rate Contracting of Medicines/Drugs, Medical Devices, Surgical Disposables, etc of the Govt. MCC for FY 2026-27
ITB 4.1	Name of Procuring Entity/agency.	Directorate General Health Services, Khyber Pakhtunkhwa, Peshawar through its notified committee's i.e., Selection & Rate Contracting Committee and Technical & Evaluation Committee.
ITB 6.1	Procuring entity/agency's address, telephone, telex, and facsimile, numbers.	Directorate General Health Services, Khyber Pakhtunkhwa, Peshawar Tel No: 091-9210269 (DGHS), 091-9211702 (MCC) Email: mccdgdcp@gmail.com
ITB 8.1	Language of the bid.	English
Bid Price and Currency		
ITB 11.2	Price quoted shall be:	Pakistani Rupees (Rs.)
ITB 11.5	The price shall be fixed	The price shall be fixed and valid till 30 th June 2027.
Preparation and Submission of Bids		
ITB 13.3 (d)	Qualification requirements.	<p>Note: The technical and financial bid shall be in conformity to Rule 39 (1) & (3) of the KPPRA Rules, any deviation from it, the bid shall be treated as non-responsive.</p> <ol style="list-style-type: none"> I. Manufacturer/s and / or Importer/s of drugs / medicines authorized by the goods' Principal Manufacturer or producer for import / supply of the said quoted goods in Pakistan, registered as such with the Drug Regulatory Authority of Pakistan (DRAP) for the quoted item/s falling under The Drug Act 1976 & Rules framed there under; and II. Manufacturer of Medical Devices in Pakistan, registered as such with the DRAP for the quoted item/s and regulated under the DRAP Act 2012 and the Rules framed there under; and III. Importer/Indenter of Medical Devices, duly authorized by the goods' Principal Manufacturer or producer to import / supply the said goods in Pakistan, as registered and regulated as such for the quoted item/s under the DRAP Act 2012 and Rules framed there under; and IV. Manufacturer of Non-Drug Items (NDIs) in Pakistan; and V. Importer/Indenter of NDIs, duly authorized by the goods' Principal Manufacturer or producer for import / supply of the said quoted goods in Pakistan, as registered and regulated as such for the quoted item/s under the DRAP Act 2012 and Rules framed there under

ITB 14.3 (b)	Spare parts required for years of operation	Not Applicable
ITB 15.1	Amount of bid security.	Rs. 10,00,000/-
ITB 16.1	Bid validity period.	180 days from the date of opening of bids
ITB 17.1	Number of copies.	One (scanned copy which is duly submitted through EPADS)
ITB 18.2 (a)	Address for bid submission	Office of the Director/Incharge Govt. Medicine Coordination Cell (MCC), Directorate General Drug Control and Pharmacy services (DGDC&PS), Old FATA Secretariat, Warsak Road, Peshawar
ITB 18.2 (b)	IFB title and number.	Selection and Rate Contracting (Contract Framework Agreement) of Drugs / Medicines, Medical Devices, Surgical Disposables & Non-Drug items for the year 2026-27.
ITB 19.1	Deadline for bid submission.	Before or up to 11:00 AM sharp on 17th February 2026 (Tuesday).
ITB 22.1	Time, Date and Place for bid opening.	11:00 AM sharp on 17th February 2026 (Tuesday) in the Committee Room of Directorate General Health Services, Old FATA Secretariat, Warsak Road, Peshawar
Bid Evaluation		
ITB 25.1	Evaluation and Comparison of Bids <i>(Limitation period for filing of a complaint against the Bid Evaluation Report (Technical/Financial))</i>	A complaint pertaining to the MCC tender process may be filed by the complainant with Grievance Redressal Committee (GRC) of the Govt. MCC in accordance with provisions of Rule-3 of the Khyber Pakhtunkhwa Public Procurement Grievance Redressal Rules, 2017. The complaint shall be restricted to the grounds mentioned in Rule-4 of the said Rules. The Procuring Entity shall process and dispose of the complaint in accordance with Rule-5 of the said Rules.
ITB 25.3	Criteria for bid evaluation.	Merit Point Evaluation (Best Evaluated Bid). The items ranked highest in merit points (obtained through, and based on, technical and financial evaluation) will get unit rate central contract. (Section-V of these BSDs).
ITB 25.4 (a) ITB 25.4 (b)	One option only Delivery schedule. Relevant parameters in accordance with option selected.	Not Applicable
Option I Option II Option III	Adjustment expressed as a percentage, or adjustment expressed in an amount in the currency of bid evaluation, or adjustment expressed in an amount in the currency of bid evaluation.	Not Applicable
ITB 25.4 (c)(ii)	Deviation in payment schedule. Annual interest rate.	Not Applicable
ITB 25.4	Cost of spare parts.	Not Applicable

(d)		
ITB 25.4 (e)	Spare parts and after sales service facilities in the Procuring agency's country.	Not Applicable
ITB 25.4 (f)	Operating and maintenance costs.	Not Applicable
ITB 25.4 (g)	Performance and productivity of equipment	Not Applicable
ITB 25.4 (h)	Details on the evaluation method or reference to the Technical Specifications	<p>As in section on Technical Evaluation of bids. The evaluation parameters of the quoted item/s may include, but not limited to, any or all of the methods including scrutiny of the bidding documents, physical inspection, examination, testing/using by the end user/s and or laboratory testing and/ or market survey including and not limited to both Public and Private Healthcare facilities, against any parameter/s, as deemed appropriate by the procuring Agency or any of its committees or sub-committees. Any discrepancy found during the market survey shall lead to disqualification of the firm/product (s).</p> <p>The test/analysis of the quoted medical devices, surgical disposables, and related items under this bidding process may be conducted by the Drug Testing Laboratory, under the supervision of the S&RCC or a sub-committee duly notified for this purpose by the S&RCC.</p> <p>Physical Inspection of manufacturers and importers/indenters will be carried out through a uniform checklist as provided at S# 9 (iv) of the Bid Form- I and S# 5 of the special conditions of contract.</p> <p>Facilitation to the inspection team for the purpose of physical inspection shall be the responsibility of the firm/(s).</p> <p>All the certifications from accredited bodies, as the case may be, shall contain the quoted product (s) in its scope, moreover the accredited body shall be authorized to certify the quoted product (s).</p> <p>In case of products having Multiple APIs/Raw material the marks for GD, CoA, APIs or Raw material Source accreditation will be awarded only where these documents are submitted for all ingredients/components of the quoted products For Example. Sitagliptin + Metformin, IV Cannula (Plastic and Needle etc.)</p> <p>In case the Supplier had been awarded marks in product evaluation parameter during the technical evaluation for API source accreditation for Drugs / Medicines, and for medical grade material certification for medical devices & Non-Drug Items, and for Pharmaceutical grade certification for immediate containers of Drugs/medicines shall warranty the supply of all such goods with the same certified quality, material and specification/s to the Purchasing Agency/ies throughout the validity period of contract agreement.</p>
ITB 25.4 (h)	Details on the evaluation method or reference to the Technical Specifications	

ITB 25.4 alternative	Specify the evaluation factors.	Not Applicable
Contract Award		
ITB 29.1	Percentage for quantity increase or decrease.	<p>In case of being best evaluated bid for the quoted item/s, an Advance Acceptance Letter shall be issued by the Govt. MCC, confirming the status of the successful bidder. Upon issuance of the Advance Acceptance Letter, the successful bidder shall be obligated to submit a duly signed contract agreement within ten (10) working days. In case of failure to comply within the specified period, the Govt. MCC shall issue a final notice, granting an additional ten (10) working days for submission of the contract agreement to the Govt. MCC. If the undersigned/successful bidder fails to submit the contract agreement on judicial stamp paper within the extended period, it shall be deemed that the successful bidder is unable to fulfill the supply obligations for the approved item(s). Consequently, the quoted item(s) shall be declared non-responsive, and the contract shall be awarded to the next eligible bidder.</p> <p>The Procuring Entity/Agency in the capacity of being the overall head of the Government Medicine Coordination Cell, or otherwise has the authority to regulate, if deemed appropriate, under the provisions in ITB 29.1 through imposing restrictions and / or classifying and / or grouping any selected quoted item/s for stopping, increasing or decreasing the purchase of such item/s by the Purchasing Agency/ies to rationalize and / or control the use and / or misuse of such item/s.</p>

Section III. Special Conditions of Contract

Notes on the Special Conditions of Contract

Similar to the Bid Data Sheet in Section II, the clauses in this Section are intended to assist the Procuring agency in providing contract-specific information in relation to corresponding clauses in the General Conditions of Contract.

The provisions of Section III complement the General Conditions of Contract included in Part one, Section II, specifying contractual requirements linked to the special circumstances of the Procuring agency, the Procuring agency's country, the sector, and the Goods purchased. In preparing Section III, the following aspects should be checked:

- a. Information that complements provisions of Part one Section II must be incorporated.
- b. Amendments and/or supplements to provisions of Part one Section II, as necessitated by the circumstances of the specific purchase, must also be incorporated.

Section III. Special Conditions of Contract

Table of Clauses

1.	DEFINITIONS (GCC CLAUSE 1)	41
2.	COUNTRY OF ORIGIN (GCC CLAUSE 3)	41
3.	STANDARD GCC (CLAUSE 4)	41
4.	PERFORMANCE SECURITY (GCC CLAUSE 7)	41
5.	INSPECTIONS AND TESTS (GCC CLAUSE 8)	41
6.	PACKING (GCC CLAUSE 9)	42
7.	DELIVERY AND DOCUMENTS (GCC CLAUSE 10)	43
8.	INSURANCE (GCC CLAUSE 11)	43
9.	INCIDENTAL SERVICES (GCC CLAUSE 13)	43
10.	SPARE PARTS (GCC CLAUSE 14)	44
11.	WARRANTY (GCC CLAUSE 15)	44
12.	PAYMENT (GCC CLAUSE 16)	44
13.	PRICES (GCC CLAUSE 17)	44
14.	LIQUIDATED DAMAGES (GCC CLAUSE 23)	44
15.	RESOLUTION OF DISPUTES (GCC CLAUSE 28)	44
16.	GOVERNING LANGUAGE (GCC CLAUSE 29)	44
17.	APPLICABLE LAW (GCC CLAUSE 30)	44
18.	NOTICES (GCC CLAUSE 31)	45
19.	DUTIES AND TAXES (GCC CLAUSE-35)	45

Special Conditions of Contract

The following Special Conditions of Contract shall supplement the General Conditions of Contract (GCC). Whenever there is a conflict, the provisions herein shall prevail over those in the General Conditions of Contract. The corresponding clause number of the GCC is indicated in parentheses.

1. Definitions (GCC Clause 1)

GCC 1.1 (c) The Goods are: **Drugs / Medicines, Surgical Disposables, Medical Devices & Non-Drug Items (NDIs)**

GCC 1.1 (g) **The Procuring Agency is:** Director General Health Services, Khyber Pakhtunkhwa being the overall head of Government Medicine Coordination Cell (MCC) Health Department Government of Khyber Pakhtunkhwa; and

The Purchasing Agency/ies include: District Health Officers, Medical Superintendents, and other Heads of the Primary, Secondary and / or Tertiary Level Health Care Institutions in the Health Department, Government of Khyber Pakhtunkhwa, including health related projects and / or vertical programs and / or interventions of / by the Health Department, Khyber Pakhtunkhwa, Healthcare Facilities of the Prisons throughout Khyber Pakhtunkhwa, and Social Security Polyclinic/Medical Centers in Khyber Pakhtunkhwa, Employee's Social Security Institution.

GCC 1.1 (i) The Supplier is: "the individual or firm supplying the Goods and Services under this Contract" and includes the following:

- i) **Manufacturer/s and / or Importer/s of drugs / medicines** authorized by the goods' Principal Manufacturer or producer for import / supply of the said quoted goods in Pakistan, registered as such with the Drug Regulatory Authority of Pakistan (DRAP) for the quoted item/s falling under The Drug Act 1976 & Rules framed thereunder; and
- ii) **Manufacturer/s** of Medical Devices in Pakistan, registered as such with the DRAP for the quoted item/s and regulated under the DRAP Act 2012 and the Rules framed thereunder; and
- iii) **Importer(s)/Indenter(s)** of Medical Devices, duly authorized by the goods' Principal Manufacturer or producer to import / supply the said goods in Pakistan, as registered and regulated as such for the quoted item/s under the DRAP Act 2012 and Rules framed thereunder; and
- iv) **Manufacturer/s** of Non-Drug Items (NDIs) in Pakistan; and
- v) **Importer(s)/Indenter(s)** of NDIs, duly authorized by the goods' Principal Manufacturer or producer for import / supply of the said quoted goods in Pakistan.

GCC 1.1 (j)—The Project Site is: **Director Govt. MCC, Directorate General Drug Control & Pharmacy Services, Warsak Road, Old Fata Secretariat Peshawar.**

2. Country of Origin (GCC Clause 3)

All countries and territories as indicated in Part Two Section VI of the bidding documents, "Eligibility for the Provisions of Goods, Works, and Services in Government-Financed Procurement".

3. Standards (GCC Clause 4): As mentioned in GCC clause 4.1.

4. Performance Security (GCC Clause-7)

GCC 7.1— The amount of performance security, as a percentage of the Contract Price, shall be: **Not Required.**

However, the bid security of Rs. 10,00,000/- from the successful bidders as received at the time of bids submission under GCC Clause 15, shall be retained by the Procuring Agency as Performance Security till the end of contract period and will be released back to successful bidders after the expiry of contract period, subject to the condition that all contractual obligations related to supplies are fulfilled. However, the warranty of the supplied goods, as issued by the Supplier under the clauses of contract agreement (Bid Form-7) and relevant applicable laws governing the nature of goods, e.g., the Drug Act 1976, The DRAP

Act 2012 and rules framed there under shall remain in force and valid despite the discharge of Performance Security to the Supplier in accordance with GCC Clause-7 and 8.

5. Inspections and Tests (GCC Clause 8 and in accordance with the clauses of contract with the Procuring Agency)

GCC 8.1: Bidders offering Medical devices, Surgical Disposables, Cotton and Related Goods, & Non-Drug Items are required to submit the sample(s) of their quoted products, along with the quoted product list, both in hard and soft form, to the office of Director Govt. MCC, in sufficient quantities (in 2 Separate Packages; one for DTL analysis and the other for end user evaluation) on the day of bid opening (Tuesday) up to 04:00 PM, 15th July 2025. Sample/s submitted after the due date shall not be accepted and the same item/s will be considered non-responsive.

If required, the Focal Person of the bidder will be informed on phone or through email to provide additional samples of the quoted items in required quantity to fulfill the need for examination and analysis at Provincial Drug Testing Lab (DTL) and/or physical evaluation by the MCC experts (Pharmacists, Consultants, Drug Inspectors, Professor of Pharmaceutics from Public Sector Universities, Health Managers and relevant experts in the field of medicines, and pharmaceutics etc.), end users/consultants (Physicians, surgeons, nephrologists, pharmacists, cardiologists etc) etc. The bidders shall provide the required samples for mandatory DTL test/analysis and MCC experts evaluations on their own risk and cost, and not later than, the time and date communicated.

The experts of the procuring entity shall inspect the premises of all applicant bidders (manufacturers) for their quoted products/items in accordance with DRAP Schedule-B, indicators of technical evaluation proformas and the Terms of Reference (TORs), including but not limited to the following:

- i. Compliance/Adherence to all the requirements of current good manufacturing practices (cGMP) in order to ensure the production of quality products.
- ii. Availability of TWO (02) Functional stability chambers i.e. Accelerated and Real time stability chambers along with the verification, of Stability studies done as per WHO/ICH guidelines, by the inspection team at the time of inspection.
- iii. The proper functioning of HVAC system, including but not limited to Air Handling Units (AHUs), HEPA Filters, testing of filters, SOPs, Maintenance of Record/documentation related to HVAC.
- iv. Adequate number of qualified staff that can fulfill the needs of Human resource of the approved sections of the manufacturing facility with a minimum of one qualified technical person per section. The qualified/ Technical person must be, as per the prevailing Laws and Rules, Pharmacists, Chemists, Microbiologists (depending upon the requirements of the relevant section) and must be on positions of in charge of specific section. The inspection team can also verify the Human resource from the appointment letters and/or contracts of the employee with the firm.
- v. Good Storage Practices (GSP) in Raw material Store (RMS). The RMS must have a separate entry for Raw materials (Receiving), Quarantine area, Rejection Area, Segregated Storage area for controlled substances (with lock and key). The active and inactive material shall be stored preferably in separate area. The RMS shall have ample temperature and humidity control facilities. The liquid Raw materials' storage shall be critically inspected with a special emphasis on organic (Flammable solvents).
- vi. Good Storage Practices (GSP) in Packaging Material Store with appropriate storage conditions of Temperature and humidity as per the requirements of the Packaging materials.
- vii. Good Storage Practices (GSP) in Finished Good Store with segregated Quarantine and release area with optimal temperature and humidity control facilities.
- viii. The compliance of all standard practices as per cGMP in the production area depending upon specific requirements of the sections approved by DRAP. The SOPs for all processes shall be checked for proper implementation. The flow of production shall be in such a way to avoid any mix ups in operations on different products. Maintenance of Plant Hygiene as well as validations of all the processes and all relevant calibrations shall remain the mainstay of inspection in production area.
- ix. Good Laboratory Practices (GLP) in the Quality Control (QC) Lab as well as in the in-process testing lab. The team will further ensure the availability of equipment necessary for Testing and Analysis including HPLC, FTIR, UV Spectrophotometer, Potentiometer etc. The Quality control lab shall be independent of all the other sections of the manufacturing facility and must have its own dedicated staff to avoid any conflict of interest. Moreover, all the QC procedures must be established, validated and implemented in true letter and spirit. In house methods used

for testing must be validated. The team can verify and report on the calibration status of the equipment in the manufacturing facility.

- x. At all times during processing, all materials, bulk containers, transfer bags, equipment etc. and rooms where required shall be properly labelled with all the requisite information for proper identification.
- xi. Water Supply/ Water treatment Plant/ Reverse osmosis etc. shall be inspected as per the requirements of the quoted items (syrups, injectables, WFI etc.)
- xii. Microbiology section with all the requisite equipment, reagents, media and human resource that must follow all the standard practices as per the requirements of the products manufactured and offered to the Govt. MCC Khyber Pakhtunkhwa.
- xiii. In addition, the manufacturer shall comply to all the requirements and conditions laid down in the BSDs of Govt. MCC FY 2026-27.

The experts of the procuring entity shall inspect the premises of all applicant bidders (importers/indenters) for their quoted products/items in accordance with Drug Sale Rules, DRAP Act 2012, The Drug Act 1976, Medical Devices Rules 2017, etc, indicators of technical evaluation proformas, mandatory documents and the Terms of Reference (TORs), including but not limited to the following:

- i. The verification of all embassy-attested/ apostilled mandatory documents (cGMP, Free Sale, COPP, COMP, Agency Agreements, Quality Assurance etc.) of the importer and imported items (as per BSDs) in original.
- ii. Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s).
- iii. Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm) Availability of adequate Qualified Human Resources, responsible for supervision of Proper Receiving, Storage, and Distribution of all the imported Drugs, Medicines, Medical Devices etc.
- iv. Evaluation of Cold Chain facility, including Power backup, Recordkeeping, Temperature and Humidity Loggers (Where Applicable).
- v. Evaluation of Good Storage Practices (GSP) by the inspection team, of the facility where the imported finished products are stored. (Airconditioning, Humidity control, Warehousing, Record Keeping, Documentation of All INs and OUTs, SOPs etc.)
- vi. Evaluation of the Standard Operating Procedure of Expiry Management (FEFO, FIFO) of the importer firm related to the quoted imported items (Drugs/Medicines, Medical Devices, Surgical Disposables etc.)

The test/analysis of the quoted medical devices, surgical disposables, and related items under this bidding process may be conducted by the Drug Testing Laboratory, under the supervision of the S&RCC or a sub-committee duly notified for this purpose by the S&RCC.

Moreover, after final approval / selection of items the successful bidders are bound to provide 05 Commercial packs of selected items, within 30 days of hoisting of approved list, to be kept as reference sample/retention sample, to check all supplies for conformity throughout the financial year. The samples shall not be returned, and no payment whatsoever shall be payable to bidder / Focal Person on this account in the name of price / transportation charges etc. or based on any other context or reason or argument.

Moreover, the cost/fee of the test analysis for samples of the item/s (approved by the Selection & Rate Contracting Committee), supplied in response to the purchase orders issued by different health facilities/purchasing entities shall be paid by the bidder(s). All successful bidders are required to pay the fee, as per the rates fixed by the Drug Testing Laboratory under the rules, for the purpose of test/analysis performed for the quality assessment of samples of the approved items.

If the provided sample/s of the selected items are not in conformity with the schedule of requirements specification, the item/s shall be considered non-responsive and next best evaluated bid shall be considered.

- i. The Technical Evaluation shall be conducted by the Inspection Team/s of MCC expert/s constituted by the Technical and Evaluation (T&E) Committee and /or by the Selection and Rate Contracting Committee (S&RCC) of the Government MCC to:
 - a. Undertake examination of the original documents as mentioned in the Bid Cover Sheet (Bid Form-

- 1) of these BSDs, and the attested copies of which had been submitted by the bidder/s along with the technical bids; and
 - b. Undertake the physical inspection of the relevant premises to verify the status of Current Good Manufacturing Practices (cGMP), and Good Storage Practices (GSP) Parameters for manufacturers and importers/indenters, as the case may be, for the quoted item/s as laid down in the Technical Evaluation Proformas (Section-V: Technical Specification of the Part-II of these BSDs); and
 - c. Examine the original documents related to the fitness of the material of immediate container/s for storage and / or dispensing of the quoted drugs / medicines item/s, e.g., Certificate of Analysis, invoice, etc. of the material/s used in manufacturing of the immediate container of quoted drug / medicine item/s, including that of its stopper / lid / cap.
 - d. The physical inspection of the manufacturers and importers/indenters, shall be intimated as a public notice on the official website of health department, Khyber Pakhtunkhwa and Authority, one week prior to the expected date of Physical inspection, and no individual notice/fixed date and time shall be served / communicated to the applicant bidders.
 - e. The DTL and panel of experts / end users test analysis and/or evaluation of the quoted samples of medical devices, surgical disposables, cotton related items and non-drug items, as the case may be, shall be conducted under the supervision of the Technical & Evaluation committee/sub-committee).
- ii. The bidder shall be disqualified for competition if Inspection Team/s declare that the bidder did not meet the mandatory requirements for qualification at the time of inspection as mentioned in the approved Technical Evaluation Proforma in these BSDs for various categories of bidders.
 - iii. The technical and financial bid shall be in conformity to Rule 39 (1) & (3) of the KPRA Rules, any deviation from it, the bid shall be treated as non-responsive.
 - iv. Medical Devices, Surgical Disposables and NDIs shall be examined and / or tested by MCC expert/s of the T&E Committee, and / or of the S&RCC of the Government MCC in a manner as deemed relevant and appropriate (including testing at Drug Testing Lab or elsewhere) for the purpose by the said expert/s, and as laid down, or otherwise, in the applicable laws and Rules, for submission of technical report to the relevant forum/quarter for the needful.
 - v. The samples of Medical Devices and Surgical Disposables shall be examined and tested for selected parameters by the Drug Testing Laboratory for submission of technical report/s to relevant forum/quarters for the needful.
 - vi. To fulfill the relevant clauses of the contract agreement (Bid Form-7 of these BSDs) for testing of supplied goods, all the successful bidders for Drugs/Medicine, Surgical Disposables, Medical Devices falling under the Drugs Act 1976, before signing the Contract Agreement (Bid Form-7) shall provide to the Procuring Agency, the Testing Method/s and Lab. protocols to test their quoted item/s in the Drugs Testing Laboratory.
 - vii. Any other appropriate method/arrangements may be adopted by the T&E Committee and / or S&RCC to assess and/or assure the quality of goods being purchased and / or supplied to the Procuring and / or Purchasing Agency/ies.
 - viii. The application fee charges @ Rs. 5000/bid are collected to carry out the purpose of printing and soliciting the bidding documents, to achieve multiple steps relating to the Govt. MCC procurement process.

GCC 8.2: The physical inspection and sampling for DTL testing / analysis of approved items, shall be conducted to conform to the laid down specifications before utilization, on the premises of purchasing entity, at the point of delivery, and/or at the Goods' final destination, for ascertaining the quality and quantity. Moreover, the cost/fee of the test analysis for samples of the item/s (approved by the Selection & Rate Contracting Committee), supplied in response to the purchase orders issued by different health facilities/purchasing entities shall be paid by the bidder(s). All successful bidders are required to pay the fee, as per the rates fixed by the Drug Testing Laboratory under the rules, for the purpose of test/analysis performed for the quality assessment of samples of the approved items.

GCC 8.3: Facilitation to the inspection team for the purpose of physical inspection shall be the responsibility of the firm(s).

6. Packing (GCC Clause 9)

The successful bidder shall make supplies of quoted item/s in accordance with the following:

- i. Provisions contained in the GCC Clause 9 of these BSDs; and
- ii. Relevant clauses of contract agreement of Government MCC with the Supplier/s (Bid Form-7 of these BSDs – Rate Contract Agreement); and
- iii. In case of item/s falling in the category of drugs / medicines, the immediate container of drug / medicine shall comply with the official monograph requirements, as submitted by the bidder to the DRAP with the dossier at the time of registration of the said quoted item/s with the DRAP in accordance with applicable provisions contained in the prevailing laws and rules.

7. Delivery and Documents (GCC Clause 10)

Applicable Delivery Mode: Delivered Duty Paid (DDP) as per contract agreement of the successful bidder with the Procuring Agency.

The Supplier shall provide the following documents to the Purchasing Agency:

- i. Copies of the Supplier's invoice showing goods' description, quantity, unit price, and total amount.
- ii. Usual transport documents which the buyer may require to take the goods.
- iii. Manufacturer's / Importer's/Indenter's prescribed warranty certificate.

The supplier shall be responsible to transport the item/s in a manner that the appropriate and required storage temperature is continuously and properly maintained during transportation from supplier till delivery to the Purchasing Agency/ies. In case of item/s requiring the maintenance of cold chain, the supplier shall be under obligation to provide valid and appropriate evidence to the Purchasing Agency to the effect that end

to end cold chain of the supplied item/s has adequately been maintained during transportation of the said item/s to the Purchasing Agency/ies.

8. Insurance (GCC Clause 11)

GCC 11.1— The Goods supplied under the Contract shall be delivered duty paid (DDP) under which risk is transferred to the buyer after having been delivered, hence insurance coverage is sellers' responsibility. Since the Insurance is seller's responsibility, they may arrange appropriate coverage.

9. Incidental Services (GCC Clause 13) Not applicable.

10. Spare Parts (GCC Clause 14) Not Applicable.

11. Warranty (GCC Clause 15)

For goods belonging to the categories of Drugs/Medicines, Medical Devices, Surgical Disposables and Cotton related materials, and falling under the Drugs Act 1976 and / or the DRAP Act-2012 and Rules framed thereunder, the Supplier, in addition to the terms and conditions of the Rate Contract Agreement with Procuring Agency (Bid Form-7), shall provide warranty to the Purchasing Agency under all the relevant Section/s of applicable government laws and rules.

In case of goods belonging to the categories of NDIs, the Supplier as per GCC Clause 15 and the clauses of Contract Agreement with the Procuring Agency (Bid Form-7), shall provide warranty to the Purchasing Agency for the duration as mentioned in GCC Clause-15 or till the expiry date of goods supplied, whichever is later.

12. Payment (GCC Clause 16):

GCC Clause 16 as well as under the terms and condition in Rate Contract Agreement (Bid Form-7) with the Procuring Agency.

Payment shall be made in **Pak. Rupees** in accordance with the relevant government rules, regulations, and procedures.

13. Prices (GCC Clause 17)

- i) The bidder shall not quote price/s of any item/s which is/are higher than the prices quoted by the bidder across the country to any entity procuring the quoted item/s through public funding.
- ii) In case of Drugs/Medicines the bidder shall not quote the price more than the trade price of individual

quoted item/s.

- iii) In case of Medical Devices, Surgical Disposables and NDIs, the bidder shall not quote the prices more than the prevailing market trade price of the quoted item/s for bulk purchases.
- iv) The procuring agency may extend the duration for the framework contract to another year, extendable up to a maximum of three years; provided that every extension shall be approved by a committee, notified by the Administrative Department, to determine competitiveness and assess value for money as per the KPPRA Rules (31A) of 2014.
- v) In case of single complying bid, the procuring entity may conclude the procurement contract through negotiation on quality upgrades, mode and schedule of delivery or cost reduction. In case the bid price is above engineer estimates or market analysis report, conducted by the procuring entity, after due diligence, in such eventuality, the successful bidder shall be asked to match that price in order to protect public interest and to ensure general principle of timelines for procurement as enunciated in section 3 of the Act as per the KPPRA Rules (42A) of 2014.

14. Liquidated Damages (GCC Clause 23)

As in relevant clauses of the Rate Contract Agreement signed by the Supplier with the Procuring Agency.

15. Disputes Resolution (GCC Clause 28)

The dispute resolution mechanism to be applied will be pursuant to relevant clauses of Rate Contract Agreement (Bid Form-7) between the Supplier and the Procuring Agency.

If at all required, the jurisdiction of Court shall be of Peshawar, Khyber Pakhtunkhwa.

16. Governing Language (GCC Clause 29)

The Governing Language shall be: **English.**

For various item/s related to drug / medicine category, the language of official Monograph of the quoted drug / medicine item/s, as registered with the DRAP, shall be acceptable for the bidding process.

17. Applicable Law (GCC Clause 30)

The Contract shall be interpreted in accordance with all the relevant laws of Islamic Republic of Pakistan which include, but not limited to, the following legislations:

- i. The KPPRA Act, 2012.
- ii. The KPPRA Rules, 2014.
- iii. KPPRA Grievance Redressal Rules, 2017.
- iv. The Drugs Act, 1976 and Rules framed thereunder.
- v. The DRAP Act, 2012 and Rules framed thereunder.
- vi. Drugs (Licensing, Registration and Advertising) Rules; 1976.
- vii. Medical Devices Rules, 2017.
- viii. Khyber Pakhtunkhwa Drug Sales Rules, 1982 (Amended 2017).
- ix. DRAP Drug Pricing Policy, 2018 (Amended 2020).
- x. All applicable S.R.O's of DRAP/Federal Government for the time being enforced.
- xi. Drugs (Imports & Export) Rules, 1976.
- xii. Drugs Labelling and Packaging Rule, 1978.
- xiii. WHO Guidelines, US-FDA guidelines etc
- xiv. The General Financial Rules of the Government of Khyber Pakhtunkhwa and all the relevant laws, rules and regulations pertaining to budgeting and financial management of public funds.
- xv. The Employment of Children (ECA) Act, 1991.
- xvi. The Bonded Labor System (Abolition) Act, of 1992.
- xvii. The Factories Act, 1934.
- xviii. The Contract Act, 1872.
- xix. The Companies Ordinance, 1984 / amended Companies Act, 2017.
- xx. Any other relevant rules/regulations for the time being enforced for therapeutic goods.

18. Notices (GCC Clause 31)

GCC 31.1—Procuring Agency address for notice purposes:

Office of the Director General Health Services Directorate General
Health Services, Khyber Pakhtunkhwa, Warsak road, old FATA
Secretariat Peshawar.

Tel: 091-9211702

091-9210269

Email mccdgdcp@gmail.com

Supplier's address for notice purposes: As mentioned in their bidding documents

19. Duties & Taxes (GCC clause 32)

The Unit price quoted by the bidder shall be: **inclusive** of all applicable duties and taxes.

Section IV. Schedule of Requirements (SOR)

GOVERNMENT MEDICINE CO-ORDINATION CELL

HEALTH DEPARTMENT GOVT. OF KHYBER PAKHTUNKHWA

MCC FORMULARY FOR THE YEAR 2026-27

NOTE:

1. All Powdered injectables shall be supplied with Sterile Water for Injection or any other required diluent packed in a single box (Combo-pack) (Specified volume / quantity sufficient as per the DRAP Guidelines).

2. In case a bidder has been awarded marks during the technical evaluation for different parameters, the successful bidder(s) shall supply the said item/s with the quoted specification(s), against which the marks have been awarded, to the Purchasing Agency/ies throughout the validity period of the contract agreement.

3. For Narcotic analgesic drugs, i.e., Morphine, proper procedure and protocol of Government shall be followed by the Purchasing Agency/ies and Supplier/s.

4. **Pack and Pack Size** means the number of Tablets, Capsules, Syrup, Injection (s) etc. packed in a unit carton with leaflet, along with spoon, dropper, and applicator etc. which so ever is required with the quoted item. The pack and pack size of the quoted item shall be the same as supplied in the commercial market.

5. **Packaging and Packing material** of the Drug / Medicine / Medical Devices etc. shall be of same quality / strength / size / gauge / glass type / grade / grammage / Artwork and Lamination as supplied in the commercial market.

6. **Liquid preparations (Syrups, Suspensions, Solutions etc.)** registered in multiple volumes, shall have a combined competition, **the comparison shall be based on per milliliter (ml), provided that the strength shall be in accordance with the advertised formulary.**

7. In **Sterile Gauze Dressing Pad**, among the advertised three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition.

8. In the case of **sutures**, a **±1 mm variation in needle size only** shall be acceptable for the respective formulary numbers; however, the item shall be selected in the combined competition for that formulary number.

AMOEBICIDES				
MCC Formulary No	Drug Name	Strength	Dosage form	Volume / Pack Size
1.	Metronidazole	200 mg	Tab.	200s or less
2.	Metronidazole	400 mg	Tab.	200s or less
3.	Metronidazole	200 mg/5ml	Susp.	120ml or less
4.	Metronidazole	500 mg	Inf.	100 ml, 1s
5.	Metronidazole	0.75%	Vag. Gel	15gm, 1s

6.	Metronidazole	0.75%	Vag. Gel	75gm, 1s
7.	Nitazoxanide	500 mg	Tab.	20s
8.	Nitazoxanide	100 mg/5ml	Susp.	30 ml
9.	Tinidazole	500 mg	Tab.	40s
	ANAESTHETIC & ADJUVANT			
10.	Atracurium	10 mg/ml	Inj.	
11.	Atracurium	10 mg/ml	Inj.	5 ml
12.	Bupivacaine	5 mg/ml	Inj.	10 ml
13.	Bupivacaine Spinal	7.5 mg/ml	Inj.	2 ml
14.	Cis-Atracurium	2mg/ml	Inj.	5 ml
15.	Dexmedetomidine	0.1mg/ml	Inj.	2 ml
16.	Glycopyrrolate + Neostigmine	0.5 mg+2.5mg	Inj.	1ml
17.	Glycopyrrolate	0.2 mg/ml	Inj.	1ml
18.	Isoflurane		Liq. for Inh.	100ml or 250ml
19.	Ketamine HCl	50 mg/ml	Inj.	10 ml
20.	Ketamine HCl	50 mg/ml	Inj.	2 ml
21.	Lignocaine HCl	2%	Inj.	10 ml
22.	Lignocaine HCl	4%	Topical Soln.	50 ml
23.	Lignocaine HCl + Adrenaline	20mg/ml + 0.001% w/v	Inj.	10 ml
24.	Lignocaine HCl + Adrenaline	1:80,000	Dental Ctg.	2 ml
25.	Lidocaine	2%	Inj.	
26.	Pancuronium	4mg/2ml	Inj.	2ml
27.	Propofol	10 mg/ml	Inj.	20 ml
28.	Propofol MCT/LCT fat emulsion	10mg/ml	Inj.	20ml
29.	Rocuronium	10 mg/ml	Inj.	5 ml
30.	Ropivacaine HCl	5mg/ ml	Inj.	10 ml
31.	Sevoflurane		Liq. for Inh.	250 ml
32.	Succinyl Choline	50 mg/ml	Inj.	2 ml
33.	Thiopentone Sodium	500 mg/Vial	Inj. (Dry Powder)	
34.	Vecuronium Bromide	4 mg/Ampule	Inj. (Dry powder)	

	ANALGESICS, ANTI-INFLAMMATORY, ANTIPYRETICS DRUGS & MUSCLE RELAXANTS			
35.	Aceclofenac	100 mg	Tab.	30s or less
36.	Acetyl Salicylic Acid (Aspirin)	300 mg	Disper. Tab.	600s or less
37.	Baclofen	10mg	Tab.	30s or less
38.	Diclofenac Sodium	25 mg	Supp.	10s
39.	Diclofenac Sodium	100 mg	Supp.	10s
40.	Diclofenac Sodium (IM/IV for Infusion)	25 mg/ml	Inj.	3 ml
41.	Diclofenac Sodium enteric coated	50 mg	Tab.	100s or less
42.	Fentanyl Citrate	0.05mg/ml	Inj.	5 ml
43.	Ibuprofen	200 mg	Tab.	100s or less
44.	Ibuprofen	400 mg	Tab.	250s or less
45.	Ibuprofen	200 mg/ 5 ml	Susp.	120ml or less
46.	Ibuprofen	100 mg/ 5ml	Susp.	120 ml or less
47.	Ketorolac	30 mg/ml	Inj.	1ml, 10s or less
48.	Mefenamic Acid	250 mg	Tab.	600s or less
49.	Mefenamic Acid	500 mg	Tab.	200s or less
50.	Mefenamic Acid	50 mg/5ml	Susp.	60 ml
51.	Meloxicam	15 mg	Tab.	20s or less
52.	Meloxicam	7.5 mg	Tab.	20s or less
53.	Morphine	15 mg	Inj.	
54.	Morphine	10 mg	Cap.	
55.	Morphine	30 mg	Cap.	
56.	Nalbuphine	10 mg	Inj.	10s or less
57.	Nalbuphine	20 mg	Inj.	10s or less
58.	Paracetamol	80mg/0.8ml	Oral Drops	
59.	Paracetamol	500 mg	Tab.	200s or less
60.	Paracetamol	120 mg/ 5 ml	Susp.	120ml or less
61.	Paracetamol	250 mg/ 5ml	Susp.	100ml or less
62.	Paracetamol	150mg/ ml	Inj.	2 ml

63.	Paracetamol	1000 mg	Inf.	100ml
64.	Paracetamol	150 mg	Supp.	20s or less
65.	Paracetamol + Orphenadrine	450 mg/35 mg	Tab.	100s or less
66.	Paracetamol+Tramadol	325mg/37.5 mg	Tab.	
67.	Serratiopeptidase	5 mg	Tab.	20s or less
68.	Tizanidine	4mg	Tab.	10s
69.	Tramadol HCl	50 mg/ml	Inj.	2ml, 10s or less
	ANTHELMINTICS DRUGS			
70.	Albendazole	200 mg	Tab.	2s
71.	Albendazole	200 mg/5ml	Susp.	10ml
72.	Levamisole	40 mg	Tab.	30s
73.	Levamisole	40 mg/5ml	Syp.	30ml
74.	Mebendazole	100 mg	Tab.	100s or less
75.	Mebendazole	500 mg	Tab.	20s or less
76.	Mebendazole	100 mg/5ml	Susp.	30 ml
77.	Niclosamide	500 mg	Tab.	4s
78.	Pyrantel pamoate	250 mg	Tab.	
	ANTI NEOPLASTIC AGENTS / IMMUNOSUPPRESSANT/IMMUNO MODULATORY DRUGS			
79.	Cyclosporine	25 mg	Cap.	
80.	Cyclosporine	50 mg	Cap.	
81.	Cyclosporine	100 mg	Cap.	
82.	Everolimus	5 mg	Tab.	
83.	Everolimus	10 mg	Tab.	
84.	Faricimab	6mg /0.05ml	Inj.	
85.	Filgrastim	300 mcg	Inj.	
86.	Hydroxyurea	500 mg	Cap.	
87.	Hydroxychloroquine	200 mg	Tab.	
88.	Mycophenolate Mofetil	250 mg	Tab. / Cap.	
89.	Mycophenolate Mofetil	500 mg	Tab. / Cap.	
90.	Mycophenolate Sodium	180 mg	Tab. / Cap.	

91.	Mycophenolate Sodium	360 mg	Tab. / Cap.	
92.	Ocrelizumab	300mg/10ml	Inj.	
93.	Sirolimus	1mg	Tab.	
94.	Tacrolimus	1mg	Tab. /Cap.	
95.	Tacrolimus	0.5 mg	Tab./ Cap.	
96.	Tofacitinib	5mg	Tab./Cap.	60s or less
97.	Tofacitinib	10mg	Tab./Cap.	60s or less
98.	Tocilizumab	162mg/0.9ml	Inj.	PFS
99.	Zoledronic Acid	4 mg /Vial	Inj.	
	ANTIDOTES			
100.	Acetyl Cysteine		Inj.	
101.	Activated Charcoal		Powder	
102.	Activated Charcoal		Tab.	
103.	Atropine Sulphate	1mg/ml	Inj.	1ml
104.	Buprenorphine	0.3 mg/1 ml	Inj.	1 ml
105.	Buprenorphine	2mg	SL. Tab.	
106.	Buprenorphine	8mg	SL. Tab.	
107.	Deferasirox	90mg	Tab.	
108.	Deferasirox	100mg	Tab.	
109.	Deferasirox	180mg	Tab.	
110.	Deferasirox	250mg	Tab.	
111.	Deferasirox	360mg	Tab.	
112.	Deferasirox	400mg	Tab.	
113.	Deferasirox	500mg	Tab.	
114.	Deferoxamine	500mg	Inj.	
115.	Dimercaprol	50 mg/ml	Inj.	
116.	EDTA		Inj.	
117.	Flumazenil	100 mcg/ml	Inj.	10 ml
118.	Fomepizole	5 mg/ml	Inj.	
119.	Glucagon	200 mg	Inj.	
120.	Methylene Blue	10 mg/ml	Inj.	

121.	N-acetylcysteine	200 mg	Sachet	
122.	Naloxone HCl	0.4 mg / ml	Inj.	
123.	Neostigmine	2.5 mg	Inj.	
124.	Penicillamine	250 mg	Tab.	
125.	Pralidoxime	20 mg/ml	Inj.	10 ml
126.	Protamine Sulphate	10 mg/ml	Inj.	5 ml
127.	Sodium Nitrite	30 mg	Inj.	
128.	Sodium Thiosulfate	250 mg/ml	Inj.	
	ANTI-FUNGAL DRUGS			
129.	Amphotericin-B	50 mg/Vial	Inj.	
130.	Caspofungin	50 mg/Vial	Inj.	
131.	Caspofungin	70 mg/Vial	Inj.	
132.	Clotrimazole	500mg	Vaginal tablet with applicator	
133.	Clotrimazole	1%	Vaginal Cream with applicator	5gm
134.	Clotrimazole	2%	Vaginal Cream with applicator	35gm
135.	Fluconazole	2 mg/ml	Inf.	50 ml
136.	Fluconazole	50 mg	Tab. / Cap.	
137.	Fluconazole	150 mg	Tab. / Cap.	1s
138.	Fluconazole	50 mg/5 ml	Susp.	
139.	Griseofulvin	500 mg	Tab.	
140.	Griseofulvin	125 mg/5ml	Susp.	120 ml
141.	Itraconazole	100 mg	Cap.	
142.	Miconazole	2%	Skin Cream	10 gm
143.	Miconazole	2%	Vaginal Cream with Applicator	
144.	Miconazole	2%	Oral Gel	
145.	Nystatin	100,000 IU/5ml	Oral Drops	30 ml

146.	Nystatin	100,000 IU	Vaginal Tablet with applicator	
147.	Terbinafine	250 mg	Tab.	
148.	Voriconazole	200 mg	Inj.	
149.	Voriconazole	200 mg	Tab.	
	ANTI-HISTAMINES & ANTI-ALLERGIC DRUGS			
150.	Betahistine	8 mg	Tab.	30s
151.	Betahistine	16 mg	Tab.	30s
152.	Betamethasone	4mg/ml	Inj.	1ml
153.	Cetirizine	10 mg	Tab.	30s
154.	Cetirizine	5 mg/5 ml	Syp.	60 ml
155.	Chlorpheniramine Maleate	4 mg	Tab.	
156.	Chlorpheniramine Maleate	2 mg/ 5 ml	Syp.	120 ml
157.	Levocetirizine	2.5 mg/5 ml	Syp.	90 ml or less
158.	Levocetirizine	5 mg	Tab.	10s
159.	Loratadine	10 mg	Tab.	10s
160.	Montelukast	10 mg	Tab.	28s or less
161.	Montelukast	5 mg	Tab.	28s or less
162.	Montelukast	4 mg	Sachet	28s or less
163.	Pheniramine Maleate	22.7 mg/ml	Inj.	2ml
	ANTI-INFECTIVE DRUGS			
164.	Amikacin Sulphate	25mg	Inj.	
165.	Amikacin Sulphate	50mg	Inj.	
166.	Amikacin Sulphate	100mg	Inj.	
167.	Amikacin Sulphate	250mg	Inj.	
168.	Amikacin Sulphate	500mg	Inj.	
169.	Amoxycillin	250mg	Cap.	100s or less
170.	Amoxycillin	500mg	Cap.	100s or less
171.	Amoxycillin	125 mg/ 5ml	Dry Susp.	90 ml
172.	Amoxycillin	500 mg/Vial	Inj.	
173.	Amoxycillin	250 mg /5ml	Dry Susp.	90 ml

174.	Amoxicillin + Clavulanic Acid	250 mg/125mg (375mg)	Tab.	6s
175.	Amoxicillin + Clavulanic Acid	500 mg/125mg (625 mg)	Tab.	6s
176.	Amoxicillin + Clavulanic Acid	875 mg/125mg (1gm)	Tab.	6s
177.	Amoxicillin + Clavulanic Acid	125 mg +31.5mg/5ml	Dry Susp.	90 ml
178.	Amoxicillin + Clavulanic Acid	50 mg + 12.5mg/1ml	Oral Drops	20 ml
179.	Amoxicillin + Clavulanic Acid	250 mg +62.5mg/5ml	Dry Susp.	90 ml
180.	Amoxicillin + Clavulanic Acid	500 mg + 100mg/vial	Inj.	
181.	Amoxicillin + Clavulanic Acid	1gm+200mg/ Vial	Inj.	
182.	Ampicillin	250 mg/Vial	Inj.	
183.	Ampicillin	500 mg/Vial	Inj.	
184.	Ampicillin	1g/Vial	Inj.	
185.	Ampicillin + Cloxacillin	250 mg+ 250mg	Cap.	100s or less
186.	Ampicillin + Cloxacillin	125mg +125mg/Vial	Inj.	
187.	Ampicillin + Cloxacillin	250 mg + 250mg/vial	Inj.	
188.	Ampicillin + Cloxacillin	125 mg + 125mg	Cap.	100s or less
189.	Azithromycin	250 mg	Tab. / Cap.	12s or less
190.	Azithromycin	500 mg	Tab. / Cap.	6s
191.	Azithromycin	500 mg/Vial	Inj.	
192.	Azithromycin	200 mg/5ml	Dry Susp.	25ml or less
193.	Benzathine Penicillin	1.2 MIU/Vial	Inj.	
194.	Benzyl Penicillin	10 Lac Units/Vial	Inj.	
195.	Benzyl Penicillin	5 Lac Units/Vial	Inj.	
196.	Cefaclor	50mg / ml	Oral Drops	15 ml
197.	Cefaclor	100mg/ml	Oral Drops	15 ml
198.	Cefaclor	125mg/ 5ml	Susp.	60 ml

199.	Cefaclor	250 mg /5ml	Susp.	60 ml
200.	Cefazolin	500 mg/Vial	Inj.	
201.	Cefazolin	1gm/Vial	Inj.	
202.	Cefepime	500 mg/vial	Inj.	
203.	Cefepime	1 gm/vial	Inj.	
204.	Cefixime	400 mg	Cap.	5s
205.	Cefixime	100 mg/5ml	Dry Susp.	30ml
206.	Cefixime	200 mg/5ml	Dry Susp.	30ml
207.	Cefoperazone + Sulbactam	1gm/Vial	Inj.	
208.	Cefoperazone + Sulbactam	2 gm/Vial	Inj.	
209.	Cefotaxime Sodium	250 mg/Vial	Inj.	
210.	Cefotaxime Sodium	500 mg/Vial	Inj.	
211.	Cefotaxime Sodium	1gm/Vial	Inj.	
212.	Cefpodoxime	100 mg	Tab.	
213.	Cefpodoxime	40 mg/5ml	Dry Susp.	50 ml
214.	Ceftaroline fosamil	600 mg/Vial	Inj.	
215.	Ceftazidime	500 mg/Vial	Inj.	
216.	Ceftazidime	1gm/Vial	Inj.	
217.	Ceftriaxone	500 mg/Vial	Inj.	
218.	Ceftriaxone	1gm/Vial	Inj.	
219.	Ceftriaxone	2 gm Vial	Inj.	
220.	Cefuroxime	1.5gm/Vial	Inj.	
221.	Cefuroxime	250 mg	Tab.	
222.	Cefuroxime	125 mg/5ml	Dry Susp.	
223.	Cefuroxime	750 mg/Vial	Inj.	
224.	Cephradine	250 mg	Cap.	
225.	Cephradine	500 mg	Cap.	
226.	Cephradine	1gm / Vial	Inj.	
227.	Cephradine	500 mg / Vial	Inj.	
228.	Cephradine	125mg / 5ml	Dry Susp.	90ml
229.	Cephradine	250 mg / 5ml	Dry Susp.	90ml

230.	Ciprofloxacin	250 mg	Tab.	10s
231.	Ciprofloxacin	500 mg	Tab.	10s
232.	Ciprofloxacin	200 mg/100ml	Inf.	100 ml
233.	Ciprofloxacin	400 mg/100ml	Inf.	100 ml
234.	Clarithromycin	250 mg	Tab.	10s
235.	Clarithromycin	500 mg	Tab.	10s
236.	Clarithromycin	250 mg/5ml	Dry Susp.	70 ml or less
237.	Clarithromycin	125 mg/5ml	Dry Susp.	60 ml
238.	Clarithromycin	125 mg/ 5 ml	Dry powder oral drops	25 ml
239.	Clarithromycin	500 mg/Vial	Inj.	
240.	Clindamycin	150 mg/ml	Inj.	2ml
241.	Cloxacillin	250 mg /Vial	Inj.	
242.	Cloxacillin	250 mg	Cap.	
243.	Colistimethate Sodium	2 MIU/vial	Inj.	
244.	Colistimethate Sodium	1 MIU/vial	Inj.	
245.	Co-Trimoxazole (Sulphamethoxazole +Trimethoprim)	400 mg + 80mg	Tab.	
246.	Co-Trimoxazole (Sulphamethoxazole +Trimethoprim)	800 mg + 160mg	Tab.	
247.	Co-Trimoxazole (Sulphamethoxazole +Trimethoprim)	400 mg + 80mg/5 ml	Susp.	50ml
248.	Co-Trimoxazole (Sulphamethoxazole +Trimethoprim)	200mg + 40mg/5ml	Susp.	50ml
249.	Dapsone	25 mg	Tab.	
250.	Dapsone	100 mg	Tab.	
251.	Doxycycline	100 mg	Cap.	
252.	Ethambutol	400mg	Tab.	
253.	Ethambutol	100mg	Disper. Tab.	
254.	Flucloxacillin + Amoxicillin	250 mg + 250mg/ Vial	Inj.	
255.	Flucloxacillin + Amoxicillin	250 mg + 250mg	Cap.	
256.	Fosfomycin	500 mg	Cap.	
257.	Fosfomycin	3 gm	Sachet	1s
258.	Gentamicin Sulphate	20 mg/ml	Inj.	1ml

259.	Gentamicin Sulphate	40 mg/ml	Inj.	2 ml
260.	Imipenem + Cilastatin	500 mg+500mg / Vial	Inj.	
261.	Isoniazid	300mg	Tab.	
262.	Isoniazid	100mg	Disper. Tab.	
263.	Levofloxacin	5 mg/ml	Inf.	100 ml
264.	Levofloxacin	250 mg	Tab.	10s
265.	Levofloxacin	500 mg	Tab.	10s
266.	Lincomycin	500 mg	Cap.	
267.	Lincomycin	300 mg/ml	Inj.	2 ml
268.	Linezolid	600mg	Tab.	12s
269.	Linezolid	100mg/5ml	Suspension	60ml
270.	Linezolid	2 mg/ml	Inf.	100 ml
271.	Linezolid	2 mg/ml	Inf.	300 ml
272.	Meropenem	500 mg/Vial	Inj.	
273.	Meropenem	1gm /Vial	Inj.	
274.	Minocycline	100 mg	Tab.	
275.	Moxifloxacin	400 mg	Tab.	
276.	Moxifloxacin	400 mg/250ml	Inf.	250 ml
277.	Nitrofurantoin	100 mg	Tab.	
278.	Oxytetracycline	250mg	Cap.	
279.	Piperacillin +Tazobactam	2 gm+0.25gm (2.25gm)/Vial	Inj.	
280.	Piperacillin +Tazobactam	4 g/0.5 g (4.5gm)/Vial	Inj.	
281.	Pyrazinamide	400mg	Tab.	
282.	Rifampicin	150 mg	Tab. / Cap.	
283.	Rifampicin	300 mg	Tab. / Cap.	
284.	Rifampicin	450 mg	Tab. / Cap.	
285.	Rifampicin	600 mg	Tab. / Cap.	
286.	Rifampicin	100 mg/5ml	Susp.	60 ml
287.	Rifampicin +Isoniazid + Pyrazinamide + Ethambutol	150mg+75mg +	Tab.	

		400mg+275mg		
288.	Rifampicin+ Isoniazid+ Pyrazinamide	75mg + 50mg+150mg	Disper. Tab.	
289.	Rifampicin +Isoniazid	150mg + 75mg	Tab.	
290.	Rifampicin+ Isoniazid	75mg+50mg	Disper. Tab.	
291.	Rifaximin	200 mg	Tab.	
292.	Rifaximin	550 mg	Tab.	
293.	Streptomycin Sulphate	1gm/Vial	Inj.	
294.	Tigecycline	50 mg /Vial	Inj.	
295.	Vancomycin	500 mg/Vial	Inj.	
296.	Vancomycin	1gm/Vial	Inj.	
	ANTI-MALARIAL DRUGS			
297.	Amodiaquine	150 mg/5 ml	Susp.	20 ml
298.	Amodiaquine	150 mg	Tab.	
299.	Artemether	80 mg/ml	Inj.	1ml
300.	Artemether + Lumefantrine	40 mg/240mg	Tab.	8s
301.	Artemether + Lumefantrine	80 mg/480mg	Tab.	6s
302.	Artemether + Lumefantrine	15 mg/ 90 mg/5ml	Susp.	60ml
303.	Artesunate	60 mg/Vial	Inj.	
304.	Artesunate	120 mg/Vial	Inj.	
305.	Artesunate + Sulfadoxine + Pyrimethamine	100mg+500mg+25 mg	Tab. Co-Blister	
306.	Artesunate + Sulfadoxine + Pyrimethamine	50mg+500mg+25 mg	Tab. Co-Blister	
307.	Chloroquine Phosphate	250 mg	Tab.	
308.	Chloroquine Phosphate	50 mg/5ml	Syp.	60 ml
309.	Dihydro artemisinin + Piperaquine Phosphate	15 mg + 120mg	Sachet	
310.	Dihydroartemisinin+ Piperaquine Phosphate	40 mg + 320mg	Tab./ Cap.	
311.	Primaquine	7.5 mg	Tab.	
312.	Primaquine	15mg	Tab.	
313.	Pyrimethamine	25 mg	Tab.	
314.	Quinine Dihydrochloride	300 mg	Tab.	

315.	Quinine Dihydrochloride	300 mg/ml	Inj.	2 ml
316.	Sulfadoxine + Pyrimethamine	501 mg + 25mg	Tab.	
317.	Sulfadoxine + Pyrimethamine	500 mg + 25mg/5ml	Susp.	15 ml
	ANTI-VIRAL DRUGS			
318.	Abacavir	600 mg	Tab.	
319.	Abacavir +Lamivudine	120+60 mg	Tab. For oral susp.	
320.	Acyclovir	200 mg	Tab.	
321.	Acyclovir	250 mg/Vial	Inj.	
322.	Acyclovir	500 mg/Vial	Inj.	
323.	Atazanavir + Ritonavir	300+100 mg	Tab.	
324.	Daclatasvir	60 mg	Tab.	
325.	Dolutegravir	50 mg	Tab.	
326.	Dolutegravir +Lamivudine +Tenofovir	50+300+300 mg	Tab.	
327.	Efavirenz	600 mg	Tab.	
328.	Efavirenz + Lamivudine + Tenofovir	600+300+300 mg	Tab.	
329.	Famciclovir	250 mg	Tab.	
330.	Ganciclovir	250 mg	Cap.	
331.	Ganciclovir	500 mg/Vial	Inj.	
332.	Lamivudine	150 mg	Tab.	
333.	Lamivudine	10mg/ml	Oral Soln.	100ml
334.	Lamivudine +Tenofovir	300+300 mg	Tab.	
335.	Lamivudine + Nevirapine + Zidovudine	30+50+60 mg	Disp. Tab.	
336.	Lopinavir +Ritonavir	80+20 mg	Oral Soln	60 ml
337.	Nevirapine	200 mg	Tab.	
338.	Nevirapine	50mg/5ml	Susp.	240ml
339.	Oseltamivir	75mg	Cap.	
340.	Ribavirin	400mg	Tab.	
341.	Sofosbuvir	400mg	Tab.	
342.	Tenofovir	300 mg	Tab.	

343.	Velpatasvir + Sofosbuvir	100 + 400 mg	Tab.	
344.	Zidovudine	300 mg	Tab.	
345.	Zidovudine	50mg/5ml	Syp.	100 ml
	BLOOD FORMING DRUGS, COAGULANTS, ANTICOAGULANTS & ANTI-ANAEMIC			
346.	Alteplase	2 mg	Inj.	
347.	Alteplase	20 mg	Inj.	
348.	Alteplase	50 mg	Inj.	
349.	Alteplase	100 mg	Inj.	
350.	Enoxaparin	20 mg	Inj.	0.2 ml
351.	Enoxaparin	40 mg	Inj.	0.4 ml
352.	Enoxaparin	60 mg	Inj.	0.6 ml
353.	Enoxaparin	80 mg	Inj.	0.8 ml
354.	Epoetin- α	2000 IU	Inj.	Vial/PFS
355.	Epoetin- α	4000 IU	Inj.	Vial/PFS
356.	Epoetin- α	10,000 IU	Inj.	Vial/PFS
357.	Epoetin- β	2000 IU	Inj.	Vial/PFS
358.	Epoetin- β	5000 IU	Inj.	Vial/PFS
359.	Epoetin- β	10,000 IU	Inj.	Vial/PFS
360.	Fondaparinux Sodium	2.5 mg	Inj.	
361.	Fondaparinux Sodium	7.5 mg	Inj.	
362.	Factor IX	500 IU/Vial	Inj.	
363.	Factor VII	1mg /Vial	Inj.	
364.	Factor VII	5mg /Vial	Inj.	
365.	Factor VIII	250 IU/vial	Inj.	
366.	Ferrous Fumarate + Folic Acid	150mg + 0.5mg	Tab.	
367.	Ferrous Sulphate	200 mg	Tab.	
368.	Ferrous Sulphate	100 mg/5ml	Syp.	120 ml
369.	Folic Acid	5 mg	Tab.	
370.	Heparin Sodium	5000 IU/ml	Inj.	5ml
371.	Iron Hydroxide poly maltose complex	100 mg	Tab.	30s or less

372.	Iron Hydroxide poly maltose complex	50 mg/5ml	Syp.	120 ml or less
373.	Iron Hydroxide poly maltose complex	50 mg/ml	Oral Drops	30 ml
374.	Iron Isomaltoside	100 mg	Inj.	1ml
375.	Iron Sucrose	20 mg/ml	Inj.	5 ml
376.	Mecobalamin	500 mcg	Inj.	1ml, 10s or less
377.	Mecobalamin	500mcg	Tab.	
378.	Methoxy PEG Epoetin-β	50 mcg	Inj.	0.3 ml
379.	Methoxy PEG Epoetin-β	75 mcg	Inj.	0.3 ml
380.	Methoxy PEG Epoetin-β	100 mcg	Inj.	0.3 ml
381.	Methoxy PEG Epoetin-β	150 mcg	Inj.	0.3 ml
382.	Methoxy PEG Epoetin-β	200 mcg	Inj.	0.3 ml
383.	Phytomenadione (vit-K1)	2mg/ml	Inj.	1ml
384.	Vitamin K	10mg/ml	Inj.	1ml
385.	Rivaroxaban	10 mg	Tab.	
386.	Rivaroxaban	15 mg	Tab.	
387.	Rivaroxaban	20 mg	Tab.	
388.	Tranexamic Acid	500 mg	Cap.	
389.	Tranexamic Acid	250 mg	Inj.	5 ml
390.	Tranexamic Acid	500 mg	Inj.	5 ml
391.	Warfarin Sodium	1 mg	Tab.	
392.	Warfarin Sodium	2.5 mg	Tab.	
393.	Warfarin Sodium	5 mg	Tab.	
	CARDIOVASCULAR AND DIURETIC DRUGS			
394.	Acetazolamide.	250 mg	Tab.	
395.	Acetyl Salicylic Acid (Aspirin) EC.	75 mg	Tab.	
396.	Adenosine		Inj.	
397.	Adrenaline	1mg/ml	Inj.	1ml
398.	Amiodarone HCl	200 mg	Tab.	
399.	Amiodarone HCl	100 mg	Tab.	
400.	Amiodarone HCl	150 mg/ml	Inj.	3 ml

401.	Amlodipine Besylate	5 mg	Tab.	30 or less
402.	Amlodipine Besylate	10 mg	Tab.	30 or less
403.	Amlodipine + Valsartan	5mg+80 mg	Tab.	30 or less
404.	Amlodipine + Valsartan	5mg+160 mg	Tab.	30 or less
405.	Amlodipine + Valsartan	10 mg+160 mg	Tab.	30 or less
406.	Amlodipine + Valsartan + Hydrochlorthiazide	10mg+160mg +12.5mg	Tab	30 or less
407.	Atenolol	50 mg	Tab.	30 or less
408.	Atenolol	100 mg	Tab.	30 or less
409.	Bisoprolol	2.5mg	Tab.	30 or less
410.	Bisoprolol	5 mg	Tab.	30 or less
411.	Bisoprolol	10 mg	Tab.	30 or less
412.	Bosenton	62.5mg	Tab.	
413.	Candesartan	4 mg	Tab.	30 or less
414.	Candesartan	8 mg	Tab.	30 or less
415.	Candesartan	16 mg	Tab.	30 or less
416.	Candesartan + Hydrochlorothiazide	16 mg+12.5mg	Tab.	30 or less
417.	Captopril	25 mg	Tab.	30 or less
418.	Carvedilol	6.25 mg	Tab.	30 or less
419.	Carvedilol	12.5 mg	Tab.	30 or less
420.	Carvedilol	25 mg	Tab.	30 or less
421.	Clopidogrel	75 mg	Tab.	30 or less
422.	Clopidogrel	300 mg	Tab.	30 or less
423.	Digoxin	500 mcg (0.5mg)	Inj.	2ml
424.	Digoxin	250 mcg	Tab.	
425.	Digoxin	50 mcg/ml	Oral Soln.	
426.	Dobutamine HCl	50 mg/ml	Inj.	5 ml
427.	Dopamine HCl	40 mg/ml	Inj.	5 ml
428.	Dopamine HCl	80 mg/ml	Inj.	10 ml
429.	Furosemide	20 mg	Tab.	
430.	Furosemide	40 mg	Tab.	

431.	Furosemide	10 mg/ml	Inj.	2ml
432.	Glyceryl Trinitrate	0.5 mg	SL. Tab.	
433.	Glyceryl Trinitrate	2.6 mg	Tab.	30 or less
434.	Glyceryl Trinitrate	6.4 mg	Tab.	30 or less
435.	Glyceryl Trinitrate	5 mg	Patch	
436.	Glyceryl Trinitrate	400 mcg	Buccal Spray	200 doses
437.	Hydralazine	20 mg	Inj.	
438.	Hydralazine	25 mg	Tab.	
439.	Hydralazine	50 mg	Tab.	
440.	Hydrochlorothiazide	25 mg	Tab.	
441.	Isoprenaline	1 mg/ml	Inj.	2 ml
442.	Isosorbide Dinitrate	1mg/ml	Inj.	10 ml
443.	Isosorbide Dinitrate	5 mg	Tab.	30 or less
444.	Isosorbide Dinitrate	10 mg	Tab.	30 or less
445.	Isosorbide-5-Mononitrate	20 mg	Tab.	30 or less
446.	Isosorbide-5-Mononitrate	40 mg	Tab.	30 or less
447.	Labetalol	50 mg	Inj.	10 ml
448.	Lisinopril	5 mg	Tab.	30 or less
449.	Lisinopril	10 mg	Tab.	30 or less
450.	Losartan + Hydrochlorothiazide	50 mg+12.5mg	Tab.	30 or less
451.	Losartan Potassium	25 mg	Tab.	30 or less
452.	Losartan Potassium	50 mg	Tab.	30 or less
453.	Methyldopa	250 mg	Tab.	
454.	Methyldopa	250 mg	Inj.	
455.	Metoprolol	25 mg	Tab.	30 or less
456.	Metoprolol	50 mg	Tab.	30 or less
457.	Metoprolol	100 mg	Tab.	30 or less
458.	Metoprolol	1mg/ml	Inj.	5 ml
459.	Metolazone	5 mg	Tab.	
460.	Milrinone	1mg/ml	Inj.	10ml
461.	Nifedipine	10 mg	Cap.	

462.	Nifedipine	30 mg	ER-Tab.	
463.	Nifedipine	30mg	Tab.	
464.	Nitro-glycerine	1mg/ml	Inj.	
465.	Noradrenaline / Norepinephrine	1mg/ml	Inj.	4 ml
466.	Phenylephrine	10 mg	Inj.	
467.	Procaine + Magnesium chloride+ Potassium chloride	0.27 mg/10ml+ 3.25mg/10ml + 1.19mg/10ml	Inj.	10 ml
468.	Propranolol	10 mg	Tab.	30 or less
469.	Propranolol	40 mg	Tab.	30 or less
470.	Ramipril	5 mg	Tab.	30 or less
471.	Rosuvastatin	10 mg	Tab.	30 or less
472.	Sodium Nitroprusside	25mg/ml	Inj.	2ml
473.	Spironolactone	100 mg	Tab.	
474.	Streptokinase	1.5 MIU/vial	Inj.	
475.	Valsartan	40 mg	Tab.	30 or less
476.	Valsartan	80 mg	Tab.	30 or less
477.	Valsartan + Hydrochlorothiazide	80 mg+12.5mg	Tab.	30 or less
478.	Valsartan + Sacubitril	100mg	Tab.	30 or less
479.	Verapamil	40 mg	Tab.	
480.	Verapamil	80 mg	Tab.	
481.	Verapamil	2.5 mg/ml	Inj.	2 ml
	CONTRACEPTIVES			
482.	Combined Oral Contraceptives	Contraceptive tablets: 21 Each tablet shall contain 0.03 mg of ethinyl estradiol and 0.15 mg of Levonorgestrel. Spacing tablets: 7	Tab.	

		Each tablet shall contain 75 mg ferrous fumarate.		
483.	Depot-Medroxyprogesterone Acetate		Inj.	
484.	Levonorgestrel	75mg	Implant	
485.	Male Latex Condom			
486.	Intra Uterine Contraceptive Devices (IUCDs)	TCu 380 A		
487.	Intra Uterine Contraceptive Devices (IUCDs)	NT380 mini		
EAR, NOSE AND THROAT PREPARATIONS				
488.	Betamethasone	0.10%	Ear /Nasal Drops	7.5 ml
489.	Betamethasone + Neomycin	0.1% + 0.5%	Ear/Nasal Drops	7.5 ml
490.	Ciprofloxacin HCl	0.30%	Ear Drops	5 ml
491.	Fluticasone	50 mcg/Actu.	Nasal Spray	15ml
492.	Lignocaine + Polymyxin	50mg/ml+10,000 IU/ml	Ear Drops	5ml
493.	Soda Glycerin (Sodium Bicarbonate + Glycerin)	5% +30%	Ear Drops	10 ml
494.	Sodium Chloride	0.65 % w/v	Nasal Drops	30 ml
495.	Xylometazoline HCl	0.05%	Nasal Drops	15ml
496.	Xylometazoline HCl	0.10%	Nasal Spray	15ml
GASTROINTESTINAL DRUGS				
497.	Aluminium Hydroxide + Magnesium Hydroxide + Simethicone		Susp.	120ml
498.	Bacillus Clausii Spores	2 Billion/ 5ml	Susp.	
499.	Bisacodyl	5 mg	Tab.	
500.	Dimenhydrinate	12.5mg/4ml	Syp.	60 ml
501.	Dimenhydrinate	50 mg/ml	Inj.	1 ml
502.	Dimenhydrinate	50 mg	Tab.	
503.	Domperidone	10 mg	Tab.	
504.	Domperidone	5 mg/5ml	Susp.	120 ml
505.	Drotaverine	40 mg	Tab.	
506.	Drotaverine	20 mg/ml	Inj.	2ml

507.	Famotidine	40 mg	Tab.	20 or less
508.	Glycerine Suppositories		Supp.	
509.	Hyoscine Butyl bromide + Paracetamol	10mg+500mg	Tab.	
510.	Itopride	150mg	Tab.	10s
511.	Lactulose	3.35gm/5ml	Syp.	120ml
512.	Liquid Paraffin + Magnesium Hydroxide	1.25ml +3.5ml	Emul.	120ml
513.	Loperamide	2mg	Cap.	
514.	Metoclopramide HCl	5mg/ml	Inj.	2ml
515.	Octreotide Acetate	0.1mg/ml	Inj.	1ml
516.	Omeprazole	40 mg / Vial	Inj.	
517.	Omeprazole	40 mg	Cap.	14s
518.	Esomeprazole	40mg	Cap.	14s
519.	Ondansetron	8 mg	Tab.	10s
520.	Ondansetron	2 mg/ml	Inj.	4 ml
521.	Pantoprazole	20mg	Tab.	20 or less
522.	Pantoprazole	40mg	Tab.	20 or less
523.	Phloroglucinol + Trimethyl Phloroglucinol	80 mg + 80 mg	Tab.	
524.	Phloroglucinol + Trimethyl Phloroglucinol	40 mg + 0.04mg	Inj.	4 ml
525.	Prucalopride	2 mg	Tab.	
526.	Simethicone	40 mg/ml	Oral Drops	30 ml
527.	Sodium Phosphate + Sodium Bi-Phosphate	7.2 gm + 19.2gm	Enema	120ml
528.	Sodium Citrate + Sodium Lauryl Sulphate + Glycerine	450mg+75mg + 90%	Enema	10ml
529.	Sodium Picosulfate	7.5mg/ml	Syp	
530.	Sodium Bicarbonate + Peppermint		Tab.	
531.	Terlipressin	1mg / Vial	Inj.	
532.	Zinc Sulphate	20 mg	Tab.	
533.	Zinc Sulphate	20 mg/5ml	Syp.	60 ml
HORMONES & DRUGS ACTING ON ENDOCRINE SYSTEM				
534.	Carbimazole	5 mg	Tab.	

535.	Clomiphene Citrate	50 mg	Tab.	
536.	Dexamethasone	0.5 mg	Tab.	
537.	Dexamethasone	4 mg/ml	Inj.	1ml, 25s or less
538.	Dinoprostone	3 mg	Vaginal Tab.	
539.	Dydrogesterone	10mg	Tab.	
540.	Empagliflozin	10 mg	Tab.	30 or less
541.	Empagliflozin	25 mg	Tab.	30 or less
542.	Empagliflozin +Linagliptin	10/5mg	Tab.	20 or less
543.	Empagliflozin +Linagliptin	25/5mg	Tab.	20 or less
544.	Fludrocortisone	0.1 mg	Tab.	
545.	Glibenclamide	5 mg	Tab.	
546.	Gliclazide	60mg	Tab.	30 or less
547.	Gliclazide	60mg	Tab.	30 or less
548.	Gliclazide	80 mg	Tab.	30 or less
549.	Glimepiride	1mg	Tab.	30 or less
550.	Glimepiride	2mg	Tab.	30 or less
551.	Glimepiride	3mg	Tab.	30 or less
552.	Glimepiride	4mg	Tab.	30 or less
553.	Glimepiride + Metformin	1 mg/500mg	Tab.	30 or less
554.	Glimepiride + Metformin	2 mg/500mg	Tab.	30 or less
555.	Human chorionic gonadotropin	1500 IU	Inj.	
556.	Human chorionic gonadotropin	5000 IU	Inj.	
557.	Hydrocortisone	100 mg/Vial	Inj.	
558.	Hydrocortisone	250 mg/Vial	Inj.	
559.	Hydroxy progesterone	250mg/ml	Inj.	1 ml
560.	Human Insulin 70/30 (Premixed)	100 IU /ml	Inj.	10ml
561.	Insulin Regular (Human)	100 IU/ml	Inj.	10ml
562.	Insulin Glargine	100 IU/ml	Inj.	3ml, Pen
563.	Insulin Glargine	100 IU/ml	Inj.	10ml, Vial
564.	Insulin Glulisine	100 IU/ml	Inj.	3ml, Pen
565.	Insulin Lispro	100 IU/ml	Inj.	10ml

566.	Insulin Isophane/ NPH	100 IU/ml	Inj.	10ml
567.	Mestranol + Norethisterone	50 mcg + 1 mg	Tab.	
568.	Metformin HCl	500mg.	Tab.	50s or less
569.	Methyl Prednisolone	500mg Vial	Inj.	1s
570.	Methyl Prednisolone	1gm Vial	Inj.	1s
571.	Methylergometrine Maleate	0.2 mg/ml	Inj.	1 ml
572.	Misoprostol	200 mcg	Tab.	
573.	Oxybutynin	5mg	Tab.	
574.	Oxytocin	5 IU/ml	Inj.	1 ml
575.	Oxytocin	10 IU/ml	Inj.	1 ml
576.	Prednisolone	5 mg	Tab.	
577.	Propylthiouracil	50 mg	Tab.	
578.	Prostaglandin F2	5mg/ml	Inj.	1ml
579.	Semaglutide	0.25mg	Inj.	PFS
580.	Semaglutide	0.5mg	Inj.	PFS
581.	Sitagliptin + Metformin	50 mg/500 mg	Tab.	30 or less
582.	Sitagliptin + Metformin	50mg /1000 mg	Tab.	30 or less
583.	Thyroxin Sodium	50 mcg	Tab.	
584.	Tibolone	2.5mg	Tab.	
585.	Triamcinolone Acetonide	40 mg	Inj.	1 ml
586.	Vildagliptin	50 mg	Tab.	
	IMMUNOLOGICAL / BIOLOGICAL DRUGS			
587.	Anti Gas Gangrene Serum	30000 Units	Inj.	
588.	Anti-Rabies Serum	200 IU/ml		5 ml
589.	Anti-Tetanus Serum	1500 IU	Inj.	1ml
590.	Anti-Tetanus Serum	10,000 IU	Inj.	
591.	Anti-Thymocyte globulin (ATG)		Inj.	
592.	Bacillus Calmette–Guérin (BCG) Vaccine		Inj.	
593.	Cholera Vaccine		Inj.	
594.	Diphtheria Anti-Toxin	20,000 IU	Inj.	

595.	Diphtheria Anti-Toxin	10,000 IU	Inj.	
596.	Hepatitis B Vaccine	10µg/0.5ml, 20µg/1ml	Inj.	
597.	Hepatitis B Immunoglobulin (Adult)		Inj.	
598.	Hepatitis B Immunoglobulin (Neonatal)		Inj.	
599.	Human Immunoglobulins for IV administration	5%	Inj.	
600.	Human Immunoglobulins for IV administration	10%	Inj.	
601.	Human Diploid Cell Rabies Vaccine (HDCV)		Inj.	
602.	Meningococcal Vaccine		Inj.	
603.	Measles, Mumps, & Rubella Vaccine (MMR)		Inj.	
604.	Mumps Vaccine		Inj.	
605.	Pentavalent vaccine (DTP + Hep B + Hib)		Inj.	
606.	Pneumococcal Vaccine	PCV13	Inj.	
607.	Pneumococcal Vaccine	PPSV23	Inj.	
608.	Polio Vaccine (Oral)			
609.	Polio Vaccine (Inactivated)		Inj.	
610.	Purified Chick Embryo Cell Rabies Vaccine (PCECV)		Inj.	
611.	Purified Vero Cell Rabies Vaccine (PVRV)		Inj.	
612.	Primary Hamster Kidney Cell Rabies vaccine (PHKCV)		Inj.	
613.	Purified Duck Embryo Rabies vaccine (PDEV)		Inj.	
614.	Rabies Immunoglobulin (Human)	150 IU/ml	Inj.	
615.	Rho (D) Immune globulin	300 mcg	Inj.	
616.	Rotavirus Vaccine (WHO Prequalified)	RV1		
617.	Rotavirus Vaccine (WHO Prequalified)	RV5		
618.	Secukinumab	150 mg	Inj.	
619.	Scorpion Venom Antiserum		Inj.	
620.	Snake Venom Antiserum		Inj.	
621.	Snake Venom Antiserum (Lyophilized) with diluent		Inj.	

622.	Tetanus Immunoglobulin (Human)	250 IU	Inj.	
623.	Tetanus Toxoid	0.5 ml	Inj.	
624.	Tocilizumab	400mg/20ml	Inj.	
625.	Trivalent Influenza Vaccine		Inj.	
626.	Typhoid Vaccine		Inj.	
INTRAVENOUS FLUIDS, ELECTROLYTES AND PARENTERAL NUTRITION				
627.	Amino Acids Solutions	3%, 4%, 7%, 8%, 5%, 10% & 20%	I/V Inf.	500 ml
628.	Balanced electrolyte solution		I/V Inf.	250ml
629.	Balanced electrolyte solution		I/V Inf.	1000 ml
630.	Calcium Chloride		Inj.	
631.	Calcium Chloride, Glucose, Potassium Chloride, Sodium Acetate	0.2g/L, 5%w/v, 1.5g/L, 3.13g/L	I/V Inf.	500ml
632.	Calcium Chloride, Glucose, Potassium Chloride, Sodium Acetate	0.2g/L, 5%w/v, 1.5g/L, 3.13g/L	I/V Inf.	1000ml
633.	Calcium Gluconate		Inj.	10ml
634.	Dextrose	25%	I/V Inf.	25ml
635.	Dextrose	25%	I/V Inf.	1000ml
636.	Dextrose	10%	I/V Inf.	500ml
637.	Dextrose	10%	I/V Inf.	1000ml
638.	Dextrose	5%	I/V Inf.	100ml
639.	Dextrose	5%	I/V Inf.	250ml
640.	Dextrose	5%	I/V Inf.	500ml
641.	Dextrose	5%	I/V Inf.	1000ml
642.	Dextrose + Sodium Chloride	5% + 0.45%	I/V Inf.	500ml
643.	Dextrose + Sodium Chloride	5% + 0.9%	I/V Inf.	250ml
644.	Dextrose + Sodium Chloride	5% + 0.9%	I/V Inf.	500ml
645.	Dextrose + Sodium Chloride	5% + 0.9%	I/V Inf.	1000ml
646.	Flavored Oral Re-hydration Salt WHO approved formula.	Sodium Chloride (3.5 g/L),	Sachet	

		Glucose Anhydrous (20g/L) Potassium Chloride (1.5g/L) Trisodium Citrate (2.9g/L)		
647.	Flavored Oral Rehydration Salt (Low Osmolarity)	Sodium Chloride Sachet (2.6 g/L) Glucose Anhydrous (13.5 g/L) Potassium Chloride (1.5 g/L) Trisodium citrate (2.9 g/L)	Sachet	
648.	Gelatin Polypeptide	3.5%	I/V Inf.	500 ml
649.	Gelatin Polypeptide	4%	I/V Inf.	500 ml
650.	Glycine		Irrigation Solution	3000 ml
651.	Haemodialysis Concentrate		Part A- Solution Part B-Powder	
652.	Lipid Emulsion	20%	I/V Inf.	250 ml
653.	Magnesium Sulphate	500 mg/ml	Inj.	2ml
654.	Magnesium Sulphate	500 mg/ml	Inj.	10 ml
655.	Mannitol	20%	I/V Inf.	500 ml
656.	Normal Saline	0.9%	I/V Inf.	100 ml
657.	Normal Saline	0.9%	I/V Inf.	250 ml
658.	Normal Saline	0.9%	I/V Inf.	500 ml
659.	Normal Saline	0.45%	I/V Inf.	500ml
660.	Normal Saline	0.9%	I/V Inf.	1000 ml
661.	Peritoneal Dialysis Soln.		Soln.	1000 ml
662.	Peritoneal Dialysis Soln.		Soln.	2000 ml
663.	Peritoneal Dialysis Soln.		Soln.	4000 ml
664.	Potassium Chloride	1 gm/ 5ml	Syp.	120 ml

665.	Potassium Chloride	7.46% w/v	Inj.	25ml
666.	Potassium Chloride	500 mg	SR-Tab.	
667.	Ringer's Lactate + Dextrose 5% Soln.		I/V Inf.	500 ml
668.	Ringer's Lactate + Dextrose 5% Soln.		I/V Inf.	1000 ml
669.	Ringer's Lactate Soln.		I/V Inf.	250 ml
670.	Ringer's Lactate Soln.		I/V Inf.	500 ml
671.	Ringer's Lactate Soln.		I/V Inf.	1000 ml
672.	Salt free Albumin	20% Soln.	I/V Inf.	50 ml
673.	Salt free Albumin	20% Soln.	I/V Inf.	100 ml
674.	Sodium Acid Citrate	1.315 gm/ 5 ml	Liq.	120 ml
675.	Sodium Bicarbonate	8.4%	I/V Soln.	
676.	Sodium Chloride + Dextrose	0.18 % + 4.3%	I/V Inf.	500ml
677.	Sterile Water for Injection	5 ml	Inj.	
678.	Total Parenteral Nutrition (Glucose, Sodium Phosphate, Zinc)		IV Inf.	1250 ml
MISCELLANEOUS THERAPEUTICS				
679.	Allopurinol	100 mg	Tab.	
680.	Allopurinol	300 mg	Tab.	
681.	Beractant	25mg/ml	Inj.	
682.	Bovine Lipid Extract Surfactant	27mg/ml	Inj.	5ml or less
683.	Calcitriol	1mcg/ml	Inj.	1ml
684.	Cinacalcet HCl	30 mg	Tab.	
685.	Febuxostat	40 mg	Tab.	
686.	Febuxostat	80 mg	Tab.	
687.	Hyaluronic Acid		Inj.	
688.	Ibandronic Acid	1mg/ml	Inj.	3 ml
689.	Ibandronic Acid	150mg	Tab.	
690.	Liquid Paraffin			450 ml
691.	Proactant alfa	120 mg/ 1.5 ml	Inj.	
692.	Proactant alfa	240 mg/ 3 ml	Inj.	

693.	Sevelamer Carbonate	800mg	Tab.	
694.	Sodium tetradecyl sulphate	10mg/ ml (1%)	Inj.	2ml
695.	Sodium tetradecyl sulphate	30mg/ml (3%)	Inj.	2 ml
696.	Solifenacin Succinate	10mg	Tab.	
697.	Tamsulosin HCl	0.4mg	Cap.	
698.	Tamsulosin HCl + Dutasteride	0.4 mg+ 0.5mg	Cap.	
	PSYCHOTROPIC AND ANTICONVULSANT DRUGS			
699.	Alprazolam	0.25 mg	Tab.	
700.	Alprazolam	0.5 mg	Tab.	
701.	Amitriptyline HCl	25 mg	Tab.	
702.	Aripiprazole	15 mg	Tab.	
703.	Carbamazepine	200 mg	Tab.	
704.	Carbamazepine	100 mg / 5 ml	Syp.	120 ml
705.	Chlorpromazine HCl	100 mg	Tab.	
706.	Citalopram	10 mg	Tab.	
707.	Citicoline	125 mg/ml	Inj.	2 ml
708.	Citicoline	250 mg/ml	Inj.	2 ml
709.	Clomipramine HCl	25 mg	Tab.	
710.	Clonazepam	0.5 mg	Tab.	
711.	Clonazepam	2 mg	Tab.	
712.	Clonazepam	0.25% w/v	Oral Drops	10 ml
713.	Clozapine	25mg	Tab.	
714.	Clozapine	100 mg	Tab.	
715.	Co- Dergocrine mesylate	1.5 mg	Tab.	
716.	Desvenlafaxine	50 mg	Tab.	
717.	Desvenlafaxine	100 mg	Tab.	
718.	Diazepam	10 mg/ml	Inj.	2 ml
719.	Duloxetine	30 mg	Cap.	
720.	Duloxetine	60 mg	Cap.	
721.	Divalproex Sodium	250 mg	Tab.	

722.	Divalproex Sodium	500 mg	Tab.	
723.	Dothiepin HCl (Dosulepin HCl)	25mg	Tab.	
724.	Dothiepin HCl (Dosulepin HCl)	75 mg	Tab.	
725.	Escitalopram	10 mg	Tab.	
726.	Fluoxetine HCl	20 mg	Cap.	
727.	Flupenthixol	40 mg/ml	Inj.	2 ml
728.	Fluphenazine Decanoate	25 mg/ml	Inj.	1 ml
729.	Haloperidol	2 mg/ ml	Oral Drops	15 ml
730.	Haloperidol	5 mg	Tab.	
731.	Haloperidol	5 mg	Inj.	1 ml
732.	Imipramine	25 mg	Tab.	
733.	Lamotrigine	50 mg	Tab.	
734.	Levodopa + Carbidopa	250 mg+25mg	Tab.	
735.	Levetiracetam	250 mg	Tab.	
736.	Levetiracetam	500mg	Tab.	
737.	Levetiracetam	100 mg/ml	Inj.	5 ml
738.	Lithium Carbonate	400 mg	Tab.	
739.	Midazolam	1mg/ml	Inj.	5ml
740.	Midazolam	5mg/ml	Inj.	
741.	Mirtazapine	15mg	Tab.	
742.	Olanzapine	5mg	Tab.	
743.	Olanzapine	10 mg	Tab.	
744.	Oxcarbazepine	300 mg	Tab.	
745.	Oxcarbazepine	600 mg	Tab.	
746.	Phenobarbital	30 mg	Tab.	
747.	Phenobarbital	200 mg	Inj.	1ml
748.	Phenobarbital	20 mg/5ml	Elixir	60 ml
749.	Phenytoin Sodium	100 mg	Tab. /Cap.	
750.	Phenytoin Sodium	30 mg/5 ml	Susp.	
751.	Phenytoin Sodium		Inj.	
752.	Piracetam	200 mg/ml	Inj.	5ml

753.	Pregabalin	50 mg	Cap.	
754.	Pregabalin	75mg	Cap.	
755.	Pregabalin	150 mg	Cap.	
756.	Prochlorperazine Maleate	5 mg	Tab.	
757.	Prochlorperazine Maleate	12.5 mg.	Inj.	1 ml
758.	Procyclidine HCl	5mg	Tab.	
759.	Procyclidine HCl	5 mg/ml	Inj.	2 ml
760.	Quetiapine	100 mg	Tab.	
761.	Risperidone	2mg	Tab.	
762.	Risperidone	4 mg	Tab.	
763.	Selegiline	5 mg	Tab	
764.	Sertraline	100 mg	Tab.	
765.	Sodium Valproate	250 mg/5ml	Syp.	120 ml
766.	Topiramate	50 mg	Tab.	
767.	Trifluoperazine	5 mg	Tab.	
768.	Valproate Sodium	500 mg/5ml	Inj.	
769.	Valproate Sodium	500 mg/5ml	Inj.	
770.	Venlafaxine	37.5 mg	Tab.	
771.	Venlafaxine	75 mg	Tab.	
772.	Zuclopenthixol	200 mg	Inj.	1 ml
	RADIOLOGICAL DIAGNOSTICS AGENTS			
773.	Barium Sulphate	60% w/v	Liq.	
774.	Barium Sulphate	99% w/w	Powder	
775.	Dimeglumine Gadopentetate	469 mg/mL	Inj.	
776.	Gadodiamide	287mg/0.5mm ol	Inj.	20ml
777.	Iohexol	300mgI/ml	Inj.	
778.	Iohexol	350mgI/ml	Inj.	
779.	Iopamidol	300mgI/ml	Inj.	
780.	Iopamidol	370mgI/ml	Inj.	
781.	Iopromide	300mgI/ml	Inj.	
782.	Iopromide	370mgI/ml	Inj.	

783.	Meglumine Iodine	76% w/v 370 mg/ml	Soln.	50 ml
784.	Meglumine Iodine	76% w/v 370 mg/ml	Soln.	100 ml
785.	Meglumine Iodine	76% w/v 370 mg/ml	Soln.	20 ml
786.	Sodium Amidotrizoate (Sodium diatrizoate) + Meglumine Amidotrizoate (Meglumine diatrizoate).	100mg+660mg/ml	Soln.	100ml
787.	Ultrasound Gel			5000ml
RESPIRATORY DRUGS				
788.	Acefylline	125 mg /5ml	Syp.	120 ml
789.	Aminophylline	25 mg/1ml	Inj.	10 ml
790.	Beclomethasone	800 mcg/2ml	Soln.	2 ml
791.	Beclomethasone + Salbutamol	50 mcg + 100 mcg	Spray / Inhaler.	
792.	Beclomethasone Dipropionate	250 mcg	Inhaler	
793.	Budesonide	50 mcg/Actuation	Inhaler	
794.	Budesonide	200 mcg	Rota Cap.	
795.	Budesonide	400 mcg	Rota Cap.	
796.	Budesonide + Formoterol	100 mcg + 6 mcg	Rota Cap.	
797.	Budesonide + Formoterol	200 mcg + 6 mcg	Rota Cap.	
798.	Budesonide + Formoterol	400 mcg + 6 mcg	Rota Cap.	
799.	Budesonide + Formoterol	400 mcg + 12 mcg	Rota Cap.	
800.	Diphenhydramine+ Aminophylline+ Ammonium Chloride	8mg+32mg+30 mg /5ml	Syp.	120ml
801.	Doxofylline	400mg	Tab/Cap.	
802.	Doxofylline	100mg/5ml	Syp.	60ml
803.	Fluticasone Propionate + Salmeterol	125 mcg + 25mcg	Inhaler	
804.	Ipratropium Bromide	20 mcg	Inhaler	
805.	Ipratropium Bromide	250 mcg/ml	Soln.	2ml
806.	Ipratropium Bromide	250mcg/ml	Soln.	20ml
807.	Ipratropium bromide + salbutamol	0.5mg/2.5mg	Soln.	2.5ml

808.	Ketotifen	1 mg	Tab.	
809.	Ketotifen	0.2 mg/ml	Syp.	60ml
810.	Salbutamol	2 mg	Tab.	
811.	Salbutamol	4 mg	Tab.	
812.	Salbutamol	2mg/5ml	Syp.	120ml or less
813.	Salbutamol	5mg/ml	Soln.	20ml
814.	Salbutamol	100 mcg	Inhaler	
815.	Salbutamol	0.5 mg/ml	Inj.	1ml
816.	Terbutaline Sulphate	2.5 mg	Tab.	
817.	Terbutaline Sulphate	0.3 mg/ml	Syp.	60ml
818.	Terbutaline Sulphate	0.5 mg/ml	Inj.	1ml
819.	Tiotropium	18 mcg	Rota Cap.	
	STERILE OPHTHALMIC PREPARATIONS			
820.	Acyclovir	3% w/w	Eye Oint.	4.5 gm
821.	Artificial Tears (Hypromellose + Dextran)	0.3% w/v + 0.1% w/v	Eye Drops	15 ml
822.	Acetylcholine	20 mg/ Vial	Inj.	
823.	Betamethasone	0.1% w/v	Eye Drops	7.5 ml
824.	Brinzolamide + Brimonidine	10mg + 2mg /ml	Eye Drops	5ml
825.	Chloramphenicol	1% w/w	Eye Ointment	5gm
826.	Chloramphenicol	0.5 % w/v	Eye Drops	10ml
827.	Ciprofloxacin	0.3% w/v	Eye Drops	5ml
828.	Cyclopentolate	1%	Eye Drops	10ml
829.	Cyclopentolate + Proparacaine	1% + 0.5%	Eye Drops	
830.	Dexamethasone	0.1% w/v	Eye Drops	
831.	Diclofenac Sodium	0.1% w/v	Eye Drops	
832.	Dorzolamide + Timolol	2 + 0.5%	Eye Drops	5ml
833.	Fluorescein	2% w/v	Eye Drops	15ml
834.	Fluorescein	0.6 mg	Strips	
835.	Fluorometholone + Neomycin	0.1%+0.5%	Eye Drops	5ml
836.	Homatropine	2% w/v	Eye Drops	15ml

837.	Latanoprost	0.05%	Eye Drops	2.5ml
838.	Levobunolol	0.5% w/v	Eye Drops	5ml
839.	Moxifloxacin	0.5% w/v	Eye Drops	5ml
840.	Phenylephrine	10 % w/v	Eye Drops	5 ml
841.	Pilocarpine HCl	2% w/v	Eye Drops	10 ml
842.	Pilocarpine HCl	4% w/v	Eye Drops	10 ml
843.	Polymyxin B+ Neomycin + Dexamethasone		Eye Drops	5 ml
844.	Polymyxin B+ Neomycin + Dexamethasone		Oint.	3.5 gm
845.	Polymyxin B Sulphate + Bacitracin	10,000 IU/gm + 500 IU/gm	Eye Oint.	6 gm
846.	Proparacaine	0.5% w/v	Eye Drops	15 ml
847.	Ranibizumab	10 mg/ ml	Inj.	
848.	Tetracycline	1%	Eye Oint.	5gm
849.	Timolol Maleate	0.25%	Eye Drops	5 ml
850.	Timolol Maleate	0.5% w/v	Eye Drops	5 ml
851.	Tobramycin	0.3% w/v	Eye Drops	5 ml
852.	Tobramycin + Dexamethasone	0.3% + 0.1% w/v	Eye Drops	5 ml
853.	Travoprost	40mcg/ml	Eye Drops	2.5ml
854.	Tropicamide	1% w/v	Eye Drops	15ml
	TOPICAL DRUGS PREPARATIONS			
855.	Acyclovir Ointment	5% w/w	Oint.	5 gm
856.	Betamethasone dipropionate	0.05%	Oint.	20 gm
857.	Betamethasone dipropionate	0.05%	Cream	20 gm
858.	Betamethasone dipropionate	0.05%	Lot.	20 ml
859.	Benzyl Benzoate	25%	Lot.	120 ml
860.	Betamethasone Dipropionate + Gentamicin sulphate	0.05 % + 0.1%	Cream	15 gm
861.	Betamethasone Dipropionate + Gentamicin sulphate	0.05 % + 0.1 %	Oint.	15gm
862.	Calamine	15%	Lot.	120 ml
863.	Clobetasol Propionate	0.05% w/w	Cream	20gm
864.	Clotrimazole	1%	Cream	10gm

865.	Clotrimazole	1%	Lot.	60ml
866.	Clotrimazole	1%	Soln.	20ml
867.	Coal Tar	4%	Soln.	
868.	Fluocinolone Acetonide	0.03%	Cream	15gm
869.	Fluocinolone Acetonide	0.03%	Gel	15gm
870.	Fusidic acid	2%	Cream	15gm
871.	Fusidic acid	2%	Oint.	15gm
872.	Gentamicin	0.10%	Cream	10gm
873.	Gentamicin	0.10%	Oint.	10gm
874.	Gentian Violet	0.50%	Aq. Soln.	
875.	Hydrocolloid		Gel	
876.	Hydrocortisone	1%	Oint.	10 gm
877.	Hydrocortisone	1%	Cream	10 gm
878.	Isotretinoin + Erythromycin	0.05 % + 2% w/w	Gel	
879.	Lignocaine HCl (Sterile)	2%	Gel	
880.	Meglumine antimoniate		Inj.	
881.	Miltefosine	10 mg	Tab. / Cap.	
882.	Miltefosine	50 mg	Tab. / Cap.	
883.	Mupirocin	2 % w/w	Cream	15 gm
884.	Mupirocin	2 % w/w	Oint.	15 gm
885.	Permethrin	5% w/w	Cream	30gm
886.	Permethrin		Lot.	60ml
887.	Polymyxin B Sulphate + Bacitracin zinc	10000 IU/g + 500 IU/g	Oint.	10 gm
888.	Polymyxin B Sulphate + Bacitracin zinc	10000 IU/g + 500 IU/g	Oint.	20 gm
889.	Salicylic Acid	5%	Soln.	
890.	Silicone		Gel	
891.	Silver Sulfadiazine	1%	Cream	50 gm
892.	Silver Sulfadiazine	1%	Cream	250 gm
893.	Sodium Stibogluconate		Inj.	
894.	Terbinafine	1%	Cream	10gm

895.	Terbinafine		Lot.	
896.	Tetrachlorodecaoxide	0.052 mg/ 5ml	Soln.	50ml
	DISINFECTANT & ANTISEPTIC			
897.	Chloroxylonol	4.80% and above	Soln.	One litre
898.	Chlorhexidine Di gluconate	7.10%	Soln.	
899.	Chlorhexidine	7.1 % w/w	Gel.	
900.	Formalin Pure	47%	Soln.	450 ml
901.	Glutaraldehyde Solution for Sterilization	2%-2.5%	Soln.	5 Liters
902.	Hand sanitizer Iso-Propyl Alcohol Based (As per WHO Recommendations) (DRAP/PSQCA Approved Registered)	75%	Soln.	1000ml
903.	Hand sanitizer Ethyl Alcohol Based (As per WHO Recommendations) ((DRAP/PSQCA Registered)	80%	Soln.	1000ml
904.	Hydrogen Peroxide	6%	Soln.	
905.	Povidone Iodine	10%	Soln.	450 ml
906.	Povidone Iodine	7.5% w/w	Scrub	450 ml
907.	Sodium Hypochlorite	10%	Soln.	500 ml
	VITAMINS / MINERALS			
908.	Alfacalcidol	0.5 mcg	Tab.	
909.	Ascorbic Acid	500 mg	Tab.	
910.	Calcium Acetate		Inf.	
911.	Calcium Acetate	667mg	Tab.	
912.	Ossein Mineral Complex + Vitamin D	830mg + 400iu	Tab.	30s
913.	Ossein Mineral Complex + Vitamin D	250mg+400iu/ 5ml	Syp.	120ml
914.	Cholecalciferol (Vitamin D3)	200000 IU	IM/ Oral Inj.	1ml
915.	Pyridoxine HCl	50 mg	Tab.	
916.	Retinol (Vitamin A)		Cap.	
	COTTON, BANDAGES, P.O.P, SURGICAL DISPOSABLES & NON-DRUG ITEMS			
917.	Absorbable Haemostatic Gelatine Sponges	Different Sizes		

918.	Abrams Pleural Biopsy Needles	All sizes		
919.	Adhesive Tapes (Paper)	1" x 5 yards		
920.	Adhesive Tapes (Paper)	2" x 5 yards		
921.	Adhesive Tapes (Paper)	3" x 5 yards		
922.	Adhesive Tapes (Paper)	4" x 5 yards		
923.	Adhesive Tapes (Plastic)	1" x 5 yards		
924.	Adhesive Tapes (Plastic)	2" x 5 yards		
925.	Adhesive Tapes (Plastic)	3" x 5 yards		
926.	Adhesive Tapes (Plastic)	4" x 5 yards		
927.	Angiography Guide Wires	All Sizes		
928.	Angiography Exchange Guide Wires	All Sizes		
929.	Arterial Catheter (Sterile, wings having holes, Spring-Wire Guide Handle, Black Feed Tube Marker, return window) The Cannula should be radio- opaque, as well as latex, pyrogen and PVC free)	Different Sizes		
930.	Arterial Sheath (Femoral)	All sizes		
931.	Automated External Defibrillator			
932.	Bacterial Binding Dressing	Different Sizes		
933.	Bacterial filter, HME Filter and Viral filter (HCV, HBS+HIV etc.)			
934.	Bain Circuit	Adult		
935.	Bain Circuit	Pediatric		
936.	Bare Metal Cardiac Stents (Cobalt Chromium)	All Sizes		
937.	Bare Metal Cardiac Stents (Platinum Chromium)	All Sizes		
938.	Bare Metal Cardiac Stents (Stainless Steel)	All Sizes		
939.	Becker Implant			
940.	Blood Bags (CPDA-1)	Single	450ml-500ml	
941.	Blood Bags (CPDA-1)	Single	250ml-350ml	
942.	Blood Bags (CPDA-1)	Double	450ml-500ml	
943.	Blood Bags (CPDA-1)	Double	250ml-350ml	
944.	Blood Bags (CPDA-1)	Triple	450ml-500ml	

945.	Blood Bags (CPDA-1)	Triple	250ml-350ml	
946.	Blood Transfusion Sets	sterile and pyrogen free, minimum 125cm tube length, blister pack		
947.	Blood Collection Tubes (Purple Top)	Various sizes		
948.	Blood Collection Tubes (Red Top)	Various sizes		
949.	Blood Collection Tubes (Black Top)	Various sizes		
950.	Blood Collection Tubes (Green Top)	Various sizes		
951.	Blood Collection Tubes (Yellow Top)	Various sizes		
952.	Blood Collection Tubes (Blue Top)	Various sizes		
953.	Blood Collection Tubes (Grey Top)	Various sizes		
954.	Blood Collection Tubes (White Top)	Various sizes		
955.	Blood Collection Tubes (Orange Top)	Various sizes		
956.	Calcium Alginate Dressing	7.5cm x12cm		
957.	Calcium Alginate Dressing	10 cm x 20cm		
958.	Calcium Alginate Dressing	15cm x 25cm		
959.	Calcium Alginate Dressing	Rope 2gm		
960.	Casting Tape	6"		
961.	Casting Tape	4"		
962.	Chest Drainage bottle with Tubing			
963.	Chest Tube (with trocar)	Different size		
964.	Chest Tube (without trocar)	Different size		
965.	Circular Stapler			
966.	Colostomy bags (Set comprising bag, adhesive ring, and clamp)			
967.	Cord Clamp			
968.	Compression face mask			
969.	Cotton (Surgical) Corded BPC	200 gm	Roll	
970.	Cotton (Surgical) Corded BPC	100 gm	Roll	
971.	Cotton Bandages (Surgical) B.P Type II	6.5 cm x 4 m		

972.	Cotton Bandages (Surgical) B.P Type II	7.5 cm x 4m		
973.	Cotton Bandages (Surgical) B.P Type II	10 cm x 4 m		
974.	Cotton Bandages (Surgical) B.P Type II	15 cm x 4 m		
975.	Couch Roll	60 cm x 80 m		
976.	Condom Catheter	All Sizes		
977.	CPAP mask (Continuous positive air pressure mask)	Adult		
978.	CPAP mask (Continuous positive air pressure mask)	Pediatric		
979.	Crepe Bandages BPC	2.5cm x 4m	Roll	
980.	Crepe Bandages BPC	5cm x 4m	Roll	
981.	Crepe Bandages BPC	7.5cm x 4.5m	Roll	
982.	Crepe Bandages BPC	10cm x 4.5m	Roll	
983.	Crepe Bandages BPC	15cm x 4.5m	Roll	
984.	CVP line (Single Lumen)	Different Sizes		
985.	CVP line (Double Lumen)	Different Sizes		
986.	CVP line (Triple Lumen)	Different Sizes		
987.	CVP line (Quad Lumen)	Different Sizes		
988.	Dental Extraction Forceps			
989.	Dental Syringe			
990.	Dental wire stainless steel			
991.	Diagnostic Catheter	All Types and sizes		
992.	Dialysis Catheters (Double Lumen)	16 cmx12F		
993.	Dialysis Catheters (Double Lumen)	20 cmx12F		
994.	Dialysis Catheters Permanent different sizes	Different size		
995.	Disposable Endotracheal Tube without Cuff	2.5 mm		
996.	Disposable Endotracheal Tube without Cuff	3 mm		
997.	Disposable Endotracheal Tube without Cuff	3.5 mm		
998.	Disposable Endotracheal Tube without Cuff	4 mm		
999.	Disposable Endotracheal Tube without Cuff	5mm		

1000.	Disposable Endotracheal Tube without Cuff	5.5mm		
1001.	Disposable Endotracheal Tube without Cuff	6mm		
1002.	Disposable Endotracheal Tube without Cuff	6.5mm		
1003.	Disposable Endotracheal Tube without Cuff	7mm		
1004.	Disposable Endotracheal Tube without Cuff	7.5mm		
1005.	Disposable Endotracheal Tube without Cuff	8mm		
1006.	Disposable Endotracheal Tube with Cuff	4 mm		
1007.	Disposable Endotracheal Tube with Cuff	4.5 mm		
1008.	Disposable Endotracheal Tube with Cuff	5mm		
1009.	Disposable Endotracheal Tube with Cuff	5.5mm		
1010.	Disposable Endotracheal Tube with Cuff	6mm		
1011.	Disposable Endotracheal Tube with Cuff	6.5mm		
1012.	Disposable Endotracheal Tube with Cuff	7mm		
1013.	Disposable Endotracheal Tube with Cuff	7.5mm		
1014.	Disposable Endotracheal Tube with Cuff	8mm		
1015.	Disposable Auto Disable Syringe (Blister packing) sterile	0.5ml		
1016.	Disposable Auto Disable Syringe (Blister packing) sterile	1ml		
1017.	Disposable Auto Disable Syringe (Blister packing) sterile	2ml		
1018.	Disposable Auto Disable Syringe (Blister packing) sterile	3 ml		
1019.	Disposable Auto Disable Syringe (Blister packing) sterile	5 ml		
1020.	Disposable Auto Disable Syringe (Blister packing) sterile	10ml		
1021.	Disposable Insulin Syringe Ordinary sterile	30 G / 31 G, 1ml		
1022.	Disposable Syringe Ordinary (Blister packing) sterile	1ml		
1023.	Disposable Syringe Ordinary (Blister packing) sterile	10ml		

1024.	Disposable Syringe Ordinary (Blister packing) sterile	20ml		
1025.	Disposable Syringe Ordinary (Blister packing) sterile	50ml		
1026.	Disposable Syringe Ordinary (Blister packing) sterile	60ml		
1027.	Disposable Syringe Ordinary with nozzle/catheter tip (Blister packing) sterile	60ml		
1028.	Disposable Syringe Ordinary with luer slip Eccentric tip/nozzle (Blister packing) sterile	50ml		
1029.	Disposable Sterile Arterial Blood Gas syringe with Needle (Blister packing)	1ml		
1030.	Disposable Sterile Arterial Blood Gas syringe with Needle (Blister packing)	2ml		
1031.	Disposable Sterile Arterial Blood Gas syringe with Needle (Blister packing)	3ml		
1032.	Disposable Sterile Nasogastric Tube	4 Fr		
1033.	Disposable Sterile Nasogastric Tube	5 Fr		
1034.	Disposable Sterile Nasogastric Tube	6 Fr		
1035.	Disposable Sterile Nasogastric Tube	8 Fr		
1036.	Disposable Sterile Nasogastric Tube	10 Fr		
1037.	Disposable Sterile Nasogastric Tube	12 Fr		
1038.	Disposable Sterile Nasogastric Tube	14 Fr		
1039.	Disposable Sterile Nasogastric Tube	16 Fr		
1040.	Disposable Sterile Nasogastric Tube	18 Fr		
1041.	Disposable Sterile Nasogastric Tube	20 Fr		
1042.	Disposable Sterile Spinal Needle	18 G		
1043.	Disposable Sterile Spinal Needle	19 G		
1044.	Disposable Sterile Spinal Needle	20 G		
1045.	Disposable Sterile Spinal Needle	22 G		
1046.	Disposable Sterile Spinal Needle	23 G		
1047.	Disposable Sterile Spinal Needle	25 G		
1048.	Disposable Sterile Spinal Needle	27 G		
1049.	Disposable Tongue depressor wooden			
1050.	Disposable Dignity Sheet having super absorbency			

1051.	Disposable Gown as per WHO or equivalent standard			
1052.	Disposable Sterile Latex Surgical Gloves (Powder Free)	6.5, 7.0, 7.5, 8.0, 8.5 Size	Pair	
1053.	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5, 7.0, 7.5, 8.0, 8.5 Size	Pair	
1054.	Disposable Sterile Nitrile Surgical Gloves (Powder Free)	6.5, 7.0, 7.5, 8.0, 8.5 Size	Pair	
1055.	Disposable Sterile Nitrile Surgical Gloves (Powdered)	6.5, 7.0, 7.5, 8.0, 8.5 Size	Pair	
1056.	Disposable Non-Sterile Latex examination gloves (Powder Free)	Size: Small, Medium, Large	Pack of 100 gloves	
1057.	Disposable Non-Sterile Latex Examination Gloves (Powdered)	Size: Small, Medium, Large	Pack of 100 gloves	
1058.	Disposable Non-sterile Nitrile Examination Gloves (Powder Free)	Size: Small, Medium, and Large	Pack of 100 gloves	
1059.	Disposable Non-sterile Nitrile Examination Gloves (Powdered)	Size: Small, Medium, and Large	Pack of 100 gloves	
1060.	Disposable Non-sterile Polyethylene Gloves		Pack of 100 gloves	
1061.	Disposable Sterile Catheter Mount			
1062.	Disposable suction nozzle			
1063.	Drill bits	1.2, 1.3mm, 1.5mm & 1.6 & 2mm		
1064.	Drug Eluting Balloon			
1065.	Drug Eluting Cardiac Stent (Everolimus)	All Sizes		
1066.	Drug Eluting Cardiac Stent (Sirolimus)	All Sizes		
1067.	Drug Eluting Cardiac Stents (Zotarolimus)	All Sizes		
1068.	Disposable OT Cap	Different Sizes		
1069.	Disposable OT Drapes	Different Sizes		
1070.	Ear Implant	all sizes		
1071.	E.C.G sticking Electrodes			
1072.	Edema compression gloves (Full finger)	Different sizes		
1073.	Edema compression gloves (Open finger)	Different sizes		

1074.	Electrosurgical/Diathermy/ Cautery Pencil			
1075.	Epidural kit/ Epidural Anesthesia set Radio-opaque	18 G		
1076.	Epidural kit/ Epidural Anesthesia set Radio-opaque	20 G		
1077.	Emergency Cross Head Screws	2.3mm		
1078.	Emergency Cross Head Screws	2.7mm		
1079.	Export Aspiration Catheter			
1080.	Extra Thin Hydrocolloid Dressing	15cm x 15cm		
1081.	Eye Pads sterile	6cm x 8cm		
1082.	Face Shield			
1083.	Feeding tube with stopper cap	6 Fr		
1084.	Feeding tube with stopper cap	8 Fr		
1085.	Feeding tube with stopper cap	10 Fr		
1086.	Feeding tube with stopper cap	12 Fr		
1087.	Feeding tube with stopper cap	14 Fr		
1088.	Feeding tube with stopper cap	16 Fr		
1089.	Feeding tube with stopper cap	18 Fr		
1090.	Feeding tube with stopper cap	20 Fr		
1091.	Fenestrated Silicon Dressing Rolls			
1092.	Fiberglass Splint	Different Sizes		
1093.	Fistula Cannula Needle (Arterial and Venous, Sterile, small holes along the circumference of end portion, Luer-Lock activated anti-reflux valve & safety cap) The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	Different Gauges		
1094.	Fissure Bur			
1095.	Flatus Tube	Different Sizes		
1096.	Gauze Cutting Scissor			
1097.	Gauze Cloth Roll packing	100 cm x 20 m		
1098.	Gauze Cloth Roll packing	100 cm x 40 m		
1099.	Gigli Saw (Martensitic steel, two T-shaped handles fitted with a hook on	All sizes		

	the base end to which a saw wire is attached)			
1100.	Goggles, protective			
1101.	Guiding Catheter	6 Fr		
1102.	Guiding Catheter	7 Fr		
1103.	Guide wire for JJ stent	0.25 mm		
1104.	Guide wire for JJ stent	0.32 mm		
1105.	Guide wire for JJ stent	0.35 mm		
1106.	Hemodialyzer	Adult (>1m ²)		
1107.	Hemodialyzer	Pediatric (≤1m ²)		
1108.	Sterile disposable hemodialysis blood tubing set (blister pack)	Adult		
1109.	Sterile disposable hemodialysis blood tubing set (blister pack)	Pediatric		
1110.	Hydrogel dressing			
1111.	Hydro fiber Dressing	10 cm ×10 cm		
1112.	Hydro fiber dressing with silver	20 cm ×30 cm		
1113.	Hydro fiber dressing with silver	15 cm×15cm		
1114.	Hydrocolloid Dressing	Different sizes		
1115.	Irrigation Cannula Stainless steel (Angled)	Different Gauges		
1116.	Irrigation Cannula Stainless steel (Straight)	Different Gauges		
1117.	Iris Retractor made of bright blue polypropylene, having adjustable silicone stopper (Disposable)			
1118.	Intra-aortic Balloon Pump			
1119.	I/V fluid administration set	sterile and pyrogen free, minimum 150cm tube length, blister pack		
1120.	I/V fluid administration set with additional “Y” injection port	Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack		

1121.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	14G		
1122.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	16G		
1123.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G		
1124.	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G		
1125.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G		
1126.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G		
1127.	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G		
1128.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G		
1129.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G		

1130.	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G		
1131.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G		
1132.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G		
1133.	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G		
1134.	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing, The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G		
1135.	IV Flow Regulator			
1136.	Intra-osseous Sterile Disposable Infusion Needle, should be latex, pyrogen and PVC free)	Different Gauges		
1137.	Infusion Chamber (Burette Type) Sterile, Disposable	100ml		
1138.	Insulated Nerve Block Needle (Sterile)	21G x 4"		
1139.	Isopropyl Alcohol 70% Disposable Nonwoven Swabs			
1140.	JJ stent	6FR		
1141.	JJ stent	4.7FR		
1142.	JJ stent	3.5FR		
1143.	K (Kirschner) Wire			
1144.	Keratome ophthalmic knife	3.2 mm, 45°		
1145.	Laryngeal mask	Different size		

1146.	LP Shunt			
1147.	2.7mm Mandible Reconstruction plates (Stainless Steel 316L / 316Lvm /) Titanium) with set	Different sizes and holes		
1148.	Manual resuscitator / Self- inflating Bag with Mask	Adult		
1149.	Manual resuscitator / Self- inflating Bag with Mask	Paediatric		
1150.	Manual resuscitator / Self- inflating Bag with Mask	Neonatal		
1151.	Medical Shoe Cover (Disposable)			
1152.	Disposable Face Mask, (Medical mask, good breathability, and clearly identifiable internal and external faces) (As per WHO or alternative equivalent standards)	Adult		
1153.	Disposable Particulate Respirator as per WHO or Alternative Equivalent standards.	Individually packed (Adult)		
1154.	Malleable Retractor	Different Sizes		
1155.	Mucus Extractor			
1156.	Nasal Oxygen Cannula	Neonatal		
1157.	Nasal Oxygen Cannula	Pediatric		
1158.	Nasal Oxygen Cannula	Adult		
1159.	Nebulizer mask with chamber and tubing	Pediatric		
1160.	Nebulizer mask with chamber and tubing	Adult		
1161.	Non-invasive Ventilation Mask	Different Sizes		
1162.	Non-Medicated sterilized adhesive post-operative wound dressing	6x7cm		
1163.	Non-Medicated sterilized adhesive post-operative wound dressing	9x10cm		
1164.	Non-Medicated sterilized adhesive post-operative wound dressing	9x15cm		
1165.	Non-Medicated sterilized adhesive post-operative wound dressing	9x20cm		
1166.	Non-Medicated sterilized adhesive post-operative wound dressing	9x25cm		
1167.	Non-Medicated sterilized adhesive post-operative wound dressing	9x30cm		
1168.	Non-woven Fabric Surgical Adhesive Fix Roll	Various sizes		
1169.	Non-rebreather mask	Adult		

1170.	Non-rebreather mask	Paediatric		
1171.	Nanocrystalline silver dressing	Different Sizes		
1172.	Nasal Implant	All Sizes		
1173.	Ophthalmic Knife 15°			
1174.	Ophthalmic Crescent Knife			
1175.	Oxygen Mask	Adult		
1176.	Oxygen Mask	Paediatric		
1177.	Oropharyngeal Airway	Size 0		
1178.	Oropharyngeal Airway	Size 1		
1179.	Oropharyngeal Airway	Size 2		
1180.	Oropharyngeal Airway	Size 3		
1181.	Oropharyngeal Airway	Size 4		
1182.	Oropharyngeal Airway	Size 5		
1183.	Oropharyngeal Airway	Size 6		
1184.	Paraffin Gauze dressing (Tulle) with Chlorhexidine	10x10 cm		
1185.	Paraffin Gauze dressing (Tulle) with Chlorhexidine	15x20cm		
1186.	Paraffin Gauze dressing with Framycetin	10x10 cm		
1187.	Partial re-breather mask	Adult		
1188.	Partial re-breather mask	Pediatric		
1189.	PCI Guide Hydrophilic			
1190.	PCI Guide Hydrophobic			
1191.	Pigtail with needle for chest drainage and ascitic fluid drainage	Size-14 Size-18, Size-24		
1192.	POP Bandages	15cm x 2.7m		
1193.	POP Bandages	10cm x 2.7m		
1194.	PU Adhesive Incise Drape Film	10 cm x 14cm		
1195.	PU Adhesive Incise Drape Film	15 cm x 28cm		
1196.	PU Adhesive Incise Drape Film	30 cm x 28cm		
1197.	PU Adhesive Incise Drape Film	45 cm x 28cm		
1198.	PU Adhesive Incise Drape Film	55 cm x 44cm		

1199.	Reloadable Linear Cutter Stapler	55mm, 60mm, 75mm, 80 mm staple length		
1200.	Scalp Vein Set/ Butterfly Needle/ Winged infusion Set	Different Gauge sizes		
1201.	Sterilized disposable needles for dental syringe	Different sizes		
1202.	Sterile External Fixators with titanium Alloy Pins	Different Sizes, Shape & Design		
1203.	Sterile Nelaton Catheter	12 Fr		
1204.	Sterile Nelaton Catheter	14 Fr		
1205.	Sterile Nelaton Catheter	16 Fr		
1206.	Sterile Skin graft blade for Dermatome Knife	Different Sizes		
1207.	Spinal Fixation System Full Instrument Set			
1208.	Spinal Fusion cage along with pedicle screws and rods	Different sizes		
1209.	Silicone rod or Hunter tendon implant	3,4 & 5 mm		
1210.	Suction Connecting tube with Yankauer suction handle/tip	3M or less		
1211.	Surgical Saw Stainless steel	All sizes		
1212.	Surgical Implants sheets			
1213.	Surgical Implants blocks			
1214.	Skin Staple Remover			
1215.	Skin Stapler Straight			
1216.	Steinmann Pins	All Types		
1217.	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP-Type IV/BP-Type-II/BPC)	Blister pack 10x10cm, 8 ply		
1218.	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP-Type IV/BP-Type-II/BPC)	Blister pack 15x15cm, 8 ply		
1219.	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP-Type IV/BP-Type-II/BPC)	Blister pack 30x30cm, 4 ply		
1220.	Sterile Gauze Dressing Pad (USP-Type IV/BP-Type-II/BPC)	Blister pack 10x10 cm, 8 ply		
1221.	Sterile Gauze Dressing Pad (USP-Type IV/BP-Type-II/BPC)	Blister pack 15x15 cm, 8 ply		

1222.	Sterile Manual Aspirator			
1223.	Sterile Suction Catheter	5 Fr		
1224.	Sterile Suction Catheter	6 Fr		
1225.	Sterile Suction Catheter	8 Fr		
1226.	Sterile Suction Catheter	10 Fr		
1227.	Sterile Suction Catheter	12 Fr		
1228.	Sterile Suction Catheter	14 Fr		
1229.	Sterile Suction Catheter	16 Fr		
1230.	Sterile Suction Catheter	18 Fr		
1231.	Colostomy Paste			
1232.	Stop Cock 3 way with Extension			
1233.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	10		
1234.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	11		
1235.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	15		
1236.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	20		
1237.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	21		
1238.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	22		
1239.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	23		
1240.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	24		
1241.	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	25		
1242.	Suprapubic Catheter			
1243.	Thermometer (Mercury)			
1244.	Three-Way Foley Catheter	6 Fr		
1245.	Three-Way Foley Catheter	8 Fr		
1246.	Three-Way Foley Catheter	10 Fr		
1247.	Three-Way Foley Catheter	12 Fr		
1248.	Three-Way Foley Catheter	14 Fr		
1249.	Three-Way Foley Catheter	16 Fr		

1250.	Three-Way Foley Catheter	18 Fr		
1251.	Three-Way Foley Catheter	20 Fr		
1252.	Three-Way Foley Catheter	22 Fr		
1253.	Two-Way Foley Catheter 100% Silicon)	6Fr		
1254.	Two-Way Foley Catheter 100% Silicon)	8Fr		
1255.	Two-Way Foley Catheter 100% Silicon)	10Fr		
1256.	Two-Way Foley Catheter 100% Silicon)	12Fr		
1257.	Two-Way Foley Catheter 100% Silicon)	14Fr		
1258.	Two-Way Foley Catheter 100% Silicon)	16Fr		
1259.	Two-Way Foley Catheter 100% Silicon)	18Fr		
1260.	Two-Way Foley Catheter 100% Silicon)	20Fr		
1261.	Two-Way Foley Catheter 100% Silicon)	22Fr		
1262.	Two-Way Foley Catheter (Silicon Coated)	6Fr		
1263.	Two-Way Foley Catheter (Silicon Coated)	8Fr		
1264.	Two-Way Foley Catheter (Silicon Coated)	10Fr		
1265.	Two-Way Foley Catheter (Silicon Coated)	12Fr		
1266.	Two-Way Foley Catheter (Silicon Coated)	14Fr		
1267.	Two-Way Foley Catheter (Silicon Coated)	16Fr		
1268.	Two-Way Foley Catheter (Silicon Coated)	18Fr		
1269.	Two-Way Foley Catheter (Silicon Coated)	20Fr		
1270.	Two-Way Foley Catheter (Silicon Coated)	22Fr		
1271.	Tissue Expander	All types & sizes		
1272.	Titanium Micro screw	All sizes		
1273.	Titanium microplate with set	1.6mm & 16 holes		
1274.	Titanium Mesh	12×6 cm× 0.3mm		

1275.	Titanium Mesh	12×6 cm× 1.6mm		
1276.	Titanium Mesh	12×6 cm×0.6mm		
1277.	Titanium mini plates	2.0mm× 20holes		
1278.	Titanium surgical screws	1.6 mm× 5 mm		
1279.	Titanium surgical screws	1.6 mm× 6 mm		
1280.	Titanium surgical screws	2.0 mm × 7mm		
1281.	Titanium surgical screws	2.0× 5.5 to 15mm		
1282.	Tracheostomy mask			
1283.	Tracheostomy Tube with cuff	Different Sizes		
1284.	Tracheostomy Tube without cuff	Different Sizes		
1285.	Titanium Ligation Clips	LT 300		
1286.	Titanium Ligation Clips	LT 400		
1287.	Transparent IV Dressing	Different Sizes		
1288.	Tru-cut disposable Biopsy Needles with gun (for solid organs)	Different sizes		
1289.	Tyvek Suit (As per WHO or alternative equivalent standards)			
1290.	Urine bag with let	2000 ml		
1291.	Umbilical Venous Catheter (Sterile)	Different sizes		
1292.	Vacuum drainage bottle (closed seal) with tube (Disposable)			
1293.	Ventilator Circuit			
1294.	Venturi Oxygen Mask with different oxygen concentration venturi valve			
1295.	VP Shunt			
1296.	Wrist Spanning Plate (screw diameter of 2.5 mm) with set			
1297.	Wrist Spanning Plate (2.3 mm locking variable angle screws) with set			
1298.	X-Ray film	8x10		
1299.	X-Ray film	12x15		
1300.	X-Ray film	10x12		
1301.	X-Ray film	14x17		

1302.	X-ray film CR for closed system of various brands	Different Sizes		
1303.	X-ray film CT scan	Different sizes		
1304.	X-ray film Dental	Different sizes		
1305.	X-ray film for MRI	Different sizes		
1306.	X-ray Developer + X-ray Fixer Set			
1307.	Zinc oxide adhesive Plaster (Cloth Tape)	2.5 cm x 5m		
1308.	Zinc oxide adhesive Plaster (Cloth Tape)	5 cm x 5m		
1309.	Zinc oxide adhesive Plaster (Cloth Tape)	7.5 cm x 5m		
1310.	Zinc oxide adhesive Plaster (Cloth Tape)	10 cm x 5 m		
	LIST OF SURGICAL SUTURES			
	Strand length mentioned against each size and type of suture is minimum, however length quoted more than the mentioned ones shall be acceptable without any leverage/extra advantage in any evaluation parameter.			
	CATGUT CHROMIC			
	Sutures	Sizes		
1311.	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	4/0		
1312.	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3/0		
1313.	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0		
1314.	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0		
1315.	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	0		
1316.	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	0		
1317.	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	1		
1318.	30mm, 3/8 circle round bodied taper point needle, strand length 70cm	1		
1319.	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	2		
	BLACK BRAIDED SILK			
	Sutures	Sizes		
1320.	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	4/0		
1321.	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0		

1322.	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0		
1323.	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	3/0		
1324.	17mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0		
1325.	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm	2/0		
1326.	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	2/0		
1327.	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm	0		
1328.	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1		
1329.	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1		
1330.	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	1		
1331.	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2		
	POLYGLACTINE 910/ LACTOMER 91			
	Sutures	Size		
1332.	7mm, 1/2 circle, micro-point spatula needle, strand length 45cm	7/0		
1333.	8mm, 1/4 circle spatulated needle, strand length 45cm	6/0		
1334.	11mm, 3/8 circle reverse cutting needle, strand length 45 cm	6/0		
1335.	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	6/0		
1336.	11mm, 3/8 circle reverse cutting needle, Strand length 45 cm	5/0		
1337.	13mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	5/0		
1338.	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	5/0		
1339.	16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm	4/0		
1340.	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	4/0		
1341.	19mm, 3/8 circle reverse cutting needle, strand length 75cm	4/0		

1342.	22mm, 1/2 circle round bodied taper point, strand length 70 cm	4/0		
1343.	16mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	3/0		
1344.	19mm, 3/8 circle reverse cutting needle, Strand length 75cm	3/0		
1345.	22mm, 1/2 circle round bodied taper point, strand length 70 cm	3/0		
1346.	26mm, 1/2 circle round bodied taper point, Strand length 70 cm	3/0		
1347.	26mm, 1/2 circle round bodied taper point, strand length 70 cm	2/0		
1348.	31mm, 1/2 circle round bodied taper point, Strand length 70 cm	2/0		
1349.	36mm, 1/2 circle round body taper cut needle, strand length 90 cm	2/0		
1350.	45mm, 1/2 circle round bodied taper cut needle, strand length 75 cm	2/0		
1351.	36mm, 1/2 circle round bodied taper cut needle, strand length 90 cm	0		
1352.	40mm, 1/2 circle round bodied taper point, strand length 90 cm	0		
1353.	40mm, 1/2 circle round bodied taper point, strand length 70 cm	1		
1354.	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	1		
1355.	40mm, 1/2 circle round bodied taper point, strand length 90 cm	2		
1356.	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	2		
	POLYGLYCOLIC ACID			
	Sutures	Size		
1357.	17mm, 1/2 circle round bodied taper point needle, Strand length 70cm	5/0		
1358.	17mm, 1/2 circle round bodied needle, Strand length 75cm	4/0		
1359.	22mm, 1/2 circle round bodied taper point needle, Strand length 75cm	4/0		
1360.	22mm, 1/2 circle round bodied taper point, strand length 75 cm	3/0		
1361.	25mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0		
1362.	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0		
1363.	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	0		

1364.	30mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1		
1365.	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1		
1366.	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2		
1367.	48mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2		
	POLYPROPYLENE			
	Sutures	Size		
1368.	8mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	12/0		
1369.	8mm, 3/8 circle round bodied taper point double armed needle, strand length 60 cm	11/0		
1370.	8mm, 1/2 circle round bodied taper point needle, strand length 60cm	10/0		
1371.	6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm	8/0		
1372.	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	7/0		
1373.	12mm, 3/8 circle reverse cutting needle, strand length 60cm	6/0		
1374.	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	6/0		
1375.	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	6/0		
1376.	16mm, 3/8 circle curved cutting needle, strand length 90cm	6/0		
1377.	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	5/0		
1378.	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	5/0		
1379.	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	4/0		
1380.	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	4/0		

1381.	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3/0		
1382.	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3/0		
1383.	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	3/0		
1384.	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0		
1385.	26mm, 3/8 circle reverse cutting needle, strand length 45cm	2/0		
1386.	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	2/0		
1387.	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm	2/0		
1388.	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0		
1389.	55mm, straight cutting needle, strand length 75cm	2/0		
1390.	60mm, straight cutting needle, strand length 75cm	2/0		
1391.	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	0		
1392.	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1		
	POLYAMIDE			
	Suture	Sizes		
1393.	6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm	10/0		
1394.	48mm, 1/2 circle round bodied taper point, strand length 150cm	1		
	POLYESTER			
	Sutures	Sizes		
1395.	26mm, 1/2 circle round bodied taper point double needle, strand length 100cm	3/0		
1396.	17mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	2/0		
1397.	26mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	2/0		
1398.	26mm, 1/2 circle round bodied taper point double needle, strand length 90cm	2/0		

	POLYDIOXANONE			
	Sutures	Sizes		
1399.	13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	7/0		
1400.	13mm, 1/2 circle round bodied taper point needle, strand length 45cm	6/0		
1401.	13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	6/0		
1402.	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	6/0		
1403.	13mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	5/0		
1404.	13mm, 1/2 circle round bodied taper point needle, strand length 75cm	5/0		
1405.	17mm, 1/2 circle round bodied taper point double needle, strand length 75cm	5/0		
1406.	17mm, 3/8 circle round bodied taper point double armed needle, strand length 75cm	5/0		
1407.	19mm, 3/8 circle round bodied taper point double armed needle, strand length 75cm	5/0		
1408.	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	4/0		
1409.	17mm, 1/2 circle round bodied taper point double armed, strand length 75cm	4/0		
1410.	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	4/0		
1411.	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	4/0		
1412.	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3/0		
1413.	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	3/0		
1414.	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	3/0		
1415.	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0		
1416.	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0		
1417.	36mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0		

1418.	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0		
1419.	40mm, 1/2 circle round bodied taper point needle, strand length 150cm.	0		
1420.	40mm, 1/2 circle round bodied taper point needle, Strand length 70cm	0		
1421.	36mm, 1/2 circle round bodied taper point needle, strand length 75cm	1		
1422.	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1		
	NYLON SUTURES			
	Sutures	Size		
1423.	6 mm, 3/8 circle micro point spatula double needle, strand length 30cm	10/0		
1424.	6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm	10/0		
	STAINLESS STEEL SUTURES/ WIRE			
	Sutures	Sizes		
1425.	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	5		
1426.	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	4		
	SURGICAL MESHES			
	Mesh Polymer	Sizes		
1427.	Polypropylene	30cm x 30cm		
1428.	Polypropylene	15cm x 15cm		
1429.	Polypropylene	15cm x 6cm		
1430.	Polypropylene	6cm x 11cm		
	BONE WAX, CEMENT & GRANULES			
1431.	Antibiotic-impregnated bone cement			
1432.	Bone Substitute Granules	0.5cc & 10cc		
1433.	Bone Wax			
1434.	Bone cement			

* In case of similar strengths, the calculations will be made on ml basis.

ANTI-CANCER MEDICINES (ONCOLOGY PRODUCTS)				
MCC Formular y No	Drug Name	Strength	Dosage form	Volume / Pack Size
1435.	5Fluorouracil	250mg	Inj.	
1436.	5Fluorouracil	500mg	Inj.	
1437.	Abiraterone acetate	250mg	Tab.	
1438.	Abiraterone acetate	500mg	Tab.	
1439.	Ado-trastuzumab	100mg	Inj	
1440.	Ado-trastuzumab	160mg	Inj	
1441.	Afatinib	40mg	Tab	
1442.	Alectinib	150mg	Cap.	
1443.	All Trans Retinoic Acid	10mg	Cap.	
1444.	Anastrozole	1mg	Tab	
1445.	Aprepitant	80mg & 125mg Combo pack	Cap.	
1446.	Atezolizumab	1200mg	Inj.	
1447.	Avelumab	200mg/10ml	Inj.	
1448.	Axitinib	5mg	Tab	
1449.	Azacitidine	100mg	Inj.	
1450.	Azathioprine	50 mg	Tab.	100s or less
1451.	Basiliximab	20 mg/ vial	Inj.	
1452.	Baxoretene	75mg	C ap.	
1453.	Baxoretene		Gel	
1454.	Bendamustine	100mg	Inj.	
1455.	Bendamustine	200mg	Inj.	
1456.	Bevacizumab	100mg	Inj.	
1457.	Bevacizumab	400mg	Inj.	
1458.	Bicalutamide	50mg	Tab.	
1459.	Bleomycin	15 mg	Inj.	
1460.	Bortezomib	1mg	Inj.	

1461.	Bortezomib	2mg	Inj.	
1462.	Bortezomib	3.5mg	Inj.	
1463.	Brentuximab	50mg	Inj.	
1464.	Cabazitaxel	60mg	Inj.	
1465.	Cabozantinib	20mg	Tab.	
1466.	Cabozantinib	40mg	Tab.	
1467.	Cabozantinib	60mg	Tab.	
1468.	Calcium Folate	100mg	Inj.	
1469.	Calcium Folate	25mg	Inj.	
1470.	Calcium Folate	50mg	Inj.	
1471.	Capecitabine	500mg	Tab.	
1472.	Carboplatin	150mg	Inj.	
1473.	Carboplatin	450mg	Inj.	
1474.	Carfilzomib	10mg	Inj.	
1475.	Carfilzomib	30mg	Inj.	
1476.	Carfilzomib	60mg	Inj.	
1477.	Ceritinib	150mg	Cap.	
1478.	Cetuximab	100mg	Inj.	
1479.	Chlorambucil	2 mg	Tab.	
1480.	Cisplatin	10mg	Inj.	
1481.	Cisplatin	50mg	Inj.	
1482.	Cladribine	10mg	Inj.	
1483.	Crizotinib	200mg	Cap.	
1484.	Crizotinib	250mg	Cap.	
1485.	Cyclophosphamide	500 mg/Vial	Inj.	
1486.	Cyclophosphamide	1gm	Inj.	
1487.	Cyclophosphamide	500mg	Inj.	
1488.	Cyclophosphamide	50mg	Tab.	
1489.	Cyproterone acetate	50mg	Tab.	
1490.	Cytarabine	100mg	Inj.	
1491.	Cytarabine	500mg	Inj.	
1492.	Dacarbazine	200mg	Inj.	

1493.	Dacarbazine	500mg	Inj.	
1494.	Dactinomycin	500mcg	Inj.	
1495.	Dasatinib	50mg	Tab.	
1496.	Dasatinib	70mg	Tab.	
1497.	Daunorubicin	20mg	Inj.	
1498.	Decitabine	50mg	Inj.	
1499.	Denosumab	120mg	Inj.	
1500.	Denosumab	60mg	Inj.	
1501.	Docetaxel	20mg	Inj.	
1502.	Docetaxel	80mg	Inj.	
1503.	Doxorubicin	10 mg/ Vial	Inj.	
1504.	Doxorubicin	50 mg/ Vial	Inj.	
1505.	Durvalumab	500mg	Inj.	
1506.	Eltrombopag	25mg	Tab.	
1507.	Eltrombopag	50mg	Tab.	
1508.	Enzalutamide	40mg	Tab.	
1509.	Enzalutamide	80mg	Tab.	
1510.	Epirubicin	10mg	Inj.	
1511.	Epirubicin	50mg	Inj.	
1512.	Erlotinib	150mg	Tab.	
1513.	Etoposide	100mg	Inj.	
1514.	Exemestane	25mg	Tab.	
1515.	Fludarabine	50mg	Inj. IV	
1516.	Flutamide	250mg	Tab.	
1517.	Fulvestrant	250mg	Inj.	Vial/PFS
1518.	Fulvestrant	500mg	Inj.	Vial/PFS
1519.	Gefitinib	250mg	Tab.	
1520.	Gemcitabine	1gm	Inj.	
1521.	Gemcitabine	200mg	Inj.	
1522.	Granisetron	1mg	Tab.	
1523.	Granisetron	3mg/3ml	Inj.	
1524.	Hydroxychloroquine	200 mg	Tab.	

1525.	Ibrutinib	140mg	Cap.	
1526.	Idarubicin	10mg	Inj.	
1527.	Idelalisib	150mg	Tab.	
1528.	Ifosfamide	1gm	Inj.	
1529.	Ifosfamide	2gm	Inj.	
1530.	Imatinib	100mg	Tab/Cap	
1531.	Imatinib	400mg	Tab/cap	
1532.	Ipilumomab	200mg	Inj.	
1533.	Ipilumomab	50mg	Inj.	
1534.	Irinotecan	100mg	Inj.	
1535.	Irinotecan	300mg	Inj.	
1536.	Irinotecan	40mg	Inj.	
1537.	Ixazomib	3mg	Cap.	
1538.	Ixazomib	4mg	Cap.	
1539.	Lapatinib	250mg	Tab.	
1540.	L-Asparaginase	5000 units	Inj.	
1541.	Leflunomide	20 mg	Tab.	
1542.	Lenalidomide	10mg	Tab/Cap.	
1543.	Lenalidomide	25mg	Tab/Cap.	
1544.	Lenvatinib	10mg	Tab.	
1545.	Lenvatinib	4mg	Tab.	
1546.	Letrozole	2.5mg	Tab.	
1547.	Leukaran	2mg	Tab.	
1548.	Leukaran	5mg	Tab.	
1549.	Leuprolide Acetate	3.75mg	Inj.	
1550.	Leuprolide Acetate	7.5mg	Inj.	
1551.	Leuprolide Acetate	11.25mg	Inj.	
1552.	Leuprolide Acetate	22.5mg (Depot)	Inj.	
1553.	Lipid Fat Emulsion	20% MCT/LCT 250ml	Inf.	
1554.	Liposomal Amphotericin B	50mg	Inj.	
1555.	Liposomal Cisplatin	150mg	Inj.	
1556.	Liposomal Doxorubicin	20mg	Inj.	

1557.	Lorlatinib	100mg	Tab.	
1558.	Lorlatinib	25mg	Tab.	
1559.	Megestrol acetate	160mg	Tab.	
1560.	Melphalan	2 mg	Tab.	
1561.	Melphalan	5 mg	Tab.	
1562.	Mercaptopurine	50mg	Tab.	
1563.	Methotrexate	10 mg	Tab.	
1564.	Methotrexate	1gm	Inj.	
1565.	Methotrexate	50mg	Inj.	
1566.	Methotrexate	500mg	Inj.	
1567.	Mitomycin	10 mg/ Vial	Inj.	
1568.	Mitomycin	2mg	Inj.	
1569.	Mitoxantrone	10mg	Inj.	
1570.	Mitoxantrone	20mg	Inj.	
1571.	Mitoxantrone	5mg	Inj.	
1572.	Morphine Sulphate	10mg	Inj.	
1573.	Morphine Sulphate	10mg	Tab.	
1574.	Morphine Sulphate	30mg	Tab.	
1575.	Multirate Infusor pumps 2, 3, 5 ml/hour			
1576.	Nab-Paclitaxel	100mg	Inj.	
1577.	Neratinib	40mg	Tab.	
1578.	Nilotinib	200mg	Cap.	
1579.	Niraparib	100mg	Cap.	
1580.	Nivolumab	10mg/ml	Inj.	
1581.	Obinutuzumab	1000mg	Inj.	
1582.	Ofatumumab	20mg/ml	Inj.	
1583.	Olaparib	150mg	Tab./Cap.	
1584.	Olaparib	50mg	Tab./Cap.	
1585.	Ondansetron	8mg	Inj.	
1586.	Ondansetron	8mg	Tab.	
1587.	Osimertinib	80mg	Tab./Cap.	

1588.	Oxaliplatin	100mg	Inj.	
1589.	Oxaliplatin	150mg	Inj.	
1590.	Oxaliplatin	50mg	Inj.	
1591.	Paclitaxel	150mg	Inj.	
1592.	Paclitaxel	300mg	Inj.	
1593.	Palbociclib	100mg	Tab.	
1594.	Palbociclib	125mg	Tab.	
1595.	Palonosetron	0.25mg	Inj.	
1596.	Pamidronate	90mg	Inj.	
1597.	Panitumomab	100mg	Inj.	
1598.	Panitumomab	400mg	Inj.	
1599.	Pazopanib	400mg	Tab.	
1600.	PEG-Asparaginase	3750mu	Inj.	
1601.	PEG-Filgrastim		Inj.	
1602.	PEG-Interferon		Inj.	
1603.	Pembrolizumab	100mg	Inj.	
1604.	Pemetrexed	100mg	Inj.	
1605.	Pemetrexed	500mg	Inj.	
1606.	Pentostatin	10mg	Inj.	
1607.	Pertuzumab / Trastuzumab	1200mg/600mg	Inj.	
1608.	Pertuzumab	420mg	Inj.	
1609.	Polatuzumab	140mg	Inj.	
1610.	Pomalidomide	4mg	Cap.	
1611.	Ponatinib	15mg	Tab.	
1612.	Ponatinib	45mg	Tab.	
1613.	Procarbazine	50mg	Cap.	
1614.	Rasburicase	1.5mg	Inj.	
1615.	Rasburicase	7.5mg	Inj.	
1616.	Regorafenib	40mg	Tab.	
1617.	Ribociclib	200mg	Tab.	
1618.	Rituximab	100mg	Inj.	
1619.	Rituximab	500mg	Inj. IV	

1620.	Rituximab	1400mg	Inj. S/C	
1621.	Ruxolitinib	15mg	Tab.	
1622.	Ruxolitinib	5mg	Tab.	
1623.	Sandostatin – LAR	20mg	Inj.	
1624.	Sandostatin – LAR	30mg	Inj.	
1625.	Sorafenib	200mg	Tab.	
1626.	Sunitinib	50mg	Tab./Cap.	
1627.	Tamoxifen	10 mg	Tab.	
1628.	Tamoxifen	20 mg	Tab.	
1629.	Temozolamide	100mg	Cap.	
1630.	Temozolamide	20mg	Cap.	
1631.	Thalidomide	100 mg	Tab. / Cap.	
1632.	Thrombopoetin		Inj.	
1633.	Topotecan	4mg	Inj.	
1634.	Trastuzumab	440mg	Inj. IV	
1635.	Trastuzumab	600mg	Inj. S/C	
1636.	Trastuzumab Deruxtecan	100mg	Inj.	
1637.	Tropisetron	5mg	Inj.	
1638.	Tropisetron	5mg	Tab.	
1639.	Tucatinib	300mg	Tab/Cap	
1640.	Uromitoxan	400mg	Inj.	
1641.	Valganciclovir	450mg	Tab.	
1642.	Vemurafinib	240mg	Tab.	
1643.	Vinblastine	10mg	Inj.	
1644.	Vincristine	1mg	Inj.	
1645.	Vincristine	2mg	Inj.	

List of Abbreviations

S.No	Words	Abbreviations	S.No	Words	Abbreviations
1.	Actuation	Actu.	48.	Stringent Regulatory Authority	SRA
2.	Aqueous	Aq.	49.	New Approach Notified Designated Organizations	NANDO
3.	Capsule	Cap.	50.	WHO Listed Authorities	WLA
4.	Cartridges	Ctg.			
5.	Centimeter	Cm			
6.	Citrate Phosphate Dextrose Adenine-1	CPDA-1			
7.	Dispersible	Disper.			
8.	Emulsion	Emul.			
9.	Enteric Coated	EC.			
10.	Extended-release Tablet	ER-Tab.			
11.	French Gauge	F / Fr			
12.	Gram	gm			
13.	Gauge	G			
14.	Infusion	Inf.			
15.	Inhalation	Inh.			
16.	Injection	Inj.			
17.	Intramuscular	IM			
18.	Intravenous	IV			
19.	International Unit	IU			
20.	Liquid	Liq.			
21.	Liter	L			
22.	Lotion	Lot.			
23.	Meter	m			
24.	Microgram	mcg			
25.	Milligram	mg			
26.	Milliliter	ml			
27.	Millimeter	mm			
28.	Million International Unit	MIU			
29.	Millimole	mmol			
30.	Ointment	Oint.			
31.	Operation theatre Cap	OT Cap			
32.	Operation theatre Drape	OT Drape			
33.	Pakistan standard and quality control authority	PSQCA			
34.	Quadruple	Quad.			
35.	Solution	Soln.			
36.	Sublingual Tablet	SL. Tab.			
37.	Suppository	Supp.			
38.	Suspension	Susp.			
39.	Sustained Release	SR-Tab.			
40.	Syrup	Syp.			
41.	Tablet	Tab.			
42.	United States Pharmacopeia	USP			
43.	Vaginal Tablet	Vag. Tab.			
44.	Weight/ Weight	w/w			
45.	Weight/Volume	w/v			
46.	Joint Commission International	JCI			
47.	Japanese Ministry of Health, Labour and Welfare	JMHLW			

Section V. Technical Specifications

Technical Evaluation Criteria for Drugs / Medicines, Medical Devices, Surgical Disposables and Non-Drug Items (NDIs)

(Maximum Allocable Marks Score for Technical Evaluation = 70 Marks)

NOTE:

For further details of evaluation criteria and marking scheme, please see relevant proformas for technical evaluation of these BSDs.

1. SYSTEM BREAKING / DISQUALIFICATION POINTS IN TECHNICAL EVALUATION CRITERIA:

- a. These system breaking / disqualification points mentioned in this section are in addition to the provision of mandatory documents, as elaborated in Bid Cover Sheet (Bid Form-1).
- b. During technical evaluation of the quoted bids, bidders may stand disqualified if the Scrutiny Committee for bids evaluation and /or Inspection Team/s find and declare any of the shortcoming/s related to the documents and/or manufacturing units and / or the premises of the manufacturers and /or Importers/Indenters regardless of completion / fulfillment or otherwise of any terms and conditions, criteria and /or codal formalities.
- c. The technical & financial evaluation system for Govt: MCC bids for the FY 2026-27 comprises Nine different evaluation proformas (Section V. Technical Specifications) each having system breaking points and non-compliance of any of these system breaking parameters on part of bidder shall lead to disqualification of firm and /or quoted item/s, whatever the case may be.
- d. Further details of system breaking points / issues for various categories of items are as follows:

A. Manufacturer of General Drugs/Medicines, I/V Fluids, Powdered Injectable Drugs, and Biological Products:

- i. Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).
- ii. Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). Non-adherence to GSP shall lead to disqualification of the firm.
- iii. Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).
- iv. Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of

inspection, Non-availability shall lead to disqualification of the section/s or firm).

- v. Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.

B. Importers of General Drugs/Medicines, I/V Fluids, Powdered Injectable Drugs and Biological products:

- i. Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, in case of CE Mark / Quality assurance certificate/Quality Control Certificate of the Principal Manufacturer for the quoted item/s, shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin/ or certificate issuing country, in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin / or certificate issuing country of the quoted good/s). Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm.
- ii. Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)
- iii. Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.
- iv. Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).
- v. Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s). Non provision of this document shall lead to disqualification of the firm.
- vi. Valid cGMP (attested/ apostilled from the embassy of the country of origin in Pakistan or Pakistani embassy in the country of origin) in

original and Valid Free sale certificate for the quoted item/s duly attested/ apostilled by the Pakistani embassy in the country of origin of quoted item/s or embassy of the country of origin in Pakistan in **original** shall be provided to the Inspection team at the time of inspection.

C. Manufacturer/s of Medical Devices, Surgical Disposables and Sutures (excluding Cardiac Stents):

- i. Valid cGMP certificate issued by DRAP.
- ii. Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods (as evaluated at the time of inspection by the MCC expert/s). Nonadherence to GSP shall lead to disqualification of the firm.
- iii. Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)
- iv. Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.
- v. Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, non-availability shall lead to disqualification of the section/s or firm).
- vi. Samples of devices will be tested and evaluated by the Drugs Testing Laboratory (DTL) as well as by a panel of experts / end users and the quoted item/s may be disqualified for further competition on the report/s of these entities.

D. Importer(s)/Indenter(s) of Medical Devices, Surgical Disposables and Sutures (excluding Cardiac Stents):

- i. Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, in case of CE Mark (or its supportive documents/confirmation letters that shall prove its validity)/ Quality assurance certificate/Quality Control Certificate of the Principal Manufacturer for the quoted item/s, shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin/ or certificate issuing country, in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin / or certificate issuing country of the quoted good/s). Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm.

(In case of non-applicability of the above-mentioned certificates for

Adhesive Tape (Non Sterile) only, provision of EC-Declaration of conformity from the principal manufacturer (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s is mandatory).

- ii. Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer/indenter shall lead to disqualification of the quoted item/s / firm)
- iii. Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm
- iv. Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).
- v. Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s). Non provision of this document shall lead to disqualification of the firm.
- vi. Samples of devices will be tested and evaluated by the Drugs Testing Laboratory as well as by a panel of experts / end users and the quoted item/s may be disqualified for further competition on the report/s of these entities.
- vii. Valid cGMP /Quality Control /Quality Assurance Certificate (attested / apostilled from the embassy of the country of origin in Pakistan or Pakistani embassy in the country of origin) in **original** and Valid Free sale certificate for the quoted item/s duly attested/ apostilled by the Pakistani embassy in the country of origin of quoted item/s or embassy of the country of origin in Pakistan in **original** shall be provided to the Inspection team at the time of inspection.

E. Manufacturer/s of Cotton & Related Goods:

- i. Functional and effective Air-conditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm).
- ii. Adequate availability of equipment / instruments in QC labs performing

relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP, cGMP shall lead to disqualification of the relevant section or firm)

- iii. Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Noncompliance to GSP shall lead to disqualification of the relevant section or firm).
- iv. Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).
- v. Samples of devices will be tested and evaluated by the Drugs Testing Laboratory as well as by a panel of experts / end users and the quoted item/s may be disqualified for further competition on the report/s of these entities.

F. Importer/s of Cotton & Related Goods:

- i. Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, in case of CE Mark / Quality assurance certificate/Quality Control Certificate of the Principal Manufacturer for the quoted item/s, shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin/ or certificate issuing country, in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin / or certificate issuing country of the quoted good/s). Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm.
- ii. Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm).
- iii. Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.
- iv. Adequate availability of qualified & relevant Human Resource (Presence of Category-A Pharmacist/s is/are mandatory) (Certified by the

senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).

- v. Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s). Non provision of this document shall lead to disqualification of the firm.
- vi. Samples of devices will be tested and evaluated by the Drugs Testing Laboratory as well as by a panel of experts / end users and the quoted item/s may be disqualified for further competition on the report/s of these entities.
- vii. Valid cGMP /Quality Control /CE Mark/Quality Assurance Certificate/COPP/COMP (attested/ apostilled from the embassy of the country of origin in Pakistan or Pakistani embassy in the country of origin) in **original** and Valid Free sale certificate for the quoted item/s duly attested/ apostilled by the Pakistani embassy in the country of origin of quoted item/s or embassy of the country of origin in Pakistan in **original** shall be provided to the Inspection team at the time of inspection.

G. Manufacturers of Non-Drug Items:

- i. Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods (as evaluated at the time of inspection by the MCC expert/s). Nonadherence to GSP shall lead to disqualification of the firm. Adherence to Good Manufacturing Practices (cGMP) in line with the DRAP regulations (to be evaluated by the MCC expert/s, Non-compliance to cGMP shall lead to disqualification of the relevant section/s or firm).
- ii. Adherence to Current Good Manufacturing Practices in line with the DRAP regulations (to be evaluated by the MCC expert/s, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm).
- iii. Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs.(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.
- iv. Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).
- v. Samples of devices will be tested and evaluated by the Drugs Testing Laboratory as well as by a panel of experts / end users and the quoted item/s may be disqualified for further competition on the report/s of these entities.

H. Importer(s)/Indenter(s) of Non-Drug Items:

- i. Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, in case of CE Mark (or its supportive documents/confirmation letters that shall prove its validity)/ Quality assurance certificate/Quality Control Certificate of the Principal Manufacturer for the quoted item/s, shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin/ or certificate issuing country, in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin / or certificate issuing country of the quoted good/s). Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm.

(In case of non-applicability of the above-mentioned certificates for Examination Gloves (Non-Sterile), Colostomy bag and colostomy paste only, provision of EC-Declaration of conformity from the principal manufacturer (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s is mandatory).

- ii. Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the warehouse at the time of inspection of the importer/indenter shall lead to disqualification of the quoted item/s and/or firm)
- iii. Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.
- iv. Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).
- v. Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s). Non provision of this document

shall lead to disqualification of the firm.

- vi. Samples of devices will be tested by the panel of experts / end users and the quoted item/s may be disqualified for further competition on the report/s of these entities.
- vii. Valid cGMP / Quality Control Certificate/Quality Assurance Certificate/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer (attested/ apostilled from the embassy of the country of origin in Pakistan or Pakistani embassy in the country of origin) in **original** and Valid Free sale certificate for the quoted item/s duly attested/ apostilled by the Pakistani embassy in the country of origin of quoted item/s or embassy of the country of origin in Pakistan in **original** shall be provided to the Inspection team at the time of inspection.

I. Importer/s of Medical Devices (Cardiac Stents)

- i. Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, in case of CE Mark / Quality assurance certificate/Quality Control Certificate of the Principal Manufacturer for the quoted item/s, shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin/ or certificate issuing country, in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin / or certificate issuing country of the quoted good/s). Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm.
- ii. Valid certification of US Food and Drug Administration (US FDA) of quoted item/s & Valid permission for sale/import of the quoted item/s in the US market (duly attested by senior executive of the firm). Non-provision of any of these certificates shall lead to disqualification of the quoted item/s.
- iii. Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm).
- iv. Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.
- v. Adequate availability of qualified, (Presence of Category-A

Pharmacist/s is/are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).

- vi. Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s). Non provision of this document shall lead to disqualification of the firm.
- vii. Samples of devices will be tested and evaluated by the Drugs Testing Laboratory as well as by a panel of experts / end users and the quoted item/s may be disqualified for further competition on the report/s of these entities.
- viii. Valid cGMP / CE Mark / Quality Control / Quality Assurance Certificate of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s) **in original** and Valid Free sale certificate for the quoted item/s duly attested/ apostilled by the Pakistani embassy in the country of origin of quoted item/s or embassy of the country of origin in Pakistan **in original**, and Valid permission of sale or import of quoted item/s for sale in the US open market **in original** shall be provided to the Inspection team at the time of inspection.

J. Manufacturer of Anti-Cancer Medicines (Oncology Products):

- i. Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) (as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).
- ii. Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). Non-adherence to GSP shall lead to disqualification of the firm.
- iii. Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).
- iv. Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of

inspection, Non-availability shall lead to disqualification of the section/s or firm).

- v. Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.

K. Importers of Anti-Cancer Medicines (Oncology Products):

- i. Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, in case of CE Mark / Quality assurance certificate/Quality Control Certificate of the Principal Manufacturer for the quoted item/s, shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin/ or certificate issuing country, in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin / or certificate issuing country of the quoted good/s). Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm.
- ii. Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)
- iii. Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.
- iv. Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).
- v. Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s). Non-provision of this document shall lead to disqualification of the firm.

- vi. Valid cGMP (attested/ apostilled from the embassy of the country of origin in Pakistan or Pakistani embassy in the country of origin) and Valid Free sale certificate for the quoted item/s duly attested/ apostilled by the Pakistani embassy in the country of origin of quoted item/s or embassy of the country of origin in Pakistan shall be provided to the Inspection team at the time of inspection.
-

Section V. Technical Specifications (Continued)
Financial Evaluation and Scoring System for Bids
(Maximum Allocable Marks Score = 30 marks)

The financial bids of technically qualified bidders will be opened publicly at the time to be announced by the Procuring Agency.

Total Allocable marks for Technical Proposal = 70

Total Allocable marks in Financial Proposal = 30

Total Combined Allocable Score for individual bids = Marks obtained in Technical Evaluation
+ Marks obtained in Financial Evaluation = 100

Scoring Methodology:

Contract will be awarded to the best evaluated firm whose product ranks highest in the Combined Evaluation scoring calculated through the Marks awarded to Technical Proposal and Financial Proposal as stated in the Bid Data Sheet of these BSDs.

The Evaluation Methodology is a combination of non-price factors (in Technical Criteria) and price factor (in Financial Criteria); and each having points as elaborated in the evaluation proformas provided in these BSDs.

As evident from allocable score above and because of the importance and complexities/sensitivities in the field of procurement and use of Drugs and other products related to human lives and health, this Methodology puts greater emphasis on non-price factors like high quality of the product derived from excellent-grade raw material, stringent product certifications, international best pharmaceutical quality control practices in laboratories, Pharmaco-vigilance systems for Drug safety reporting and monitoring; and the most efficient industrial processes in the manufacturing premises.

Procedure for the Marks Scoring: Marks will be awarded or otherwise for various technical parameters to each quoted product based on the prescribed Technical and Financial criteria. The total combined marks will determine the highest-ranking product in each product category for contract award.

The formula to calculate the marks for the price by the bidders other than lowest bidder is given below:

Financial Evaluation Score of individual quoted Product:

= [Lowest quoted Price of the item ÷ Next higher proposed Price of the competing item] X Total allocable financial score

Solved Example of Financial Scoring:

- If the lowest quoted price of an item is Rs. 86/-, the same lowest bidder will obtain score as below:
= $[86 \div 86] \times 30$
= 30 marks, being the lowest bidder for the quoted item.
- If the next higher quoted price of the same item is Rs. 105/-, the marks obtained will be:
= $[86 \div 105] \times 30 = 24.57$ Marks
- If the next higher quoted price of the same item is Rs. 130/-, the marks obtained will be:
= $[86 \div 130] \times 30 = 19.84$ Marks and so on.

ALL TECHNICAL EVALAUTION PROFORMAS IN MS-EXCEL FORMAT ARE AVAILABLE ON OFFICAL WEBSITE OF KPPRA (www.kppra.gov.pk) and HEALTH DEPARTMENT. (www.healthkp.gov.pk)

[illegible]

S. No	Proforma Description (Click on the hyperlink for access to the relevant proforma's)
1	Importer of General Medicine Drugs, IV Fluids, Powder Injectable Drugs and Biological Products (FY2026-27)
link	https://docs.google.com/spreadsheets/d/1VRi6l7wOkW_G0zBD4KTyamWjusPX9sDE/edit?usp=sharing&ouid=102746330185139301207&rtpof=true&sd=true

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2026-27																																																																																
S. No.	Name of Firm																																																																															
					Factory Technical Evaluation Parameters												Technical Evaluation Matrix																																																															
																	Total Factory Evaluated Score												Product Evaluation Parameters																																																			
																													Product Technical Parameters																																																			
Product General Information				Documents Based Factory Score												Factory Evaluation Visit Score												Product Evaluation Parameters												Total Product Evaluated Score	Grand Technical Score																																							
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26																																																							
MCC Secretary (b)					Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001 certificate of the facility where the general product is manufactured, issued by WHO, as accredited body duly attested by the Ministry of Health, Government of India.	Valid WHO 1000-A/0001

S.No	Proforma Description (Click on the hyperlink for access to the relevant proforma’s)
2	Manufacturer of General Medicine, Drugs, IV Fluids, Powder Injectable Drugs and Biological Products (FY 2026-27)
link	https://docs.google.com/spreadsheets/d/1tkg-y0NIRoXHnWWrhMV3fuN_oCq-cy6G/edit?usp=drive_link&ouid=102746330185139301207&rtpof=true&sd=true

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27																
Name of the firm																					
S. No.		Product General Parameter				Technical Evaluation Matrix															
	Principal's and Importer's Evaluation Parameters						Product Technical Evaluation									Product Evaluated Score	Total Technical Score				
	Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score														
MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or in relevant sections by the US FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. Online verification link shall be provided	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist's is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, compiled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CnA will not be awarded.	Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 06 Tender approvals- 02 marks 06 Tender approvals- 03 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US fire sale certificate of the quoted products, 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.					
	MCC formulary No.	Generic Name of item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70	
																			0	0	
																			0	0	

S.No	Proforma Description (Click on the hyperlink for access to the relevant proforma’s)
3	Importer/Indenter of Medical Devices, Surgical Disposables and Sutures (FY2026-27)
Link	https://docs.google.com/spreadsheets/d/1fc45-Gcn2B354cary-AL5MCWix4tEZAW/edit?usp=drive link&ouid=102746330185139301207&rtpof=true&sd=true

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27																									
S.No.	MCC Formulary No.	Product General Information				Factory Technical Evaluation Parameter										Technical Evaluation Matrix						Product Evaluated Score	Total Technical Score		
						Documents Based Factory Score										Evaluation Visit Score		Product technical Evaluation Parameters							
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21					
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PHAC, accredited body duly attested by senior executive of the firm) Online verification link shall be provided.	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PHAC, accredited body duly attested by senior executive of the firm. Online verification link shall be provided.	Valid Calibration Certificates attested by Quality head of the firm.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Minimum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods regulations. As evaluated at the time of inspection by the MCC experts, Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (CGMP) in line with the DRAP regulations. As evaluated by the MCC experts at the time of inspection, Non-compliance to CGMP shall lead to disqualification of the relevant section or firm)	Availability of functional and validated equipment, testing and test with the DRAP regulations. As evaluated by the MCC experts at the time of inspection, Non-availability or non-functionality of the firm's equipment shall lead to disqualification of the relevant section or firm.	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods regulations. As evaluated by the MCC experts at the time of inspection, Non-compliance to CGMP shall lead to disqualification of the relevant section or firm.	Goods Declaration certificate of imported raw material of the quoted items from Pakistan Customs, coupled with valid surveyor bill or Bill of Lading for the quoted items, not older than 24 months on the call date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid tradeLink/DRAP clearance/ NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GDI) provided in item hospitals of Pakistan In case of Non-provision of matching CD the marks for C&A will not be awarded. Note: Tender approval means an approval											

S. No	Proforma Description (Click on the hyperlink for access to the relevant proforma's)
4	Manufacturer of Medical Devices, Surgical Disposables and Sutures (FY2026-27)
link	https://docs.google.com/spreadsheets/d/1Sydv5zFZe3KDYKEbdG36zOvlgzpt3kTp/edit?usp=drive link&ouid=102746330185139301207&rtpof=true&sd=true

Evaluation Criteria for Importers of Cotton & Related Goods for Government MCC 2026-27																					
S. No.		Name of the Firm																			
						Principal's and Importer's Evaluation Parameters							Suppliers Technical Score	Product Technical Parameters					Product Evaluated Score	Total Technical Score	
						Principal Manufacturer Evaluation			Importer's Evaluation												
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11		12	13	14	15	16			17
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant sections by the US- FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. Online verification link shall be provided.	Availability of minimum 20% inventory of the total import of the quoted item's during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert's). Non availability of the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item's / firm	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item's. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/ Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert's at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified & relevant Human Resource (Presence of Category-A Pharmacist's is/are mandatory) (Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	Goods Declaration certificate of imported finished quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Duly attested by the senior executive of the firm).	Certificate of Analysis of finished quoted item's from the Principal Manufacturer as mentioned in the goods declaration (GD) certificate provided in column 12. (Duly attested by the senior executive of the firm). In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination and / or evaluation of the quoted item's by the MCC expert's. Rejection of the quoted item's by the MCC expert's shall lead to disqualification of the said quoted item's.					
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	3	3	5	7	7	7	35	5	5		5	10	10	35	70
													0							0	0
													0							0	0

S.No	Proforma Description (Click on the hyperlink for access to the relevant proforma’s)
5	Importers of Cotton and Related Goods (FY2026-27)
Link	https://docs.google.com/spreadsheets/d/19DTTLjFkmGYMfJVntApcyJON-o-PcyZm/edit?usp=drive_link&ouid=102746330185139301207&rtpof=true&sd=true

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27																						
S. No.	Name of Firm				Technical Evaluation Matrix																	
	General Product Information				Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score		
					Documents Based Factory Score					Evaluation Visit Score												
					MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
	MCC formulary No.					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC Labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate equipment / instruments and non-compliance to GLP, cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	15	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/es, etc. The Bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted items by the MCC expert/s. Rejection of the quoted items by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation: by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)			
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70	
																0				0	0	
																0				0	0	

S. No	Proforma Description (Click on the hyperlink for access to the relevant proforma’s)
6	Manufacturers of Cotton & Related Goods (FY2026-27)
Link	https://docs.google.com/spreadsheets/d/1a5p1GKKmV54B_GwI9O_JyUH_dbq9KAFy/edit?usp=drive_link&ouid=102746330185139301207&rtpof=true&sd=true

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27																					
Name of the firm					Technical Evaluation Matrix																
Product General Information					Factory Technical Evaluation Parameter								Factory Evaluated Score					Product Evaluated Score	Total Technical Score		
					Documents Based Factory Score				Evaluation Visit Score												
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023/24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material. In-process and Finished Goods. (as evaluated at the time of inspection by the MCC experts). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC experts, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for Ca will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Online verification link shall be provided.	Physical examination of the quoted item/s by the MCC experts. Rejection of the quoted item/s by the MCC experts shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70
														0						0	0
														0						0	0

S. No	Proforma Description (Click on the hyperlink for access to the relevant proforma’s)
8	Manufacturers of Non-Drug Items (FY2026-27)
Link	https://docs.google.com/spreadsheets/d/1e4UBcb1t6BaGZO1K6i3WiLJ_sq7JhLxC/edit?usp=sharing&ouid=102746330185139301207&rtpof=true&sd=true

Evaluation Criteria for Importers of Cardiac Stents for Government MCC 2026-27																				
S.No		Name of the firm				Technical Evaluation Matrix														
	MCC formulary No.	Product General Parameters				Principal's & Importer's Evaluation Parameters														
						Principal's Evaluation					Importer's Evaluation			Product Technical Parameters						
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	
					Valid cGMP / CE Mark / Quality Assurance Certificate/ Quality Control. Certificate 'COPP/COMP' (attested from the embassy of the country of origin in Pakistan or Pakistani embassy in the country of origin). In case of CE Mark / Quality assurance certificate the certificate shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union Shall be accepted only. Certificate on company's own letter head shall not be acceptable. (duly attested by senior executive of the firm). Non provision of the certificate shall lead to disqualification of firm Online verification link shall be provided.	Valid certification of US Food and Drug Administration (US FDA) of quoted item's Valid permission for sale/import of the quoted item's in the US market (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid JIS certification of quoted item's from Japanese Ministry of Health, Labour & Welfare (JMHLW) (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 14001 certificate of the facility where the quoted products are manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted products are manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Availability of minimum 20% inventory of the total import of the quoted item's during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert's). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item's / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item's. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert's at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist's is/are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert's at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	Total Score of Principal's & Importer's Evaluation	Goods Declaration certificate of imported finished quoted item's from Pakistan Customs, complied with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid link /link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Duly attested by the senior executive of the firm).	Certificate of Analysis of finished quoted item's from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 13. (Duly attested by the senior executive of the firm). In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity (purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item's by the MCC expert's. Rejection of the quoted item's by the MCC expert's shall lead to disqualification of the said item's.	Product Evaluated Score	Total Technical Score	
	MCC formulary No.	Generic Name of item	Strength	Dosage Form	Brand Name	5	5	5	5	5	5	5	40	5	5	5	15	30	70	
																	0			
																	0			

S.N o	Proforma Description (Click on the hyperlink for access to the relevant proforma’s)
9	Importers of Cardiac Stents (FY2026-27)
Link	https://docs.google.com/spreadsheets/d/1pCGjvIlz_qbFVdvkzwTXI50IVdjCJgIT/edit?usp=sharing&oid=102746330185139301207&rtpof=true&sd=true

S.No	Proforma Description (Click on the hyperlink for access to the relevant proforma's)
10	Manufacturer & Importers for Oncology medicines (FY 2026-27)
Link	https://docs.google.com/spreadsheets/d/1k3769Jsu5htPsc0PypAhHdzR9QmRQzAU/edit?usp=sharing&ouid=102746330185139301207&rtpof=true&sd=true

Section VI. Sample Forms

MANDATORY STANDARD FORMS FOR APPLICANT BIDDERS	
BID FORM 1	BID COVER SHEET
BID FORM 2	LETTER OF INTENT
BID FORM 3	AFFIDAVIT
BID FORM 4	INTEGRITY PACT
BID FORM 5	TECHNICAL PROPOSAL FORMAT
BID FORM 6	FINANCIAL PROPOSAL FORMAT/SCHEDULE (To Be Submitted Through EPADS)
BID FORM 7	BANK GUARANTEE

GOVT. MCC STANDARD FORMS	
BID FORM 8	CONTRACT AGREEMENT (for information only, shall be signed by the successful bidders only)
BID FORM 9	CODE OF ETHICS
BID FORM 10	PHYSICAL INSPECTION REPORT FOR MCC APPROVED ITEMS IN HEALTH FACILITIES OF KHYBER PAKHTUNKHWA
BID FORM 11	GOVT. MCC CLINICAL EFFICACY REPORTING FORM

Bid Form-1(to be submitted by bidder)

Mandatory

BID COVER SHEET

Mandatory General Information of Applicant Firm

INSTRUCTIONS: Complete filling of this form along with the provision of all requisite information is mandatory. Missing or not providing any of the requisite information may lead to disqualification of the bidder/s from the bidding competition without any correspondence. Any appeal from bidder/s, for whatsoever reasons, shall not be entertained in such a case.

S.No.	Name of the Bidding Firm:	
1.	Please indicate whether the firm is: <ul style="list-style-type: none"> i. Manufacturer, or ii. Importer/Indenter, or iii. Both; Manufacturer as well as Importer/Indenter For various MCC formulary items offered for this bidding competition. iv. Manufacturer/Import License Number Issued by DRAP: 	
2.	Please indicate out of the following category/ies, under which the Firm is applying for bidding: <ul style="list-style-type: none"> i. General medicines ii. I/V Fluids iii. Biological drugs iv. Medical devices including Surgical Disposables, Cotton & related goods, gauze, adhesive tapes, bandages, etc., but excluding cardiac stents v. Cardiac Stents vi. Non drug items (NDIs). vii. Anti-Cancer Medicines (Oncology Products) 	
3.	Please provide names, attested copies of CNICs, two recent attested photographs, valid street addresses in Pakistan, all working landline, mobile phone numbers and valid email address of the following: <ul style="list-style-type: none"> i. Owner/Proprietor of the Firm; and ii. Managing Director / CEO of the Firm; and iii. Focal person shall be an employee of the firm/bidder officially authorized for day to day official correspondence/communication if required with the procuring agency along with valid mobile number. 2. Please provide clear, legible and visible attested photocopies of all the valid requisite items mentioned items)	
4.	Please provide the following valid information regarding applicant Firm: <ul style="list-style-type: none"> i. Complete street address of the: <ul style="list-style-type: none"> a. Head Office b. Main warehouse; and ii. Valid & working official Landline Phone and Fax Numbers; and iii. Valid Mobile phone number/s of the Focal Person registered which should be registered his/her CNIC No. and name; and 	

	<p>iv. Valid and functional Email address of the firm for all correspondence; and</p> <p>v. Official Website address/es.</p> <p>In case of provision of wrong contact information (address, email, phone etc) by the bidder, leading to any miscommunication or delay in the timely/ effective information/correspondence between the bidder and the procuring entity in the bidding process particularly and procurement cycle in general shall have no responsibility on the procuring entity.</p>	
5.	<p>i. Please provide the original bids security (Call Deposit Receipt (CDR)/ Bank Guarantee) amounting to Rupees Ten Hundred Thousands only (Rs.10,00,000/-) in the name of Director General Health Services, Khyber Pakhtunkhwa in a sealed envelope, from a scheduled Bank of Pakistan at the time of Technical Bid Opening. Ordinary crossed or open Cheques shall not be acceptable as Bids security.</p> <p>ii. Note: The bidders must submit attested scanned copy of the Bid Security (CDR/ Bank Guarantee) in its technical bid, duly submitted through EPADS.</p>	
6.	<p>Please provide attested copies of the following Tax related valid documents:</p> <p>i. National Tax Number (NTN) of the Firm for Income Tax, and</p> <p>ii. Sale Tax Registration Certificate of the Firm; and</p> <p>iii. Certificate of Professional Tax of the Firm.</p> <p>iv. Last year Income Tax Return of the Firm</p>	
7.	<p>In case of being a Manufacturer, the Firm should provide attested copies of the following documents, in accordance with the Drugs (Licensing, Registering and Advertising) Rules, 1976:</p> <p>i. Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and</p> <p>ii. Valid cGMP certificate issued by DRAP or cGMP inspection report by the DRAP (only quoted products of the Section (s) shall be considered whose GMP Inspection Report is declared satisfactory and/or which are mentioned in the GMP Certificate). Satisfactory inspection report of the area Federal Inspector of Drugs (FID) duly signed by him/her on the original inspection book of the manufacturer. Copies of the cGMP inspection report shall not be considered. Moreover, routine inspections carried out by the FID shall not fulfill this requirement and only the inspections carried out for issuance of cGMP certificate shall be considered (Application of Renewal of cGMP along with copy of the fee challan shall be submitted with the cGMP inspection report and the same shall be verified by the MCC experts during physical inspection of the firm). Moreover, the mandatory certificates of cGMP, DML and Drug Registration certificate expired during the tendering process i.e., from the date of advertisement (18-01-2026) and bid submission (17-02-2026) shall be considered valid subject to the timely application for renewal to the DRAP along with the Bank receipt and acknowledgement receipt.</p> <p>iii. Valid DRAP Approved Price List of the quoted item/s, in accordance with the DRAP Pricing Policy 2018 (Amended)</p> <p>iv. Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.</p>	
8.	<p>In case of being Importers/Indenters, the Firm should provide attested copies of the following documents also:</p> <p>i. Establishment of Medical Device License issued by DRAP where applicable for the item/s quoted by the firm for bidding competition.</p> <p>ii. Valid Drugs Sales License for the importer; and</p> <p>iii. Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and</p> <p>iv. Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, in case of CE Mark (or its supportive documents/confirmation letters that shall prove its validity) / Quality assurance certificate/Quality Control Certificate of the Principal Manufacturer for the quoted item/s, shall be issued by conformity assessment bodies enlisted in NANDO database under the relevant European Directive for medical devices of European Union (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin/ or certificate issuing country, in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin / or certificate issuing country of the quoted good/s). Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. (In case of Non-applicability of the above mentioned certificates for items such as Examination Gloves (Non Sterile), Adhesive Tapes (Non Sterile), Colostomy bag and colostomy paste only, provision of EC-Declaration of conformity from the principal manufacturer (duly attested/apostilled from the Embassy / High Commission / Consulate (as the case</p>	

	<p>may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s is mandatory) and</p> <p>v. Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s). Non provision of this document shall lead to disqualification of the firm; and</p> <p>vi. Valid Price List of the quoted items.</p> <p>vii. Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and</p> <p>viii. For cardiac stents, provision of the following documents is mandatory apart from those mentioned in clause a & b above:</p> <ol style="list-style-type: none"> Valid US-FDA certificate of the quoted item/s; and Valid permission of sale or import of quoted item/s for sale in the US open market. <p>Note: Valid cGMP/Quality Control Certificate/CE Mark/Quality Assurance Certificate/COPP/COMP certificate/s of the principal manufacturer of the quoted item/s and Valid Free Sale Certificate/s for the quoted item/s, as issued by relevant authority of the country of origin of the quoted imported good/s (duly attested/ apostilled from the Embassy / High Commission / Consulate (as the case may be) of the country of origin in Pakistan or Pakistani Embassy / High Commission / Consulate (as the case may be) in the country of origin of the quoted good/s), as elaborated in the relevant section of these BSDs, shall be presented in original by the bidder to the inspection team of MCC expert/s at the time of inspection. Failure to comply with this instruction shall lead to disqualification of the firm for the quoted item/s and/or firm. Photocopy or scanned copy or any receipt claiming constructive possession of the same shall not be considered in lieu of the original.</p> <p>For Anti-Cancer Medicines (Oncology Products), the mandatory documents for importers in this category are given in the technical evaluation proforma of oncology medicines.</p>
9.	<p>The bidding Firm shall also provide an Affidavit on Judicial Stamp Paper of the value of at least Rs. 100/- (Rs. One Hundred Only) for the following undertaking:</p> <ol style="list-style-type: none"> I / We have carefully read the whole set of Bid Solicitation Documents for this bidding competition and that I / We have fully understood and agree to all the provisions (including, but not limited to, those provided under ITB 11.5, 16.1 and 29.1 of the Bid Data Sheet), terms and conditions, evaluation criteria, mechanism of evaluation & selection of items for which the Firm has applied for competition; and I / We fully understand and agree that the bidding competition for which I / We have applied to enter in, shall be based on merit-based scoring system for the evaluation of technical bids which has inverse relationship with
	<p>the rates quoted by the bidders in their financial bids submitted; and that in this situation, the lowest financial bid/s may or may not win the bidding competition; and</p> <p>iii. I / we guarantee that the quoted drug / medicine, surgical disposables, medical devices and non-drug items are, and shall be, freely available in the market of Pakistan; and particularly in the market of Khyber Pakhtunkhwa province and/or available in public and private sector health facility (ies); and</p> <p>iv. I / We shall provide to the inspection team/s of expert/s authorized for the purpose by the Directorate General Health Services, Govt. MCC Khyber Pakhtunkhwa an uninterrupted and free access to all relevant documents, sections of the manufacturing facilities / unit, storage and warehousing facilities as well as any other area relevant, as deemed appropriate by the above-mentioned team for their purpose of visit/s as enshrined in S.# 5 of the special conditions of contract.</p> <p>v. In case of any collusive, coercive, corrupt, obstructive, fraudulent practices and/or any act of misconduct by the bidding firm/focal person, in this bidding competition in relation to the decision making by the procuring entity (Selection & Rate Contracting Committee notified for FY 2026-27), shall be liable to be proceeded under KPPRA Act 2012, Rules framed thereunder, Departmental Debarment/Blacklisting Guidelines Notified vide Letter No. 2440-2500/Proc. Cell, Dated: 30-08-2018, for debarment, blacklisting for a specified period and/or forfeiture of the bid security/performance guarantee of the bidding firm, and / or any other lawful action as deemed appropriate by the procuring entity, including that to be taken up with the DRAP or any other body / entity of the Federal Government; and</p> <p>vi. I / We have fully understood that the medical devices and items in the categories of cotton, bandages, adhesive tapes, etc. including other non-drug items shall be evaluated / examined by expert/s nominated by the Technical Evaluation Committee / Selection & Rate Contracting Committee of the Government MCC of the Health Department, Khyber Pakhtunkhwa at its sole discretion; and that the Firm shall fully agree and abide by the decision / opinion, whatsoever, of the said expert/s regarding the selection, or otherwise, of the quoted item/s for purchase / rate contracting.</p> <p>vii. I / We also undertake that submission of any false/bogus/fake/forged/ fabricated/tampered document shall lead</p>

	<p>to disqualification of our firm from this bidding competition by the procuring entity as well as communicate the same for lawful action/s to be taken by the concerned authority/ies.</p> <p>viii. I / We have fully understood that no such documents shall be entertained by the Procuring Agency, which is issued after due date of Bid opening.</p>
10.	I / We declare and undertake that in case of award of product/s in the bidding competition, the API source quoted in the bid shall provide during the supply period of the financial year 2026-27 and the quarter reports of the batches and the API source import documents shall be submitted to the Govt. MCC, Directorate General Drug Control & Pharmacy Services Khyber Pakhtunkhwa till completion of the contract period.
11.	I / We declare and undertake that for the items falling in the category of medical devices and Non drug Items, the documents submitted for medical grade material certification and for pharmaceutical grade certification for immediate containers shall supply all such goods with the same certified quality, material and specification/s to the Purchasing entity/ies throughout the validity period of contract agreement.
12.	I / We have fully understood that in case of being best evaluated bid for the quoted item/s, an Advance Acceptance Letter shall be issued by the Govt. MCC, confirming the status of the successful bidder. Upon issuance of the Advance Acceptance Letter, the successful bidder shall be obligated to submit a duly signed contract agreement within ten (10) working days. In case of failure to comply within the specified period, the Govt. MCC shall issue a final notice, granting an additional ten (10) working days for submission of the contract agreement to the Govt. MCC. If the undersigned/successful bidder fails to submit the contract agreement on judicial stamp paper within the extended period, it shall be deemed that the successful bidder is unable to fulfill the supply obligations for the approved item(s). Consequently, the quoted item(s) shall be declared non-responsive, and the contract shall be awarded to the next eligible bidder.
13.	I / We hereby declare and undertake that the firm will provide full access to the import trail including WEBOC and other ancillary documents of API Sources & medical grade material certifications to the Govt. MCC team during the technical evaluation and in case of award of product(s) in this bidding competition.
14.	<p>I certify and affirm that I have attached /provided all the requisite mandatory documents / information including Bids Security with this Bid and that I fully understand that any document if not provided / missing shall result in the disqualification and declaring my bid as ineligible and thus non-responsive.</p> <p>Signatures:</p> <p>Name:</p> <p>CNIC No.</p> <p>Designation:</p> <p>Address:</p>

Bid Form-2 (to be submitted by bidder)
Mandatory

Letter of Intention

Bid Ref No.

Date of the Opening of Bids

Name of the Contract : { Add name, e.g, Supply of Dugs and Medicines, etc. }

To: *[Name and address of Procuring Agency]*

Dear Sir/Madam

Having examined the bidding documents, including Addenda Nos. *[insert numbers& Date of individual Addendum]*, the receipt of which is hereby acknowledged, we, the undersigned, offer to supply and deliver the Goods under the above-named Contract in full conformity with the said bidding documents and at the rates/unit prices described in the financial bid are not more than the trade price of quoted item/s in the market.

We undertake, if our bid is accepted, to deliver the Goods in accordance with terms and condition of contract agreement.

We agree to abide by this bid, for the Bid Validity Period specified in the Bid Data Sheet and it shall remain binding upon us and may be accepted by you at any time before the expiration of that period.

Until the formal final Contract is prepared and executed between us, this bid, together with your written acceptance of the bid and your notification of award, shall constitute a binding Contract between us.

We understand that you are not bound to accept the lowest or any bid you may receive.

We undertake that, in competing for (and, if the award is made to us, in executing) the above contract, we will strictly observe the laws against fraud and corruption in force in Pakistan in general and the KPPRA Act & Rules in particular.

Dated this *[insert: number]* day of *[insert: month]*, *[insert: year]*.

Signed:

In the capacity of *[insert: title or position]*
Duly authorized to sign this bid for and on behalf of *[insert: name of Bidder]*

Bid Form-3 (to be submitted by bidder)
Mandatory

AFFIDAVIT (on Judicial Stamp Paper)

I/We, the undersigned [**Name of the Supplier**] hereby solemnly declare and undertake that:

- 1) I / We, the undersigned, have read the contents of the Bidding Document and have fully understood it.
- 2) The Bid being submitted by the undersigned complies with the requirements enunciated in the bidding documents.
- 3) I / We undertake that the undersigned will not perform any act intended to hinder a procurement process or contract execution by harming or threatening persons or property, falsifying or concealing evidence, making false statements, or impeding investigations or audits related to corrupt, fraudulent, coercive, or collusive practices.
- 4) The Goods that I / We, the undersigned, propose to supply under this contract are eligible goods within the meaning of this BSD.
- 5) The undersigned are also eligible Bidders within the meaning of the Bid Solicitation Documents.
- 6) The undersigned are solvent and competent to undertake the subject contract under the Laws of Pakistan.
- 7) The undersigned have not paid nor have agreed to pay, any Commissions or Gratuities to any official or agent related to this bid or award or contract.
- 8) The undersigned are not blacklisted or facing debarment from Health Department, or its organization or project in Khyber Pakhtunkhwa.
- 9) The undersigned has not manufactured /import /supplied any batch of Medicine(s), Drugs, Medical Device(s), Surgical Disposables, Cotton and related goods etc., being declared as **Spurious / Adulterated /Counterfeit/ Substandard**, by DTL of Khyber Pakhtunkhwa or any other Public Drug Testing Laboratory in Pakistan, and found guilty of manufacturing/ import/supplied of spurious/adulterated/counterfeit/ substandard medicines, and convicted/ delisted/ de-registered for the quoted item(s) by any court of law or Drug Regulatory Authority of Pakistan in last three years which attained finality.
- 10) That undersigned has not employed any child labor in the organization/unit.
- 11) We understand that the Procuring Agency or any of its committees are not bound to accept the lowest or any other bid they may receive.

I / We affirm that the contents of this affidavit are correct to the best of my/our knowledge and belief.

Signatures with stamp

Name: _____

Designation: _____

CNIC No. _____

For Messrs. [**Name of Supplier**]

Bid Form-4 (to be submitted by bidder)

Mandatory

INTEGRITY PACT (on Judicial Stamp Paper)

Declaration of Fees, Commission and Brokerage Etc. Payable by Suppliers of Drugs/Medicines, Surgical Disposables, Medical Devices & Non Drugs Items for Govt: MCC 2026-27

In response to advertisement related to the bidding process / competition regarding purchase and supply of drugs, non-drugs and surgical disposable items for 2026-27 for the health facilities / institutions through the Govt. MCC Khyber Pakhtunkhwa in financial year 2026-27, Peshawar, I, Mr. / Ms. _____

_____ s/o, d/o _____ bearing CNIC No. _____

_____, and having the Designation of _____ in Messrs.

(M/S) [***Name of Supplier***] do hereby solemnly affirm, declare and certify on behalf of M/S [***Name of Supplier***] that:

1. [***Name of Supplier***] has not obtained or induced the procurement of any contract, right, interest, privilege or other obligation or benefit from Govt. MCC, Health department Khyber Pakhtunkhwa or any administrative subdivision or agency thereof or any other entity owned or controlled by Government of Khyber Pakhtunkhwa (GoKP) through any corrupt business practice; and
2. That without limiting the generality of the foregoing, [***Name of Supplier***] represents and warrants that it has fully declared the brokerage, commission, fees etc. paid or payable to anyone and not given or agreed to give and shall not give or agree to give to anyone within or outside Pakistan either directly or indirectly through any natural or juridical person, including its affiliate, agent, associate, broker, consultant, director, promoter, shareholder, sponsor or subsidiary, any commission, gratification, bribe, finder's fee or kickback, whether described as consultation fee or otherwise, with the object of obtaining or inducing the procurement of a contract, right, interest, privilege or other obligation or benefit in whatsoever form from GoKP, except that which has been expressly declared pursuant hereto; and
3. That [***Name of Supplier***] has made and will make full disclosure of all agreements and arrangements with all persons in respect of or related to the transaction with Govt. MCC, Health department Khyber Pakhtunkhwa and has not taken any action or will not take any action to circumvent the above declaration, representation or warranty; and
4. That [***Name of Supplier***] accepts full responsibility and strict liability for making any false declaration, not making full disclosure, misrepresenting facts or taking any action likely to defeat the purpose of this declaration, representation and warranty. It agrees that any contract, right, interest, privilege or other obligation or benefit obtained or procured as aforesaid shall, without prejudice to any other rights and remedies available to Govt. MCC, Health department Khyber Pakhtunkhwa under any law, contract or other instrument, be voidable at the option of Govt. MCC, Health department Khyber Pakhtunkhwa; and
5. That notwithstanding any rights and remedies exercised by Govt. MCC, Health department Khyber Pakhtunkhwa in this regard, [***Name of Supplier***] agrees to indemnify Govt. MCC, Health department Khyber Pakhtunkhwa for any loss or damage incurred by it on account of its corrupt business practices and further pay compensation to Govt. MCC, Health department Khyber Pakhtunkhwa in an amount equivalent to ten times the sum of any commission, gratification, bribe, finder's fee or kickback given by [name of Supplier] as aforesaid for the purpose of obtaining or inducing the procurement of any contract, right, interest, privilege or other obligation or benefit in whatsoever form from Govt. MCC, Health department Khyber Pakhtunkhwa.

Signatures with stamp

Name: _____

Designation: _____

CNIC No. _____

For Messrs. [***Name of Supplier***]

Witness No. 1

Witness No. 2

(Signatures, name, father's name, CNIC & address of each Witness)

Bid Form-5 (to be submitted by bidder)
(Mandatory)

Technical Proposal format of the Government MCC for the year 2026-27

1. All the bidders must submit the quoted product list/technical proposal on the following format:

S.No.	MCC Formulary No.	Drug Name	Strength	Dosage form	Brand Name	Pack Size
1						

Example:

S.No.	MCC Formulary No.	Drug Name	Strength	Dosage form	Brand Name	Pack Size
1	67	Paracetamol + Orphenadrine	450 mg + 35 mg	Tab.	Nuberol	100s or less

Bid Form-6 (to be submitted by bidder)

Mandatory

Price Schedule format for Financial Bid of Government MCC for the year 2026-27

2. In case of Drugs/Medicines, the unit price of each item shall be quoted and submitted in the following format:

S.No.	MCC Formulary No.	Drug Name	Strength	Dosage form	Brand Name	Pack Size	Maximum Retail Price (MRP)	Trade Price (Unit price)	Rate Offered per unit in PKR
1									

Note: Quoted price of the items shall be rounded up to two decimal points. For Example, Rs. 16.34/.

2. In case of Surgical Disposables, Medical Devices & NDIs, the unit price of each item shall be quoted and submitted in the following format:

S.No.	MCC Formulary No.	Drug Name	Strength	Dosage form	Brand Name	Pack Size	Maximum Retail Price (MRP)	Trade Price (Unit price)	Rate Offered per unit in PKR
1									

Note: Quoted price of the items shall be rounded up to two decimal points. For Example, Rs. 16.34/-

Free Of Cost (FOC), if any, shall be mentioned separately in the financial bid for the purpose of comparison. The procuring entity will compare unit price as follows:

$$\text{Price offered} + \text{FOC} / \text{number of units} = \text{Offered Rate Per Unit in PKR}$$

Example:

S.No.	MCC Formulary No.	Drug Name	Strength	Dosage form	Brand Name	Pack Size	Maximum Retail Price (MRP) Per Unit	Trade Price (Unit price)	Rate Offered per unit in PKR
1	67	Paracetamol + Orphenadrine	450 mg + 35 mg	Tab.	Nuberol	100s or less	16.7	14.2	10.50

Bid Form-7 (to be submitted by bidder)

BANK GUARANTEE (*Specimen*)

Guarantee No.	_____
Initial Date of Issue:	_____
Amount of Guarantee PKR:	Rs: 10,00,000/-Rupees Ten Hundred Thousand Only)
Date of expire of Guarantee:	31.07.2027 (Extendable)
Claim Lodgment Date:	31.07.2027 or Later as decided by the procuring entity.

From: **(Bank Name and complete address)**

To: **Director General Health Services
Khyber Pakhtunkhwa Peshawar.**

We “**(Bank Name)**” having its place of business at **(Address of the Bank)** and Head office **(Address of the head office)** (Hereinafter referred to as the Guarantor), understand that **Name and Address of the Bidder** (hereinafter referred to as the Customer/Bidder) as per requirement of Bid Solicitation Documents (BSDs) for FY 2026-27, required to furnish a Bank Guarantee in respect of said BSDs for an amount of **Rs. 10,00,000/- (PKR Ten Hundred Thousand Only) for (Name of the Customer/Bidder).**

Now therefore in consideration of the above, we the Guarantor, guarantee unconditionally the due payment to you unconditionally upon demand of such sum or sums not exceeding **Rs. 10,00,000/- (PKR Ten Hundred Thousand Only)** in the event that Customer/Bidder fail to perform or fulfill any of the terms and conditions of the BSDs at the time or during the period specified in the guarantee, provided that any such demand here under is received in writing at this office within the validity of this Guarantee period accompanied by your written declaration to us that the Customer/Bidder has failed to comply with the terms of the conditions/Regulations and such declaration shall be accepted by us as conclusive proof that the amount claimed is due to you and we shall pay you the amount under this Guarantee. Our liability under this guarantee shall not be affected by any dispute or difference between you and the Customer/Bidder or by forbearance or indulgence granted by you to the Customer/Bidder or by any other security held by you from the Customer/Bidder relating to the above-mentioned Regulations or any violation in the Regulations or any other manner or thing which might affect our liability hereunder.

Notwithstanding anything contrary contained herein above, our maximum liability under this guarantee shall not in any case exceed **Rs. 10,00,000/- (PKR Ten Hundred Thousand Only)**. This guarantee shall remain valid up to **31.07.2027 (or Later as may be decided by the procuring entity)**. Any claims under this guarantee must be received in writing along with the original bank guarantee and all the amendments if any, on or before expiry of this guarantee i.e., **31.07.2027**. After which date this guarantee will become automatically void and bank will be absolved of its liability under this guarantee whether or not the original is returned to us for cancellation. This agreement shall be governed by and construed in accordance with the laws of Pakistan.

For and on behalf of (Bank Name)

Authorized Person Signature with Stamp/Seal

Bid Form-8

(to be submitted by approved bidders after award of contract)

GOVERNMENT MCC RATE CONTRACT AGREEMENT

THIS RATE CONTRACT AGREEMENT is made and agreed today on the ____ day of [Month], 2026 between the Director General Health Services, Health Department, Government of Khyber Pakhtunkhwa (*hereinafter referred to as the Procuring Agency or first party, which expression shall, where the context admits, be deemed to include the successors and / or assignee/s of the Provincial Government of Khyber Pakhtunkhwa*); and Messrs. [Name of Supplier] through Mr. _____, Designation _____ CNIC No. _____, (*hereinafter referred to as the Supplier or second party or he or his or him, which expression, unless repugnant to the context, means and includes their legal heir/s, successors-in-interest, assignee/s and legal representative/s*) that:

WHEREAS the Procuring Agency has made a bidding competition under the approved Bid Solicitation Documents for the year 2026-27 (*hereinafter referred to as the BSDs*) approved for the selection and rate contracting of drugs/medicine, medical devices, surgical disposables and other non-drug items (*hereinafter referred to as goods*) for actual purchases of the selected and rate contracted goods to be made by the offices / officers of the Health Department, Government of Khyber Pakhtunkhwa (*hereinafter called the Purchasing Agency or Purchasing Agencies or Purchasing Agency/ies, where the context so admits*); and

WHEREAS the Supplier has won the bidding competition for selected goods, as listed in the Schedule-1 of this contract agreement; and

WHEREAS the Supplier declares that he is not a broker, middle-man, distributor or authorized dealer of, or acting on behalf of any entity or person, but himself a genuine Manufacturer and / or direct Importer/Indenter of the goods for which he has won the bidding competition for supply of the same to the Purchasing Agency/ies, as defined in the BSDs, throughout the province of Khyber Pakhtunkhwa (*hereinafter referred to as the Province*); and

WHEREAS both the parties have agreed that the Purchasing Agencies in the Province shall purchase all, or some, or none of the goods, as of details given in the Schedule-1 of this Contract Agreement, from the Supplier at the sole discretion of the individual Purchasing Agency/ies in subordination to laws and matters ancillary to the terms and conditions of the BSDs; and **WHEREAS** the Supplier shall supply all the goods ordered by the Purchasing Agency/ies to the latter in the quantity as mentioned in the supply order to be issued by the Purchasing Agency within the timeframe as mentioned in clause-22 of this contract agreement;

Now, therefore, both the parties hereby mutually agreed to enter into this contract agreement as under:

1. The Supplier agrees to take full responsibility of the validity and implications, that may arise in future, of declaration as submitted by him through an affidavit on judicial stamp paper along with the Bid Form-1 of the BSDs along with his bid; and also that in case of any kind of breach of the said declaration, the Supplier shall be liable to be proceeded against by the Procuring Agency and / or Purchasing Agency concerned, as the case may be, in accordance with the clauses of this rate contract agreement as well as relevant laws, rules and regulations of the Government of Khyber Pakhtunkhwa, as amended from time to time, to govern the situation/s.
2. The Supplier shall supply the ordered goods to the concerned Purchasing Agency exactly at the address of the official premises situated within the district of the official jurisdiction of the latter as provided in the supply order issued to the former.
3. The Supplier shall be solely responsible for the safe and appropriate method and mode of transportation, loading, unloading and staking of the supplied items till, and at the time of delivery to the destination address indicated by the Purchasing Agency in the district of its jurisdiction.
4. The Supplier shall be solely responsible for any damage, untoward incidence, maintenance of required temperature and protection from light and other environmental conditions as well as other

hazards that may possibly or potentially affect the safety, quality and efficacy of the supplied goods till the time of delivery and the consequences arising therefrom, if any.

5. The Supplier shall not claim or charge any transportation, loading / unloading, labour or any other charges, whatsoever, related to or in the name of logistics, accidents, insurance, freight, toll tax, etc.
6. The Supplier shall supply all the goods in full conformity to the specifications as laid down in the BSDs.
7. The Purchasing Agency shall arrange to obtain randomized sample/s for each formulary item of the supplied goods, as in the BSDs and belonging to the categories of drug/medicine, medical devices and surgical disposables through the notified Drug Inspector/s concerned for sending the same to the concerned Drug Testing Laboratory for Test / Analysis as provided in the Drugs Act 1976, DRAP Act 2012 and rules frame thereunder as well as provisions of the BSDs, further subject to the following condition/s:
 - a. The supplied goods declared in contravention to any provision of the Drugs Act 1976, DRAP Act 2012 and rules made thereunder, shall be re-supplied by the Supplier at his sole risk and cost and at no cost to the Purchasing Agency, within 07 days from the date of intimation to the Supplier or his focal person, as nominated by the Supplier in the Bid Form-1 of his bid submitted under the BSDs, at such place as the Purchasing Agency may direct in accordance with clause-2 of this contract agreement.
 - b. The Purchasing Agency shall arrange to obtain sample/s of the re-supplied goods as in clause- 7 (a) above, for the purpose of Test / Analysis as provided in the Drugs Act 1976, DRAP Act 2012 and rules made thereunder.
 - c. In case of non-supply or delayed supply or partial supply of replacement items, as in clause-7 (a) above, the Supplier shall be liable for imposition of one or more penalties as provided in clause-22 of this contract agreement.
 - d. All the contravened stock of goods, as in clause-7(a) above, if seized by the authorities shall be the case property under the provisions contained in the Drugs Act, 1976 and the rules made thereunder.
 - e. The supplier shall be responsible to make arrangements for appropriate storage and the matters ancillary to the safe custody of the seized case property as in clause-7(d) above at his sole risk, cost and responsibility with no claim, whatsoever, from the concerned Purchasing Agency, and / or the Drug Inspector, and / or Procuring Agency. The firm will also produce batch wise cold chain data from the source of origin & thermoLog data from factory to ware house for temperature sensitive drugs.
 - f. In case the destruction of the seized stock, as in clause-7(d),(e) above, is required to be undertaken under the applicable laws and rules, all the costs involved in the execution of the decision and destruction, whatsoever, shall be solely borne by the supplier without any claim of any nature, whatsoever, from the concerned Purchasing Agency or Drug Inspector or Procuring Agency.
 - g. Any of the item, as per clause-7 above, if initially declared to be in contravention with any provision of Drugs Act 1976, but later on declared as of standard quality by the concerned Appellate Drugs Testing Laboratory, shall be returned to the supplier by the concerned Drug Inspector in a lawful manner.
8. The cost/fee of the test analysis for samples of the item/s (approved by the selection & rate contracting committee), supplied in response to the purchase orders issued by different health facilities/purchasing entities shall be paid by the bidder(s). All successful bidders are required to pay the fee, as per the rates fixed by the Drug Testing Laboratory under the rules, for the purpose of test/analysis performed for the quality assessment of samples of the approved items.
9. Supplier shall supply to the Purchasing Agency the freshly manufactured goods having maximum possible long expiry dates with the minimum remaining shelf life of at least 65% in case of imported goods and at least 85% in case of locally manufactured goods within Pakistan.
10. The Supplier shall hoist the list of supplied goods on his official website, while indicating name of items, name of manufacturer / importer/indenter, Invoice No., warranty & date, Registration

- No., Batch No., quantity, unit price and expiry date of the supplied goods along with the name of the Purchasing Agency.
11. In case of taking any action in contravention to any provision of the applicable law and rules, the Supplier shall render himself liable to such lawful action/s as deemed appropriate and taken against him under any or all the applicable law/s, rule/s of the Government of Khyber Pakhtunkhwa, terms and conditions of the BSDs and the clauses of this contract agreement.
 12. The Purchasing Agency shall recommend to the Procuring Agency for taking legal / lawful action against the Supplier regarding non-supply, short supply, substituted supply, delayed supply or any other unlawful action / shortcoming, on the part of Supplier, pertaining to the Drugs Act 1976 or in the execution of this contract agreement.
 13. The Procuring Agency shall take lawful / legal action against the Supplier in accordance with the clauses of this contract agreement as well as relevant and applicable laws, rules and regulations of the Government of Khyber Pakhtunkhwa, as amended from time to time, to govern suchlike situation/s, which may, inter alia, include but not limited to blacklisting, forfeiture of earnest money and performance guarantee, if any.
 14. The Supplier agrees to the following conditions related to packing, packaging and labelling of the goods to be supplied to Purchasing Agencies under this contract agreement:
 - a. Each item shall be supplied to Purchasing Agency in the packing and packaging unit as approved and registered by the DRAP. The supplier shall supply all the unit items bearing the words **"GOVERNMENT OF KHYBER PAKHTUNKHWA MCC SUPPLY"** and **"NOT FOR SALE"** in block letters and clearly visible manner with indelible ink, **along with the name of the Purchasing Agency concerned** on the label, outer packing of each individual unit item as well as on its outer carton/s.
 - b. The labels shall comply with all the requirements as laid down under the Drugs Labelling and Packing Rules 1986. The strip / blister shall clearly indicate expiry date of the same medicine in a clear and legible manner.
 - c. The goods shall be packed and transported to the Purchasing Agency in accordance with the provisions contained in the Bid Solicitation Documents.
 - d. The items related to the category of Absorbent Cotton / Surgical Gauze / Cotton Bandages / Crepe bandage, etc. shall be supplied in strict compliance with the instructions contained in Notification No. F.6-6/2005-Reg-II (south) dated 13/9/2006 of the then Federal Ministry of Health, Pakistan.
 15. The Procuring Agency or its representative shall have the right to inspect the manufacturing facilities, premises, warehouses, godowns, laboratories etc. at any time during the financial year 2026-27 /or till the execution of supply orders given under this contract agreement by the Purchasing Agency of the Province. If anything found in contravention of cGMP, clauses of Drugs Act 1976 or of this Contract Agreement the Procuring Agency shall have the sole right and authority to take any lawful action as deemed appropriate, against the Supplier which may include, but not limited to cancellation of supply order/ orders given to the Supplier by the Purchasing Agency as well as imposition of penalties, forfeiture of supplied stock, forfeiture of performance guarantee or earnest money as the case may be, stoppage or recovery of payment made to the supplier as well as taking any other lawful action.
 16. The Supplier agrees that the approved price of all individual items in Schedule-1 of this contract agreement, as quoted by him in the financial bid, shall remain valid till and up to 30th June 2027.
 17. As mentioned in Special Conditions of Contract, the bid security of Rs. 10,00,000/- from the Supplier as already received by the Procuring Agency at the time of bids submission under GCC Clause 15, shall be retained by the Procuring Agency as Performance Security till the end of contract period and will be released back to supplier in response to applying for the same by him to the Procuring Agency after successful completion of all the contractual obligations of this contract agreement and the BSDs.
 18. The Supplier shall provide legal and valid warranty to the Purchasing Agency for all the goods supplied under this contract agreement, which fall under the provisions of Drugs Act 1976, DRAP Act 2012 and the rules framed thereunder, on prescribed Form-2A in accordance with

- the mechanism prescribed for the purpose.
19. For Non-Drug Items, the Supplier shall provide appropriate warranty to the Purchasing Agency in accordance with Special Conditions of Contract of the BSDs for this bidding competition, for each item supplied in response to supply orders.
 20. In case the Supplier had been awarded marks during the technical evaluation for API source accreditation for Drugs / Medicines, and for medical grade material certification for medical devices & Non-Drug Items, and for pharmaceutical grade certification for immediate containers of Drugs/medicines shall warranty the supply of all such goods with the same certified quality, material and specification to the Purchasing Agency throughout the validity period of this contract agreement.
 21. Bill for payment in triplicate along with all other relevant and required documents shall be submitted by the Supplier to the Purchasing Agency immediately after completion of supply of ordered stock. The Supplier shall be bound to pay all sorts of government taxes, duties and stamp duties, imposed earlier or during the financial year by the Government of Pakistan or by the Provincial Government of Khyber Pakhtunkhwa on any supplied / purchased item.
 22. In case of any collusive, coercive, corrupt, obstructive, fraudulent practices and/or any act of misconduct by the approved firm and/or its focal person, during the contract period in relation to the decision making by the procuring entity (Selection & Rate Contracting Committee notified for FY 2026-27), shall be liable to be proceeded under Departmental Debarment/Blacklisting Guidelines Notified vide Letter No. 2440-2500/Proc. Cell, Dated: 30-08-2018, for debarment, blacklisting for a specified period and /or forfeiture of the bid security/performance guarantee of the bidding firm, and / or any other lawful action as deemed appropriate by the Government of Khyber Pakhtunkhwa, including that to be taken up with the DRAP or any other body / entity of the Federal Government; and
 23. In case of situation related to Force Majeure, the Supplier may immediately without delay inform the Procuring Agency as well as the Purchasing Agency in writing about the situation along with solid proof of the situation through the fastest, lawful and available means of communication, but not through the electronic mail, and request the Procuring Agency for the grant of extension in the supply period.
 - a. The Procuring Agency, in case of being fully satisfied with the genuineness of situation arising from the claimed Force Majeure by the Supplier, may extend the period of supply of goods up to a maximum of not more than thirty days.
 - b. The Procuring Agency and / or Purchasing Agency shall, in no case, be responsible or held responsible for any complications in making payments to Supplier by the Purchasing Agency that may arise from the closure of financial year, and / or lapse, and/ or surrender of public funds, vis-à-vis, the standard and normal public sector financial management laws, rules, regulations, procedures and practices governing the Procuring Agency, and / or Purchasing agency/ies.
 - c. After the expiry of extended period as in clause-22(a) above, the supply order shall stand cancelled to the extent of non-supplied goods and the performance security in the form of retained bids security, as in clause-16 of this contract agreement shall be forfeited in favour of the Procuring Agency.
 24. The Supplier agrees that the supply of the ordered goods under this agreement shall be completed by the Supplier i.e., Local Manufacturer within thirty (30) days and Importer/Indenter Supplier within sixty (60) days after the receipt of supply order/s from the Purchasing Agency/ies, except in situation/s covered under clause-22 above regarding Force Majeure. In case of delay in supplies reaching to the Purchasing Agency, the following penalties shall be imposed by the Purchasing Agency upon the Supplier:
 - a. Upon delay in supply beyond 30 and 60 days for local manufacturer supplier and for importer/indenter supplier respectively a lump sum penalty of 1% per week shall be deducted up to a maximum of 7% penalty for 7 weeks, of the total quoted price of such goods, whose supply was delayed out of the same supply order as issued to the supplier, shall be

b. In case of delay in supply beyond 7 weeks after the cutoff days, as mentioned in clause-23(a) above, the supply order issued by the Purchasing Agency shall stand cancelled to the extent of non-supplied items and in such a case, the Procuring Agency shall have the right, duty and authority to impose any or all of the below mentioned penalties; that is

- i.** Forfeiting the bids security and / or performance guarantee of the Supplier as related to this contract agreement; and / or
- ii.** Immediately debarring the selected item/s and/or Supplier/firm from future participation and business not less than one year and up to next three (03) calendar years with the Government of Khyber Pakhtunkhwa through MCC or any other health institution, project and / or Program directly or indirectly run or implemented by or through the provincial Health Department or Purchasing Agencies in the Province, as defined in the BSDs, and District Governments in the Province; and / or
- iii.** Initiating the process for and recommending for permanent blacklisting of the Supplier with the Purchasing Agencies under Debarment/Blacklisting Guidelines Notified vide Letter No. 2440-2500/Proc. Cell, Dated: 30-08-2018.
- iv.** The applicant bidder shall be debarred/blacklisted from the process of contract framework agreement 2026-27 either for its quoted item/s and/or firm from the bidding competition at any stage where the bidder has been declared defaulter firm/non-supplier firm in the Govt. MCC contract agreement period of FY 2025-26 (30th June 2026) and/or current FY 2026-27 reported by purchasing agencies as a non-supplier firm and proceeded by procuring entity as per Debarment/Blacklisting Guidelines of Health Department.

25. The Supplier agrees that the supply order/s of the goods which are issued till the last day of the financial year (30th June, 2027) by the purchasing entity/ies under this agreement shall be completed, in case of failure the supplier shall be liable to all the penalties enunciated in clause 23(a) & (b) of this agreement.

26. Notwithstanding any rights, duties and / or remedial measures and / or managerial actions taken and / or to be taken and / or any powers exercised and / or to be exercised by the Procuring Agency and / or Purchasing Agency and / or Purchasing Officer/s with regard to the execution of this contract agreement, the Supplier agrees to indemnify all of them for any loss or damage incurred or inflicted upon by them in individual or official capacity upon the Supplier whether through any of their actions and / or practices and / or otherwise.

27. The Supplier further agrees to pay compensation to the Government of Khyber Pakhtunkhwa of an amount equivalent to ten times the sum of any commission, gratification, bribe or kickback and / or finder's fee given by the Supplier for the purpose of obtaining and / or inducing the procurement of any contract, right, interest, privilege or other obligation/s or benefit/s in whatsoever form, from the Procuring Agency or any of the Purchasing Agencies.

28. The supplier further agrees that all the data related to supplies throughout the financial year shall be provided to the procuring entity by the end of financial year. The CDR/Bank Guarantee of the supplier shall not be released till the provision of the said data.

29. The Procuring Agency and / or Purchasing Agency, as the case may be, and the Supplier shall make every effort to resolve amicably by direct negotiation any disagreement or dispute arising between them under or in connection with the contract / supplies. However, despite such negotiation if the Purchasing Agency & Supplier have been unable to resolve amicably a contract dispute, either party may refer the case to Secretary to Government of Khyber Pakhtunkhwa, Health Department, Peshawar for decision through a Dispute Resolution Committee under the chairmanship of Special Secretary Health with Additional Secretary Health (Development) or Additional Secretary Health (Establishment) and Deputy Secretary Drugs as members.

30. Both the parties agree that the Procuring Agency in the capacity of being the overall head of the Government Medicine Coordination Cell, or otherwise, has the authority to regulate, if deemed appropriate, under the provisions in the BSDs, through imposing restrictions and / or

classifying and / or grouping any selected quoted item/s for stopping, increasing or decreasing the purchase of such item/s by the Purchasing Agency/ies to rationalize and / or control the use and / or misuse of such item/s.

31. The procuring agency may extend the duration for the framework contract to another year, extendable up to a maximum of three years; provided that every extension shall be approved by a committee, notified by the Administrative Department, to determine competitiveness and assess value for money as per the KPPRA Rules (31A) of 2014.
32. The supplier agrees that in the event of award of contract for the quoted product(s) through the bidding process, the approved products shall be manufactured with the same Active Pharmaceutical Ingredient (API) source specified in the bid consistently throughout the supply period of the financial year 2025–26 with Govt. MCC.
33. The supplier agrees that for items falling under the category of medical devices and non-drug items, all supplies shall conform to medical-grade material certification and pharmaceutical-grade certification for immediate containers submitted in the bid. The quality, material composition, and specifications of such goods shall remain consistent and in accordance with the certified standards throughout the validity period of the contract agreement, and shall be supplied without deviation to the purchasing entity/(ies).
34. The supplier agrees to submit quarterly batch-wise reports, along with relevant API source import documentations, medical grade material certifications and pharmaceutical grade certifications for immediate container submitted in the bid to the Government MCC, Directorate General Drug Control & Pharmacy Services, Khyber Pakhtunkhwa, until the completion of the contract period.
35. In case of single complying bid, the procuring entity may conclude the procurement contract through negotiation on quality upgrades, mode and schedule of delivery or cost reduction. In case the bid price is above engineer estimates or market analysis report, conducted by the procuring entity, after due diligence, in such eventuality, the successful bidder shall be asked to match that price in order to protect public interest and to ensure general principle of timelines for procurement as enunciated in section 3 of the Act as per the KPPRA Rules (42A) of 2014.

<p>_____ Director General Health Services Khyber Pakhtunkhwa For and on behalf of Government of Khyber Pakhtunkhwa, Health Department, Peshawar</p>	<p>_____ Signature: Name: Designation CNIC No. Stamp: For and on behalf of Manufacturers /Importer/Indenter</p>
<p>WITNESS NO. 1 Director Govt. MCC, DGDC&PS, Health Department, Khyber Pakhtunkhwa, Peshawar</p>	<p>WITNESS NO. 2 Signature: Name: Father's Name: Address: CNIC No.</p>

Schedule -1 of the Govt. MCC Contract Agreement

Directorate General Health Services, Khyber Pakhtunkhwa

Government MCC 2026-27

1. Name and Address of Supplier:

2. List of Selected/Approved Item/s from the Supplier along with quoted unit price/s:

S.No.	MCC Formulary No.	Generic Name of the Item	Strength,	Dosage form	Brand Name	Volume / Pack Size	Approved Rate/Unit
1							
2							
3							
4							
5							
6							

BID FORM-9

(for use of Govt. MCC committee only)

DECLARATION/CODE OF ETHICS FOR THE MEMBERS OF THE PROCUREMENT COMMITTEES GOVT. MCC, KHYBER PAKHTUNKHWA

In performing the operations as a member/s of the procurement committees of the bidding process/competition regarding purchase and supply of drugs, non-drugs and surgical disposable items for the year 2026-27 for the health facilities / institutions through Directorate General Health Services, Khyber Pakhtunkhwa, Peshawar, I/We do hereby solemnly affirm, declare and certify that:

- (1) I/We shall perform my/our official duties in compliance with the approved BSDs, and the prevailing laws. When performing the operations of this procurement, the member shall act exclusively in the public interest and shall ensure equal treatment of the bidders/products.
- (2) I/We shall perform my/our activities with full diligence, honesty and to a high professional level, which shall be continuously upgraded.
- (3) I/We shall not be engaged in any activities that are contrary to the legitimate performance of my/our official duties, and I/We shall do everything to avoid situations and conduct that could impair the interest or the reputation of the Govt. MCC in which I/We am/are nominated/employed.
- (4) When performing my/our official duties, as member/s of the procurement committees, I/We shall not be influenced by partiality for achieving certain results.
- (5) While performing specific tasks and deciding about the rights, the duties and the interests of the citizens and the legal entities, I/We being member/s of the procurement committees shall not be led by incorrect, unjustified or unreasonable assessment of the factual situation due to prejudice, realization of ambitions for conflict of interests, intimidation or threats by the superior member of the procurement committees, the official managing the body in which the civil servant is employed or by the persons affected by the respective act or decision and shall provide equal treatment to the bidders to ensure the realization of the rights and the legitimate interests of the bidders and the other entities.
- (6) I/We shall independently reach to the decisions and shall decide objectively on the basis of the facts of the case, taking into consideration only the legally relevant facts and acting without unnecessary delay.
- (7) I/We shall adhere to the appropriate procedure when performing the official duties within my/our competence, especially rejecting any pressure, even the one from my/our superiors.
- (8) I/We shall not use advantages arising from my/our status as member/s of the procurement committees nor shall I/We use the information acquired due to my/our position for my/our personal benefit. My/our duty shall be to avoid any conflict of interests, as well as situations that could lead to suspicion for conflict of interests.
- (9) I/We shall not consciously mislead the public or the other member/s of the procurement committees within the body.
- (10) I/We shall treat the information I/We acquired due to my/our position in the procurement process with the all necessary secrecy and shall provide appropriate information protection.
- (11) I/We shall not represent or express my/our political view in performing the official duties.

(12) I/We shall not let my/our personal financial interest, or my/our family, relatives, and friends to be in conflict with my/our position and the status of authorization as member/s.

(13) I/We shall not ask for nor accept, for myself/ourselves or for others, gifts, services, assistance or any other benefit that could affect or that could seem to affect my/our decision/s for certain issues, or that could corrupt my/our professional approach towards certain issues in this bidding process.

(14) I/We shall not accept gifts or gratitude that could be deemed as reward for those activities, the performance of which is my/our responsibility.

1. Dr. /Mr./Ms. _____ Designation _____

2. Dr. /Mr./Ms. _____ Designation _____

3. Dr. /Mr./Ms. _____ Designation _____

4. Dr. /Mr./Ms. _____ Designation _____

5. Dr. /Mr./Ms. _____ Designation _____

6. Dr. /Mr./Ms. _____ Designation _____

7. Dr. /Mr./Ms. _____ Designation _____

8. Dr. /Mr./Ms. _____ Designation _____


9. Dr. /Mr./Ms. _____ Designation _____

Physical Inspector Report for MCC approved items in Health facilities of Khyber Pakhtunkhwa

[illegible]

BID FORM-11 (for use of End User Consultants)

Govt. MCC Clinical Efficacy Reporting Form



GOVT. MCC CLINICAL EFFICACY REPORTING FORM

This form is for voluntary reporting of adverse drug reactions caused by the approved items in Govt. MCC.

For Healthcare Professionals

For MCC Office Use Only

Report No. _____

Directorate General Drug Control & Pharmacy Services
 Govt. Medicine Coordination Cell (MCC)
 Old Fata Secretariat, Warsak Road, Peshawar
 Telephone No: 091-9211702

A. PATIENT DETAILS
 Total No. of Patients on Whom Subject Drug was used _____
 Patient's Initials or Name: ^ _____ Identification Number (Medical/Hospital Ref): _____
 Sex: Male / Female: _____ If Female, pregnant or not: _____ Age (at the time of reaction): _____ Weight (kg) _____

B. SUSPECTED DRUG(S)/VACCINE(S)/ALTERNATIVE MEDICINE(S) (use additional pages if necessary):

Drug/Vaccine/Alternative Medicine (Brand Name & Generic Name)	Batch No:	Manufacturer /importer	Route of Administration & Daily Doses	Dosage & Strength	Start Date	Stop Date	Prescribed For

C. EFFICACY REPORT OR SUSPECTED REACTION(S) (use additional pages if necessary):
 1. When reaction started (DD/MM/YY): _____ 2. When recovery started (DD/MM/YY): _____

3. Describe the reaction(s): (use additional pages if necessary):

4. Other relevant history of the patient (Allergies, Smoking, Alcohol Use, Hepatic/Renal Problems, and Pre-Existing Medical Problems etc.):

5. Relevant tests/Laboratory data with dates: (use additional pages if necessary):

6. Do you consider the reaction(s) to be serious? Yes/No
 If yes, please tick all that apply of the following:
☐ Patient died due to reaction:
☐ Life Threatening:
☐ Involved or prolonged inpatient hospitalization:
☐ Involved persistent or significant disability or incapacity:
☐ Congenital anomaly/Birth Defects:
 Other Serious (Medically Important Condition): please give details: _____

7. Reaction abated after use stopped or dose reduced?
☐ Yes ☐ No ☐ Doesn't apply

8. Reaction reappeared after reintroduction?
☐ Yes ☐ No ☐ Doesn't apply

9. Outcomes:
☐ Fatal ☐ Recovering ☐ Unknown
☐ Continuing ☐ Recovered
 Other _____

10. You consider the problem related to which of the following:
☐ Quality Problem ☐ Medication Error ☐ Adverse Event/Reaction
 If other, please specify _____

D. OTHER CONCOMITANT DRUG(S)/VACCINE(S)/ALTERNATIVE MEDICINE(S) (use additional pages if necessary):

Drug/Vaccine/Alternative Medicine (Brand Name & Generic Name)	Batch No:	Manufacturer /importer	Route of Administration & Daily Doses	Dosage & Strength	Start Date	Stop Date	Prescribed For

E. SUSPECTED MEDICAL DEVICE(S) fill this area for suspected Device only (use additional pages if necessary):

Medical Device Common Name / Brand Name	Lot No/ Batch No:	Manufacturer /importer	Model No:	Unique Identifier No:	Serial No:	If Implanted enter date	If Explanted enter date

F. REPORTER DETAILS

Name: _____ Professional Address: _____
 Specialty: _____ Tel No: _____ Email Address: _____
 Date of this report: _____ Signature _____
 Have you reported this problem to Provincial Pharmacovigilance Centre or Manufacturer? If yes, please specify: _____

"This form neither has any legal value nor can be presented before any Court of Law as an Evidence."

Detail Clinical Efficacy Reporting Form can be downloaded from:

https://drive.google.com/file/d/13NTyaB9U30F3pTRPF6LfCYEYNZlzyk9r/view?usp=drive_link